<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.3"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Rev Chem</journal-id><journal-id journal-id-type="iso-abbrev">Nat Rev Chem</journal-id><journal-title-group><journal-title>Nature Reviews. Chemistry</journal-title></journal-title-group><issn pub-type="epub">2397-3358</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8374425</article-id><article-id pub-id-type="pmid">34426795</article-id><article-id pub-id-type="publisher-id">313</article-id><article-id pub-id-type="doi">10.1038/s41570-021-00313-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Roadmap</subject></subj-group></article-categories><title-group><article-title>Towards the sustainable discovery and development of new antibiotics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Miethke</surname><given-names>Marcus</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pieroni</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8260-5120</contrib-id><name><surname>Weber</surname><given-names>Tilmann</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Br&#x000f6;nstrup</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hammann</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Halby</surname><given-names>Ludovic</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Arimondo</surname><given-names>Paola B.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Glaser</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5266-5926</contrib-id><name><surname>Aigle</surname><given-names>Bertrand</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6048-5909</contrib-id><name><surname>Bode</surname><given-names>Helge B.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yanyan</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Luzhetskyy</surname><given-names>Andriy</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2191-2821</contrib-id><name><surname>Medema</surname><given-names>Marnix H.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6129-7093</contrib-id><name><surname>Pernodet</surname><given-names>Jean-Luc</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Stadler</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Tormo</surname><given-names>Jos&#x000e9; Rub&#x000e9;n</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Genilloud</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5453-7485</contrib-id><name><surname>Truman</surname><given-names>Andrew W.</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3012-2960</contrib-id><name><surname>Weissman</surname><given-names>Kira J.</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6791-3256</contrib-id><name><surname>Takano</surname><given-names>Eriko</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0971-3536</contrib-id><name><surname>Sabatini</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Stegmann</surname><given-names>Evi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Br&#x000f6;tz-Oesterhelt</surname><given-names>Heike</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Wohlleben</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2615-1574</contrib-id><name><surname>Seemann</surname><given-names>Myriam</given-names></name><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name><surname>Empting</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hirsch</surname><given-names>Anna K. H.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Loretz</surname><given-names>Brigitta</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lehr</surname><given-names>Claus-Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7408-5084</contrib-id><name><surname>Titz</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Herrmann</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jaeger</surname><given-names>Timo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Alt</surname><given-names>Silke</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hesterkamp</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1604-3318</contrib-id><name><surname>Winterhalter</surname><given-names>Mathias</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9823-2090</contrib-id><name><surname>Schiefer</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3096-2465</contrib-id><name><surname>Pfarr</surname><given-names>Kenneth</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Hoerauf</surname><given-names>Achim</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff27">27</xref></contrib><contrib contrib-type="author"><name><surname>Graz</surname><given-names>Heather</given-names></name><xref ref-type="aff" rid="Aff28">28</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0818-2614</contrib-id><name><surname>Graz</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name><surname>Lindvall</surname><given-names>Mika</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name><surname>Ramurthy</surname><given-names>Savithri</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name><surname>Karl&#x000e9;n</surname><given-names>Anders</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name><surname>van Dongen</surname><given-names>Maarten</given-names></name><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name><surname>Petkovic</surname><given-names>Hrvoje</given-names></name><xref ref-type="aff" rid="Aff34">34</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5361-0895</contrib-id><name><surname>Keller</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name><surname>Peyrane</surname><given-names>Fr&#x000e9;d&#x000e9;ric</given-names></name><xref ref-type="aff" rid="Aff36">36</xref></contrib><contrib contrib-type="author"><name><surname>Donadio</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name><surname>Fraisse</surname><given-names>Laurent</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1460-473X</contrib-id><name><surname>Piddock</surname><given-names>Laura J. V.</given-names></name><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5238-1314</contrib-id><name><surname>Gilbert</surname><given-names>Ian H.</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8013-2139</contrib-id><name><surname>Moser</surname><given-names>Heinz E.</given-names></name><address><email>heinz.moser@novartis.com</email></address><xref ref-type="aff" rid="Aff41">41</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1042-5665</contrib-id><name><surname>M&#x000fc;ller</surname><given-names>Rolf</given-names></name><address><email>rolf.mueller@helmholtz-hips.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.11749.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 7588</institution-id><institution>Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), and Department of Pharmacy, </institution><institution>Saarland University Campus E8.1, </institution></institution-wrap>Saarbr&#x000fc;cken, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.452463.2</institution-id><institution>German Center for Infection Research (DZIF), </institution></institution-wrap>Braunschweig, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.10383.39</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 0937</institution-id><institution>Food and Drug Department, </institution><institution>University of Parma, </institution></institution-wrap>Parma, Italy </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.5170.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 8870</institution-id><institution>The Novo Nordisk Foundation Center for Biosustainability, </institution><institution>Technical University of Denmark, </institution></institution-wrap>Lyngby, Denmark </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.7490.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2238 295X</institution-id><institution>Department of Chemical Biology (CBIO), </institution><institution>Helmholtz Centre for Infection Research (HZI), </institution></institution-wrap>Braunschweig, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.8664.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2165 8627</institution-id><institution>Infectious Diseases &#x00026; Natural Product Research at EVOTEC, and Justus Liebig University Giessen, </institution></institution-wrap>Giessen, Germany </aff><aff id="Aff7"><label>7</label>Epigenetic Chemical Biology, Department of Structural Biology and Chemistry, Institut Pasteur, UMR n&#x000b0;3523, CNRS, Paris, France </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.428999.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2353 6535</institution-id><institution>Ecology and Evolution of Antibiotic Resistance Unit, </institution><institution>Microbiology Department, Institut Pasteur, CNRS UMR3525, </institution></institution-wrap>Paris, France </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.29172.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2194 6418</institution-id><institution>Universit&#x000e9; de Lorraine, INRAE, DynAMic, </institution></institution-wrap>Nancy, France </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.7839.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9721</institution-id><institution>Department of Biosciences, </institution><institution>Goethe University Frankfurt, </institution></institution-wrap>Frankfurt, Germany </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.419554.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0491 8361</institution-id><institution>Max Planck Institute for Terrestrial Microbiology, Department of Natural Products in Organismic Interactions, </institution></institution-wrap>Marburg, Germany </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.9983.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 4263</institution-id><institution>Faculty of Pharmacy, </institution><institution>University of Lisbon, </institution></institution-wrap>Lisbon, Portugal </aff><aff id="Aff13"><label>13</label>Unit MCAM, CNRS, National Museum of Natural History (MNHN), Paris, France </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.11749.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 7588</institution-id><institution>Pharmaceutical Biotechnology, </institution><institution>Saarland University, </institution></institution-wrap>Saarbr&#x000fc;cken, Germany </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.4818.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0791 5666</institution-id><institution>Bioinformatics Group, </institution><institution>Wageningen University and Research, </institution></institution-wrap>Wageningen, Netherlands </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.460789.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 4910 6535</institution-id><institution>Institute for Integrative Biology of the Cell (I2BC) &#x00026; Microbiology Department, </institution><institution>University of Paris-Saclay, </institution></institution-wrap>Gif-sur-Yvette, France </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.7490.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2238 295X</institution-id><institution>Microbial Drugs (MWIS), Helmholtz Centre for Infection Research (HZI), </institution></institution-wrap>Braunschweig, Germany </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.424782.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1778 9140</institution-id><institution>Fundaci&#x000f3;n MEDINA, </institution></institution-wrap>Granada, Spain </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.14830.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2175 7246</institution-id><institution>Department of Molecular Microbiology, </institution><institution>John Innes Centre, </institution></institution-wrap>Norwich, United Kingdom </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.29172.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2194 6418</institution-id><institution>Molecular and Structural Enzymology Group, </institution><institution>Universit&#x000e9; de Lorraine, CNRS, IMoPA, </institution></institution-wrap>Nancy, France </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.5379.8</institution-id><institution-id institution-id-type="ISNI">0000000121662407</institution-id><institution>Manchester Institute of Biotechnology, Department of Chemistry, School of Natural Sciences, </institution><institution>Faculty of Science and Engineering, University of Manchester, </institution></institution-wrap>Manchester, United Kingdom </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="GRID">grid.9027.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 3630</institution-id><institution>Department of Pharmaceutical Sciences, </institution><institution>University of Perugia, </institution></institution-wrap>Perugia, Italy </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="GRID">grid.10392.39</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1447</institution-id><institution>Department of Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, </institution><institution>University of T&#x000fc;bingen, </institution></institution-wrap>T&#x000fc;bingen, Germany </aff><aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="GRID">grid.10392.39</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 1447</institution-id><institution>Department of Microbiology/Biotechnology, Interfaculty Institute of Microbiology and Infection Medicine, </institution><institution>University of T&#x000fc;bingen, </institution></institution-wrap>T&#x000fc;bingen, Germany </aff><aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="GRID">grid.11843.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 9291</institution-id><institution>Institute for Chemistry UMR 7177, </institution><institution>University of Strasbourg/CNRS, ITI InnoVec, </institution></institution-wrap>Strasbourg, France </aff><aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="GRID">grid.15078.3b</institution-id><institution-id institution-id-type="ISNI">0000 0000 9397 8745</institution-id><institution>Life Sciences &#x00026; Chemistry, </institution><institution>Jacobs University Bremen, </institution></institution-wrap>Bremen, Germany </aff><aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="GRID">grid.15090.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 8786 803X</institution-id><institution>Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), </institution><institution>University Hospital Bonn, </institution></institution-wrap>Bonn, Germany </aff><aff id="Aff28"><label>28</label>Biophys Ltd., Usk, Monmouthshire, United Kingdom </aff><aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="GRID">grid.5337.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7603</institution-id><institution>School of Law, </institution><institution>University of Bristol, </institution></institution-wrap>Bristol, United Kingdom </aff><aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="GRID">grid.505135.7</institution-id><institution>Recursion Pharmaceuticals, </institution></institution-wrap>Salt Lake City, UT USA </aff><aff id="Aff31"><label>31</label>Drug Discovery/Medicinal Chemistry, HiberCell, New York, NY USA </aff><aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution>Department of Medicinal Chemistry, </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff><aff id="Aff33"><label>33</label>AMR Insights, Amsterdam, Netherlands </aff><aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="GRID">grid.8954.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0721 6013</institution-id><institution>Department of Food Science and Technology, Biotechnical Faculty, </institution><institution>University of Ljubljana, </institution></institution-wrap>Ljubljana, Slovenia </aff><aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="GRID">grid.11749.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 7588</institution-id><institution>Chair for Clinical Bioinformatics, </institution><institution>Saarland University, University Hospital, </institution></institution-wrap>Saarbr&#x000fc;cken, Germany </aff><aff id="Aff36"><label>36</label>BEAM Alliance, Paris, France </aff><aff id="Aff37"><label>37</label>NAICONS Srl, Milan, Italy </aff><aff id="Aff38"><label>38</label><institution-wrap><institution-id institution-id-type="GRID">grid.428391.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0618 1092</institution-id><institution>Drugs for Neglected Diseases initiative (DNDi), </institution></institution-wrap>Geneva, Switzerland </aff><aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="GRID">grid.509622.a</institution-id><institution>The Global Antibiotic Research and Development Partnership (GARDP), </institution></institution-wrap>Geneva, Switzerland </aff><aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="GRID">grid.8241.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0397 2876</institution-id><institution>Division of Biological Chemistry and Drug Discovery, </institution><institution>University of Dundee, </institution></institution-wrap>Dundee, United Kingdom </aff><aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="GRID">grid.418424.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0439 2056</institution-id><institution>Novartis Institutes for BioMedical Research (NIBR), </institution></institution-wrap>Emeryville, CA USA </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>8</month><year>2021</year></pub-date><pub-date pub-type="ppub"><year>2021</year></pub-date><volume>5</volume><issue>10</issue><fpage>726</fpage><lpage>749</lpage><history><date date-type="accepted"><day>1</day><month>7</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; Springer Nature Limited 2021</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations.</p><p id="Par2">
<graphic position="anchor" xlink:href="41570_2021_313_Figa_HTML" id="d32e1036"/>
</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par3">Antimicrobial resistance is an increasing threat to public health and encouraging the development of new antimicrobials is one of the most important ways to address the problem. This Roadmap article aims to bring together industrial, academic and political partners, and proposes both short-term and long-term solutions to this challenge.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Drug therapy</kwd><kwd>Business strategy in drug development</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par4">This article is conceived as a general roadmap with the central aim of promoting and accelerating translational science in the early stages of novel antibiotic discovery towards lead candidate development. The overuse and misuse of antibiotics in healthcare and agriculture, together with inappropriate waste management and environmental transmission, have led to substantially increased antimicrobial resistance (AMR)<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref></sup> and associated bacterial persistence<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. This is of major public concern, since most areas of modern medicine are inconceivable without access to effective antimicrobial treatment<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. It is estimated that at least 700,000 people worldwide die each year as a result of drug-resistant infections, and this could rise to as much as 10 million by 2050 if the problem of AMR is not addressed<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>.</p><p id="Par5">The anticipated death toll caused by drug-resistant infections over the next years and decades may be compared with the global fatality rate of the current SARS-CoV-2 (COVID-19) pandemic (<ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/">https://coronavirus.jhu.edu/</ext-link>), which has already led to multibillion-dollar investments in vaccine development, repurposing existing drugs and antiviral discovery. A perhaps overlooked aspect of concern with the COVID-19 pandemic is the high numbers of secondary infections, often associated with multidrug-resistant bacteria, which are observed especially in hospitalized patients and those with already compromised immune systems<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. Associated with this problem is the massive use of antibiotics as a COVID-19 (co)treatment worldwide<sup><xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref></sup>, which is predicted to add to the ongoing emergence of AMR<sup><xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref></sup>. This multiplying effect of COVID-19 on the spread of bacterial resistance will most likely have further negative clinical, economic and societal consequences in the near future<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>.</p><p id="Par6">Unfortunately, the dramatic worldwide rise of bacterial pathogens resistant to antibacterial agents<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> cannot be counteracted by the current low development pace of therapeutics with new mode(s) of action (MoA(s)). While there are nearly 4,000 immuno-oncology agents in development<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, only about 30&#x02013;40 new antibacterial compounds are currently in the clinical trial phases of development, and, notably, those candidates targeting World Health Organization (WHO) priority pathogens are derivatives of existing classes<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Indeed, less than 25% of current drugs in the clinical development pipeline represent a novel class or act through a novel mechanism, and none of these are potentially active against Gram-negative&#x000a0;<xref rid="Glos1" ref-type="list">ESKAPE</xref> or WHO critical threat pathogens<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. In fact, only a small fraction of the antibiotics approved over the past 40 years represents new compound classes, while the majority were derived from already known chemical structures, and the most recent new class of antibiotics was discovered during the 1980s<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p><p id="Par7">Thus, strategic investment in new therapeutic options to fight AMR is urgently required to address unmet patient need and, additionally, to counterbalance the exponentially increasing financial burden on global health systems<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Consequently, the research field should aim to leverage hit identification and hit-to-lead optimization programmes to ensure a sustainable flow of new antibacterial drug candidates into the development pipeline. For this purpose, the initial stages of drug discovery and development need to be strengthened, since they are essential to identify and validate novel therapeutic candidates effective to fight antibacterial resistance. However, for many years, such early-stage projects have been mainly conducted by academia and are generally underfunded, while increased allocation of funding into early-stage and mid-stage research and development (R&#x00026;D) has been recommended to make the pipeline more robust<sup><xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref></sup>. Our network has identified major funding gaps especially within the academic sector, as well as for small and medium-sized enterprises (SMEs), where research is mainly associated with the early hit discovery and hit-to-lead phases, as well as with late lead optimization prior to preclinical candidate nomination (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Large pharmaceutical companies across the globe are extremely hesitant to fund early antibiotic R&#x00026;D and, particularly, new classes of compounds, since the return on investment in this area is generally low or even negative. Further, the costs of developing entirely new scaffolds are much higher than for derivatives of established compound classes, while the attrition rate in antibacterial drug discovery has been particularly high in the recent decades, reflected by the fact that no new class of Gram-negative antibiotics has been launched for more than 50 years<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. In the commercial sector, innovation has, thus, been left to SMEs, which must deal with high attrition associated with the early phases of discovery and optimization<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref></sup>, and the huge capital risks<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>.<fig id="Fig1"><label>Fig. 1</label><caption><title>General scheme of antimicrobial drug development.</title><p>Large funding gaps can be seen in the early stages of hit discovery, as well as during hit and lead optimization, which are associated mainly with academic research and small and medium-sized enterprises (SMEs). Indicated figures are representative numbers of typical broad-spectrum antibiotic development programmes leading from several thousands of initial hits to the approval of at least one marketable candidate<sup><xref ref-type="bibr" rid="CR72">72</xref>,<xref ref-type="bibr" rid="CR318">318</xref>&#x02013;<xref ref-type="bibr" rid="CR321">321</xref></sup>. *Timings are dependent on a number of factors and can vary greatly. A minimum to maximum range for complete development (discovery to market) is 8&#x02013;18 years (average 13&#x02013;14 years). **The cost per molecule/candidate (in million euros, m&#x020ac;) does not include extended costs for attrition (failed programmes) and lost opportunities associated with increased cycle time until reaching the next development phase; such extensions can increase the required budget for the early stages up to 50&#x02013;100&#x02009;m&#x020ac; (refs<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR322">322</xref></sup>). N (orange diamond), nomination of (pre)clinical candidate(s); PPPs, public&#x02013;private partnerships; ROI, return on investment.</p></caption><graphic xlink:href="41570_2021_313_Fig1_HTML" id="d32e1213"/></fig></p><p id="Par8">New economic models for development specifically designed for this area are sorely needed to ensure future advancements<sup><xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref></sup>. A recent initiative that supports SMEs in the late-stage development of new antibiotics is the AMR Action Fund, which was launched by more than 20 leading biopharmaceutical companies to <xref rid="Glos2" ref-type="list">push</xref> mainly phase II and III trials of advanced candidates<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Unfortunately, the fund does not cater for the early stages of research. In addition, several countries are implementing new&#x000a0;<xref rid="Glos3" ref-type="list">pull</xref> incentive programmes with different priorities. While the Swedish model aims at securing sustained access to relevant antibiotics that have already been approved<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>, plans in the UK<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup> as well as in the USA (e.g. PASTEUR<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> and DISARM<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> acts) strive to stimulate the development of new antibacterial products by using&#x000a0;<xref rid="Glos4" ref-type="list">subscription models</xref> or <xref rid="Glos5" ref-type="list">delinkage models</xref><sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Such initiatives are promising, as they introduce much-needed market entry rewards, but they might fall short on a global scale if they do not include the &#x02018;critical mass&#x02019; of the world&#x02019;s largest economies.</p><p id="Par9">Innovation in the early stages of antibiotic drug discovery can also be driven by the academic sector. However, from the academic perspective, partnering with external funders such as the pharmaceutical industry is, in many cases, only realistic after the nomination of extensively validated preclinical candidates, and often even requires phase I clinical data. Typically, this cannot be achieved by research-driven funding and infrastructure alone. Several global health organizations and public&#x02013;private partnerships (PPPs), including the Global Antibiotic Research and Development Partnership (GARDP), Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Innovative Medicines Initiative (IMI) and others, started to support, at least partially, the mid-to-late lead optimization through to clinical proof of concept<sup><xref ref-type="bibr" rid="CR61">61</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref></sup>, possibly accompanied by stakeholders associated with the Biotech companies in Europe combating AntiMicrobial resistance (BEAM) Alliance or the Replenishing and Enabling the Pipeline for Anti-Infective Resistance (REPAIR) Impact Fund<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup>. However, even the growing diversity of such push incentives are, in many cases, insufficient and primarily focused on companies. In addition to these approaches, a strategy is required that helps academic researchers to advance their project portfolio to a level that facilitates early interaction and possibly partnering with pharmaceutical companies in the interest of a successful, cross-sectoral development pipeline<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. Hence, creating new incentive models in the field is an essential process that can only be moved forward if the public, academic and industrial sectors join forces<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR67">67</xref>&#x02013;<xref ref-type="bibr" rid="CR69">69</xref></sup>.</p><p id="Par10">In this respect, our position paper provides an overview of the early phases of antibacterial drug discovery, including hit and lead identification, optimization and development to the (pre)clinical stages by summarizing current limitations, relevant approaches and future perspectives, as well as by presenting selected case studies. In terms of a principal guidance for researchers in the field, we suggest possible solutions for a number of obstacles to improve both quality and quantity of antibacterial hits and leads. To strengthen and emphasize these early stages as an absolute necessity for a sustained generation of novel antibiotics, we are recommending a new level of interaction between the various stakeholders and academic disciplines in the area of antibiotic drug research. The strengths and opportunities that small-molecule therapeutics offer can help address antibiotic resistance more successfully during the coming years, in the interests of both patients and investors, provided that the multiplicity of hurdles along the translational path will be overcome (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Altogether, our aims are in line with the &#x02018;One Health Action Plan against Antimicrobial Resistance&#x02019; introduced by the European Commission<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>, as well as the WHO programme to fight the rising number of bacterial priority pathogens with steadily growing impact on global public health<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>SWOT (strength, weaknesses, opportunities and threats) analysis summarizing a path forward in the development of novel antibiotic drugs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Strengths</th><th align="left">Weaknesses (current limitations)</th><th align="left">Opportunities (possible solutions)</th><th align="left">Threats</th></tr></thead><tbody><tr><td><p>Successful clinical proof of concept for antibiotics over ~100 years</p><p>Critical need for intensive care units</p><p>Novel antibiotics are last resort against MDR pathogens</p><p>Knowledge and technologies for antibiotic R&#x00026;D established and steadily advancing</p><p>High chance of finding new antibiotic classes due to largely underexplored biodiversity</p><p>Large and increasingly diverse chemical libraries available for screening</p><p>Increasingly large and diverse online databases on antibiotic compounds, targets and resistance genes available</p><p>Predictive models available (via integrative chem-bioinformatics, for example PBPK modelling)</p><p>Loss of efficacy controllable by antibiotic stewardship</p><p>Increasing public awareness of AMR demands for and facilitates national and transnational solutions</p></td><td><p>Unavoidable resistance development with classic antibiotics</p><p>Use of antibiotics in agriculture and aquaculture not globally regulated</p><p>Paucity of novel antibiotic classes against Gram-negative priority pathogens</p><p>Lack of innovative assays for hit discovery</p><p>Capacities in academia (MedChem, PK/PD etc.) insufficient for R&#x00026;D project expansion</p><p>High attrition rates until market entry, especially in the early stages of discovery and optimization</p><p>High capital risk and negative ROI mainly for industrial sector</p></td><td><p>New incentives (push and pull factors) to attract industrial stakeholders:</p><p>1. Grants (from governments, health foundations etc.) for innovative programmes, for example, early R&#x00026;D with academia (PPPs)</p><p>2. Alliances of physicians, patients and politics (WHO, EU etc.) advocating for novel antibiotics</p><p>3. Market entry rewards like transferable exclusivity extensions/vouchers (for example, prolonged IP protection of new antibiotic classes or extended protection of other products)</p><p>4. Delinkage models for novel antibiotics (benchmark-based to ensure innovation-driven development)</p><p>5. Patent buyouts or payer licenses in return for public control over pricing and distribution</p><p>6. Long-term benefits through public prestige, advertisement etc.</p><p>Advancing cooperation between academia, health foundations and industry (sharing of libraries, data, discovery and translational know-how, IP etc.)</p><p>Emerging national or international antibiotics research networks, virtual centres and innovation funds</p><p>Academic entrepreneurship (foundation of spin-outs etc.)</p><p>Multiple innovative concepts for non-traditional antibiotics (virulence inhibitors etc.)</p><p>Overcoming existing resistances and/or increase efficiency of antibiotics by using molecules with synergistic action or innovative conjugates</p><p>Hit discovery becoming more efficient by emerging artificial intelligence technologies</p><p>Innovative concepts can improve: (i) in vivo drug delivery, (ii) antibiotic influx in bacterial cells, (iii) antibiotic efflux inhibition</p><p>Careful evaluation of regulatory guidelines based on regional discrepancies (high need versus safety)</p></td><td><p>Rising death toll per year due to AMR</p><p>Loss of expertise in antibiotic R&#x00026;D in both academia and industry</p><p>Disconnect between early R&#x00026;D (left to academia) and clinical stages (industry-dependent)</p><p>Disconnect between researchers and regulatory agencies</p><p>Low-cost structure of generic antibiotics impedes the development of novel classes</p><p>High cost to society (socio-economic burden, increasing patient mortality etc.) over the next decades</p><p>Risk of empty development pipeline if problems (for example, lack of R&#x00026;D funding) are ignored</p></td></tr></tbody></table><table-wrap-foot><p>AMR, antimicrobial resistance; EU, European Union; IP, intellectual property; MDR, multidrug-resistant; MedChem, medicinal chemistry; PBPK, physiologically based pharmacokinetic; PK/PD, pharmacokinetics/pharmacodynamics; PPPs, public&#x02013;private partnerships; R&#x00026;D, research and development; ROI, return on investment; WHO, World Health Organization.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec2"><title>Synthetic hit compounds</title><p id="Par11">Here, we address the development of profitable strategies to identify and prioritize novel antibacterial&#x000a0;<xref rid="Glos6" ref-type="list">hit compounds</xref>, with a particular focus on synthetic small molecules. As a foundation, we introduce three main pillars that represent core elements of fruitful hit discovery programmes.</p><sec id="Sec3"><title>Hit definition, chemical libraries and medicinal chemistry</title><p id="Par12">The concept of &#x02018;hit compound&#x02019;<sup><xref ref-type="bibr" rid="CR72">72</xref></sup> as it is widely accepted today needs to be expanded to address the needs imposed by the threat of antibacterial resistance. In this context, a hit compound is a molecule with reproducible activity, with a defined chemical structure (or set of structures), against one or more bacterial target(s). Although the selectivity and cytotoxicity of initial hits are seen as important characteristics, their improvement should remain tasks for the hit-to-lead optimization phase (see below). The activity of hits against (selected) pathogens must be proven in relevant assays, initially in vitro (for example, using exposed/isolated targets or a whole-cell approach), which can be complemented later in the process by the use of animal models of infection to evaluate pharmacokinetic (PK) and pharmacodynamic (PD) properties. In any event, the chemical identity and integrity of a hit must be demonstrated, whereas the actual target and the precise MoA may remain unknown until a later stage. Thus, the initial activity readout for a hit can be on either the molecular or the cellular level (Box&#x000a0;<xref rid="Sec4" ref-type="sec">1</xref>).</p><p id="Par13">When considering the definition of valuable hits, it is important to look beyond the simple model of a single molecule addressing one particular target. Compounds that hit multiple defined targets (known as polypharmacology<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>), or a combination therapy, in which the effects of several molecules are combined, can be equally valuable<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. Depending on the target(s), hit combinations may act synergistically, preferably with different MoAs, or in an additive fashion. Such combinations can be useful in potentiating the activity of an existing antibiotic, slowing the onset of resistance and restoring the activity of antibiotics that have become inefficient because of resistance.</p><p id="Par14">A major approach to identify novel hit compounds is by high-throughput screening of chemical libraries. It is important to select the correct set of compounds for each screen, for example, a (large) diverse set, a target-focused set or a fragment library. The make-up of a library should be based on specific characteristics or property space requirements, including chemical, structural and physicochemical aspects (Box&#x000a0;<xref rid="Sec5" ref-type="sec">2</xref>); these may be tailored to a particular disease area<sup><xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR76">76</xref></sup>. We believe that carefully designed, and possibly even preselected (&#x02018;biased&#x02019;), chemical libraries, which enable screening of a suitable chemical space against the bacterial target(s) of interest, represent an important first step to start a reliable hit identification campaign towards treatment of a specific bacterial infection. The design, assembly and curation of such libraries are costly processes that require the input of highly skilled practitioners. This frequently falls outside the funding range of most academic groups and, indeed, of many small companies. Models need to be found to grant access to the most useful libraries or compound collections for hit discovery, which should be facilitated at least for non-profit research entities.</p><p id="Par15">Interactions and collaborations between academic researchers and pharmaceutical companies can accelerate hit discovery by, for example, using the high-throughput screening infrastructure of companies to interrogate novel targets. At the same time, pharmaceutical partners might search for close analogues of hits initially identified in academic labs, possibly together with existing biological and chemical property profiles. Such analogue series and accompanying data sets can be extremely valuable in enabling early improvement of antibacterial potency, as well as hit series validation. Pharmaceutical partners might also begin building profiles of absorption, distribution, metabolism, excretion and toxicity (ADMET) parameters, thus, accelerating the hit-to-lead transition. Sharing the relevant information will reinforce the efforts of medicinal chemistry and enhance its reliability and robustness. This, in turn, allows programmes to reach Go/No-Go decisions more quickly and can improve the chances of securing external funding or early partnering deals based on the impact of the medical need.</p><p id="Par16">Notably, medicinal chemistry is the key discipline for the subsequent optimization of hits (see case studies in Boxes&#x000a0;<xref rid="Sec4" ref-type="sec">1</xref>&#x02013;<xref rid="Sec7" ref-type="sec">4</xref>). A lack of sufficient funding and expertise to support medicinal chemistry at this early stage is highly detrimental for the entire translational process. Encouragingly, in 2016, a large number of pharmaceutical companies with interests in AMR signed the AMR Industry Declaration<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>, in which they jointly committed to support antibiotic R&#x00026;D processes at virtually all stages. This has led to the formation of the AMR Industry Alliance (<ext-link ext-link-type="uri" xlink:href="https://www.amrindustryalliance.org/">https://www.amrindustryalliance.org/</ext-link>). Additionally, the implementation of new AMR-specific capital resources, for example, through the REPAIR Impact Fund and the AMR Action Fund, and the direct involvement of PPPs like CARB-X in hit-to-lead campaigns during recent years should lead to intensified collaborations between industry and academia as a near-term goal to drive the chemical optimization of hits and leads forward towards new preclinical candidates.</p><p id="Par17">Those academic groups that have already built the capacity to carry out such optimization efforts, including broad know-how in medicinal chemistry, biological assays and <xref rid="Glos7" ref-type="list">ADMET studies</xref>, would still benefit greatly from early partnering with biopharmaceutical companies, particularly as their projects will stand a greater chance of attracting external investment. Both not-for-profit initiatives, like the European Research Infrastructure Consortium for Chemical Biology and early Drug Discovery (EU-OPENSCREEN; <ext-link ext-link-type="uri" xlink:href="https://www.eu-openscreen.eu/">https://www.eu-openscreen.eu/</ext-link>), and collaborative PPP models as implemented by the European Lead Factory (ELF)<sup><xref ref-type="bibr" rid="CR78">78</xref>,<xref ref-type="bibr" rid="CR79">79</xref></sup>, allowing for open drug discovery programmes based on Europe-wide screening resources (for example, the Joint European Compound Library, JECL), could pave the way for such early cross-sectoral interactions and exchanges for the benefit of all involved partners<sup><xref ref-type="bibr" rid="CR80">80</xref></sup>.</p></sec><sec id="Sec4"><boxed-text><label>Box 1 Early-stage development of a synthetic antibiotic against <italic>Mycobacterium tuberculosis</italic></label><p id="Par18">Historically, the whole-cell assay has generally outclassed target-based methods as the main approach to discover novel antimicrobial drugs. This is particularly true for antitubercular drugs, where the peculiar cellular structure of <italic>Mycobacterium tuberculosis</italic> (Mtb) is responsible for a lack of correspondence between the biochemical and the phenotypic assays. In the case study pictured, a small in-house chemical library was evaluated using phenotypic screening against Mtb to identify novel antitubercular chemotypes. A few 2-aminothiazoles were found to be moderately active, and the initial hit series was expanded to investigate the structure&#x02013;activity relationship (SAR) by iterative medicinal chemistry (MedChem) efforts<sup><xref ref-type="bibr" rid="CR323">323</xref></sup>, leading to highly potent derivatives (minimum inhibitory concentrations (MICs) in the submicromolar range) towards susceptible Mtb. To further promote the advancement of these compounds, additional biological assays were carried out to investigate the activity against multidrug-resistant and extensively drug-resistant Mtb strains, the selectivity over other bacterial species and eukaryotic cells, and the susceptibility to the action of efflux pumps<sup><xref ref-type="bibr" rid="CR324">324</xref></sup>. The next research step was focused on a hit-to-lead optimization based on the convergent analysis of the SAR and structure&#x02013;metabolism relationship. Two metabolic soft spots were identified, and these findings were instrumental for the design of compounds that escaped rapid clearance by human liver microsomes and, at the same time, maintained good antitubercular activity against both drug-susceptible and drug-resistant strains. At this stage, determination of the&#x000a0;<xref rid="Glos8" ref-type="list">mode of action</xref> at a molecular level and assays in animal model(s) of infection represent the next research progressions. Generally, academic drug discovery can suffer from long timescales and limited resources, which, in turn, make the research process difficult to move forward. For instance, academic chemical libraries are unlikely to yield a significant number of hits from a whole-cell screening, despite the intrinsic chemical novelty that characterizes their creation. Partnership with industrial stakeholders should fill the funding gap and add further expertise, for example, on advanced compound design and in vivo studies, to overcome the limitations mentioned above.</p><p id="Par19">ADME, absorption, distribution, metabolism and excretion; <italic>C.alb</italic>, <italic>Candida albicans</italic>; CL&#x02032;<sub>int</sub>, intrinsic clearance; <italic>E.coli</italic>, <italic>Escherichia coli</italic>; <italic>E.fae</italic>, <italic>Enterococcus faecium</italic>; HLM, human liver microsomes; HMDM, human monocyte-derived macrophages; IC<sub>50</sub>, half-maximal inhibitory concentration; MIC<sub>90</sub>, minimum concentration at which 90% of isolates were inhibited; <italic>P.aer</italic>; <italic>Pseudomonas aeruginosa</italic>; <italic>S.aur</italic>, <italic>Staphylococcus aureus</italic>; <italic>T</italic><sub>1/2</sub>, half-life; TB, tuberculosis.<graphic position="anchor" xlink:href="41570_2021_313_Figb_HTML" id="d32e1572"/></p></boxed-text></sec><sec id="Sec5"><boxed-text><label>Box 2 Theoretical example of a focused library design generating new chemical entities within a preferred property space</label><p id="Par20">The chemical drug space has been described as almost infinitely large, with an estimated 10<sup>60</sup> compounds<sup><xref ref-type="bibr" rid="CR325">325</xref></sup>. To exemplify the ease of accessing novel chemical matter within a desired property space<sup><xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR76">76</xref></sup>, a focused small library could be based on commercially available building blocks. In the example shown, the central building block remains constant and two substituents are added, first by arylation of the Boc-deprotected secondary amine<sup><xref ref-type="bibr" rid="CR326">326</xref></sup>, followed by alkylation of the Fmoc-deprotected primary amine following a reductive amination<sup><xref ref-type="bibr" rid="CR327">327</xref></sup>. The in silico design is driven by diversity, clogD (pH 7.4)<sup><xref ref-type="bibr" rid="CR328">328</xref></sup> between &#x02212;2 and 2, molecular weight below 450&#x02009;Da and increased sp<sup>3</sup> content (i.e. level of heavy atom saturation)<sup><xref ref-type="bibr" rid="CR329">329</xref></sup>. This hypothetical pilot library represents 15 aldehydes and 15 heteroarylchlorides to provide a hypothetical 225-compound library, which is shown in comparison with the Novartis (NVS) archive based on polarity (clogD<sub>7.4</sub>) and fraction of sp<sup>3</sup> hybridized carbon atoms (fCsp<sup>3</sup>). All 225 compounds are yet unknown in the public domain (Reaxys, <ext-link ext-link-type="uri" xlink:href="https://www.elsevier.com/solutions/reaxys">https://www.elsevier.com/solutions/reaxys</ext-link>; last accessed May 2021) and absent from the Novartis archive (April 2018).<graphic position="anchor" xlink:href="41570_2021_313_Figc_HTML" id="d32e1629"/></p></boxed-text></sec><sec id="Sec6"><boxed-text><label>Box 3 Development of an anti-virulence therapeutic (&#x02018;pathoblocker&#x02019;) against <italic>Pseudomonas aeruginosa</italic></label><p id="Par21">The concept of interfering with the <italic>Pseudomonas</italic> quinolone signal quorum sensing system for the discovery of pathoblockers against <italic>Pseudomonas aeruginosa</italic> (PA) has been explored in detail by multiple research groups<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. Target validation of the bacterial signal molecule receptor PqsR, which functions as a global virulence regulator, has been achieved using mainly acute murine infection models. A target-driven medicinal chemistry campaign tackling this transcriptional regulator has achieved pre-candidate status starting from a fragment-based approach<sup><xref ref-type="bibr" rid="CR330">330</xref>&#x02013;<xref ref-type="bibr" rid="CR332">332</xref></sup>. After biophysical screening, initial hit selection was guided by selection of enthalpy-driven binders (as determined by isothermal titration calorimetry). Successful growth vector identification enabled the detection of qualified hits with cellular anti-virulence activity and potential for advancement to the lead generation and optimization stages<sup><xref ref-type="bibr" rid="CR331">331</xref></sup>. Hit identification was achieved with institutional resources. However, cost-intensive medicinal chemistry and compound profiling work towards a preclinical profiling candidate was only possible through non-dilutive joint funding, which amounted to approx. 3.5 million euros (m&#x020ac;). The chosen target product profile (TPP) is defined as a pathogen-specific inhaled adjunctive treatment of chronic respiratory PA infections in combination with a standard-of-care (SoC) backbone antibiotic. Resulting pre-candidates have nanomolar on-target and cellular efficacy, potentiate tobramycin efficacy against PA biofilms, show high exposures in vivo (various routes intratracheal, intravenous, subcutaneous, peroral) and no overt findings in safety pharmacology screens<sup><xref ref-type="bibr" rid="CR333">333</xref></sup>. While demonstration of in vivo target engagement by means of signal molecule quantification was achieved swiftly in a mucoid acute murine lung infection model, assaying in vivo treatment efficacy related to the pathoblocker-specific activities remains a considerable challenge. Candidate nomination is, therefore, pending on tedious and expensive exploration of suitable pharmacodynamic (PD) models. Currently, this milestone is pursued through further public funding.</p><p id="Par22">ADMET, absorption, distribution, metabolism, excretion and toxicity; MTD, maximum tolerated dose; PK, pharmacokinetics.<graphic position="anchor" xlink:href="41570_2021_313_Figd_HTML" id="d32e1667"/></p></boxed-text></sec><sec id="Sec7"><boxed-text><label>Box 4 Reassessing chelocardin for improved lead development towards complicated urinary tract infection therapy</label><p id="Par23">The natural product chelocardin (CHD), a member of the atypical tetracyclines that was first described about 60 years ago<sup><xref ref-type="bibr" rid="CR334">334</xref>,<xref ref-type="bibr" rid="CR335">335</xref></sup>, has recently been recovered to generate a novel lead scaffold, amidochelocardin (2-carboxamido-2-deacetyl-chelocardin, CDCHD), by rational biosynthetic engineering<sup><xref ref-type="bibr" rid="CR336">336</xref></sup>. For this purpose, the CHD biosynthetic gene cluster in <italic>Amycolatopsis sulphurea</italic><sup><xref ref-type="bibr" rid="CR337">337</xref></sup> was combined with genes from the oxytetracycline biosynthesis pathway of <italic>Streptomyces rimosus</italic>, and production peak titres of the novel hybrid compound CDCHD up to 400&#x02009;mg&#x02009;l<sup>&#x02212;1</sup> were achieved<sup><xref ref-type="bibr" rid="CR191">191</xref></sup>. CDCHD represents a new broad-spectrum antibiotic active against pathogens of the ESKAPE panel (including a large number of clinical isolates)<sup><xref ref-type="bibr" rid="CR106">106</xref></sup>, which can be routinely supplied at the multi-gram scale with &#x0003e;95% purity by using large-scale in-house fermentation at the Helmholtz Centre for Infection Research (HZI) (~100-l batch cultures) and optimized downstream processing. Due to the lack of cross-resistance to known antibiotics (for example, preserved activity against pathogens carrying multiple tetracycline (TET) resistance determinants), the good production yield and the fact that efficacy for CHD treatment was already shown in a small phase II study<sup><xref ref-type="bibr" rid="CR338">338</xref></sup>, CDCHD was chosen to enter a lead optimization programme (see Acknowledgements). Optimization of CDCHD includes further bioengineering and medicinal chemistry (MedChem) approaches for extensive structure&#x02013;activity relationship profiling, which is currently based on &#x0003e;70 generated analogues with modifications achieved at about ten different scaffold positions<sup><xref ref-type="bibr" rid="CR192">192</xref>,<xref ref-type="bibr" rid="CR339">339</xref></sup>. Extended CDCHD profiling by absorption, distribution, metabolism, excretion and toxicity (ADMET), pharmacokinetics/pharmacodynamics (PK/PD), toxicity studies and validation of therapeutic efficacy in an ascending kidney infection model indicated the use of CDCHD for the treatment of complicated urinary tract infection (cUTI) caused by extended-spectrum &#x003b2;-lactamase (ESBL)-producing Enterobacteriaceae according to the selected target product profile (TPP)<sup><xref ref-type="bibr" rid="CR340">340</xref></sup>. However, further increase in potency is required to achieve higher efficacy in kidneys against clinically most relevant uropathogens, which is essential for preclinical candidate nomination in this project. To achieve this goal, funding limitations in the academic sector shall be overcome by partnering with an industrial stakeholder.</p><p id="Par24">DSP, downstream processing; FoR, frequency of resistance; GN, Gram-negative; m&#x020ac;, million euros; MBC, minimum bactericidal concentration; MIC, minimum inhibitory concentration; MoR, mechanism of resistance.<graphic position="anchor" xlink:href="41570_2021_313_Fige_HTML" id="d32e1724"/></p></boxed-text></sec><sec id="Sec8"><title>Nature of the target</title><p id="Par25">We recommend that hit identification against bacteria follows two convergent approaches: (i) identification of molecules active against molecular targets that are vital for all stages of the bacterial life cycle (&#x02018;essential targets&#x02019;), thus, directly promoting clearance of the bacteria from the host/patient, and (ii) searching for molecules that inhibit so-called &#x02018;non-essential targets&#x02019;<sup><xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR81">81</xref>,<xref ref-type="bibr" rid="CR82">82</xref></sup>. The latter can be defined as bacterial structures that are not vital under standard laboratory growth conditions but become critical during processes of host colonization and infection, for example, by regulating virulence development, by evading host immune response or by triggering bacterial defence mechanisms<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>. Molecules hitting such targets may have weak or even no activity towards bacterial cells under non-infectious (in vitro) screening conditions, but might display highly synergistic or additive effects when tested in relevant in vivo infection models, either alone or in combination with antibacterial agents addressing essential targets. The latter molecules may be found among the current antibacterial arsenal or may be new chemical entities, identified as described above.</p><p id="Par26">Compounds interacting with non-essential targets are usually classified as antibiotic adjuvants, potentiators or resistance breakers<sup><xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup>. Examples of non-essential target inhibitors are represented by:<list list-type="simple"><list-item><label>(i)</label><p id="Par27">Inhibitors of virulence-conferring factors or pathways (also known as anti-virulence compounds or <xref rid="Glos9" ref-type="list">pathoblockers</xref><sup><xref ref-type="bibr" rid="CR86">86</xref></sup> that target, for example, quorum sensing mechanisms<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>, biofilm formation<sup><xref ref-type="bibr" rid="CR88">88</xref></sup>, bacterial secretion systems<sup><xref ref-type="bibr" rid="CR89">89</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>, enzymes for tissue penetration<sup><xref ref-type="bibr" rid="CR91">91</xref></sup> or intracellular survival<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>).</p></list-item><list-item><label>(ii)</label><p id="Par28">Efflux pump inhibitors<sup><xref ref-type="bibr" rid="CR93">93</xref></sup>.</p></list-item><list-item><label>(iii)</label><p id="Par29">Suicide substrates such as &#x003b2;-lactamase inhibitors<sup><xref ref-type="bibr" rid="CR94">94</xref>,<xref ref-type="bibr" rid="CR95">95</xref></sup>.</p></list-item><list-item><label>(iv)</label><p id="Par30">Inhibitors of pathways serving as a mechanism of defence, e.g. glutathione biosynthesis<sup><xref ref-type="bibr" rid="CR96">96</xref>,<xref ref-type="bibr" rid="CR97">97</xref></sup>.</p></list-item><list-item><label>(v)</label><p id="Par31">Modulators and inhibitors of energy metabolism<sup><xref ref-type="bibr" rid="CR98">98</xref>,<xref ref-type="bibr" rid="CR99">99</xref></sup>.</p></list-item><list-item><label>(vi)</label><p id="Par32">Host/pathogen epigenetic modulators<sup><xref ref-type="bibr" rid="CR100">100</xref>,<xref ref-type="bibr" rid="CR101">101</xref></sup>.</p></list-item></list></p><p id="Par33">For some of the mentioned targets, such as efflux pumps, it has been demonstrated that their inhibition can reverse resistance to several antibacterials<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>. Therefore, an attractive therapeutic combination might be composed of a bactericidal agent and an adjuvant molecule, with the aim of potentiating the antibacterial effect(s) and significantly reducing resistance (either intrinsic or evolved)<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. Since the pathoblocker approach is anticipated to be less susceptible towards resistance development and, in addition, to preserve the commensal bacteria of the microbiome<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>, it represents a non-traditional strategy for a focused disarming of resistant high-priority pathogens, most likely to be deployed as an adjunctive therapy in addition to antibiotic standard treatment<sup><xref ref-type="bibr" rid="CR81">81</xref></sup> (Box&#x000a0;<xref rid="Sec6" ref-type="sec">3</xref>).</p></sec><sec id="Sec9"><title>Advanced screening and profiling based on standardized assays</title><p id="Par34">There is a fundamental need for assays to identify hit compounds (both synthetic and natural-product-based hits, the latter are addressed below) specifically for the clinically most relevant indications. In addition to using focused libraries that cover desirable chemical diversity and property space, innovative screens are essential to increase the chances for identifying potent hits against most prevalent common infections associated with <xref rid="Glos10" ref-type="list">Gram-positive</xref> or <xref rid="Glos11" ref-type="list">Gram-negative</xref> pathogens, such as hospital-acquired pneumonia, community-acquired pneumonia, complicated urinary tract infection or complicated intra-abdominal infection<sup><xref ref-type="bibr" rid="CR104">104</xref></sup>. To establish a reliable foundation for future development, both academia and industry must use state-of-the-art library screening procedures based on generally accepted rules and basic concepts of standardization.</p><p id="Par35">It is important that a range of relevant assays is used to thoroughly select and profile novel hit compounds. These assays should have a high physiological significance, which may be applicable to biomimetic assays<sup><xref ref-type="bibr" rid="CR105">105</xref></sup>, for example, by using defined culture media such as artificial urine for activity screens with uropathogens<sup><xref ref-type="bibr" rid="CR106">106</xref>,<xref ref-type="bibr" rid="CR107">107</xref></sup>, iron-depleted media that simulate bacterial growth conditions during bloodstream or wound infections<sup><xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR109">109</xref></sup> or assaying host&#x02013;bacteria interactions<sup><xref ref-type="bibr" rid="CR110">110</xref></sup>. Such schemes can further include the screening for new MoA(s), new drug sensitizing modes, non-killing mechanisms (e.g. anti-virulence factors like pathoblockers), compounds acting against biofilms and molecules acting synergistically with existing or new antimicrobials to overcome drug resistance<sup><xref ref-type="bibr" rid="CR111">111</xref>&#x02013;<xref ref-type="bibr" rid="CR114">114</xref></sup>. Similarly, because hits generated by conventional biochemical assays or screens often fail to become whole-cell active leads, alternative phenotypic assays such as novel target-based whole-cell screening<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> are also a promising foundation for the identification of useful hits. Even known chemical libraries (including proprietary compound archives of pharmaceutical companies), which have failed to deliver antibacterial hits by simple growth inhibition measurement, might bear fruit if reassayed following these approaches. The way in which these innovative screens are envisaged could make them a more appropriate strategy to provide novel hits with a potential therapeutic impact compared with the molecular-target-based drug design approach<sup><xref ref-type="bibr" rid="CR116">116</xref></sup>.</p><p id="Par36">A further aim of the consortium is to design and develop informative assays that can provide information about the desired antibacterial effect, together with further characteristics such as target engagement, bacterial penetration characteristics (for example, kinetics of compound permeation through Gram-negative cell envelope models<sup><xref ref-type="bibr" rid="CR117">117</xref>,<xref ref-type="bibr" rid="CR118">118</xref></sup>) and potential cytotoxicity.</p><p id="Par37">In addition to devising standardized panels of assays according to contemporary technology, developing the respective standard operating procedures (SOPs) is mandatory to meet the requirements for good research practice, which facilitates the transfer of compounds with potential to become new drugs from academia to non-profit or private organizations for continued development. By using standardized proof-of-concept assays under predefined SOPs, more robust hit series will emerge, increasing their potential for late-stage development and minimizing reproducibility issues. For example, <xref rid="Glos12" ref-type="list">minimum inhibitory concentrations</xref>, and possibly also&#x000a0;<xref rid="Glos13" ref-type="list">minimum bactericidal concentrations</xref>, should always be evaluated in a screening campaign, for example, by using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (<ext-link ext-link-type="uri" xlink:href="https://eucast.org/">https://eucast.org/</ext-link>) or the Clinical and Laboratory Standards Institute (CLSI) (<ext-link ext-link-type="uri" xlink:href="https://clsi.org/meetings/ast/">https://clsi.org/meetings/ast/</ext-link>) guidelines. In addition, selected hits from standard screening panels should be consequently tested against contemporary clinical isolates to demonstrate that they overcome existing resistance mechanisms.</p><p id="Par38">Owing to the high attrition rates from early hit discovery to advanced hits and leads, it is especially important in the field of antibacterials to diversify and generate multiple hit series, and to characterize them thoroughly regarding all features that appear relevant to the intended therapeutic use. This includes explorations to expand scaffold diversity in the context of understanding the target-based chemical and physicochemical requirements, as well as potential liabilities, like ADMET.</p><p id="Par39">A summary of early target hit profiles is essential to nominate the most valuable hit series acting against the pathogen(s) or medical indication(s) of interest. The selection of hit series for lead generation follows the <xref rid="Glos14" ref-type="list">target candidate profile</xref> (TCP), which is predefined at the outset of the development programme according to the desired&#x000a0;<xref rid="Glos15" ref-type="list">target product profile</xref> (TPP) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Thus, the optimization of hits should generally be driven by TCPs and compound progression criteria that, in turn, are driven by chosen TPPs. If several TPPs have been selected or outlined for a campaign, for example, based on different indications, together with their corresponding TCPs, it has to be decided which TCP should be used as a base to aim at for a given chemical series or possibly natural-product-based hit that emerges from mining of biological sources (see below).<fig id="Fig2"><label>Fig. 2</label><caption><title>Summary of major steps and processes in antibacterial drug discovery and development.</title><p>Approaches marked with * can be linked with emerging artificial intelligence (AI)-based technology, for example, for advanced data mining, screening or property predictions, to increase efficiency and outcome. ADMET, absorption, distribution, metabolism, excretion and toxicity; CTA, clinical trial application; DRF, dose range finding; EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; FoR, frequency of resistance; GLP, good laboratory practice; ICH, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; IND, investigational new drug; MedChem, medicinal chemistry; MICs, minimal inhibitory concentrations; MoR, mechanism of resistance; phys-chem, physicochemical properties; PK/PD, pharmacokinetics/pharmacodynamics; POC, proof of concept; SAR, structure&#x02013;activity relationship; TPP, target product profile.</p></caption><graphic xlink:href="41570_2021_313_Fig2_HTML" id="d32e1978"/></fig></p><p id="Par40">It is important to implement physicochemical and in vitro ADMET profiling at the start of hit optimization, to make sure that any PK issues are identified early and can be addressed through the entire chemistry programme. In this respect, a standardized list of essential compound properties is required for successful transfer of hits and early leads into the following discovery and development stages. Depending on the defined TPP, such a dossier on physicochemical and biological properties should comprise a set of minimal criteria for compound progression based on selected, standardized assays or attributes with clear benchmarks for transition to the next stages in the drug discovery pathway and for continued (pre)clinical development according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines (<ext-link ext-link-type="uri" xlink:href="https://www.ich.org/page/ich-guidelines">https://www.ich.org/page/ich-guidelines</ext-link>). This will help to ensure developable compounds of clinical relevance are produced, which are also attractive for potential industrial partners. Relevant parameters (depending on the particular stage of transition) may include:<list list-type="bullet"><list-item><p id="Par41">Potency/cellular activity (e.g. based on minimum inhibitory concentrations and minimum bactericidal concentrations).</p></list-item><list-item><p id="Par42">Chemical and metabolic stability, solubility, permeability (e.g. based on logP or, for ionizable compounds, logD, or complex membrane partitioning).</p></list-item><list-item><p id="Par43">Distribution, efflux avoidance, selectivity/off-target avoidance (e.g. inhibition assays on receptor panels, hERG etc.).</p></list-item><list-item><p id="Par44">Acid/base properties based on p<italic>K</italic><sub>a</sub>.</p></list-item><list-item><p id="Par45">Cytotoxicity (especially human cell lines).</p></list-item><list-item><p id="Par46">Lack of reactive metabolites.</p></list-item><list-item><p id="Par47">Phototoxicity.</p></list-item><list-item><p id="Par48">Protein binding.</p></list-item><list-item><p id="Par49">In vivo efficacy and human dose prediction.</p></list-item><list-item><p id="Par50">(Oral) bioavailability.</p></list-item><list-item><p id="Par51">Genotoxicity (e.g. based on Ames or mouse micronucleus tests).</p></list-item><list-item><p id="Par52">Drug&#x02013;drug interactions.</p></list-item><list-item><p id="Par53">PK linearity.</p></list-item><list-item><p id="Par54">Safety (in vivo toxicity).</p></list-item><list-item><p id="Par55">Compound access (e.g. synthetic feasibility and scaling up to gram or kilogram).</p></list-item><list-item><p id="Par56">Achievable degree of purity.</p></list-item><list-item><p id="Par57">Formulation.</p></list-item></list></p><p id="Par58">Once the hit discovery transitions into the hit-to-lead and lead optimization phases (see below), it is necessary to enlarge the scope of biological studies. These may include bacterial killing kinetics, MoA, frequency of resistance, <xref rid="Glos16" ref-type="list">mechanism of resistance</xref> and PK/PD analyses, which will deliver valuable parameters to assess a compound&#x02019;s in vivo efficacy (assuming sufficient free drug exposure in a relevant animal model with acceptable tolerability). At this level, it is, once again, important to acquire information on a substantial number of structurally related analogues through extensive medicinal chemistry efforts (perhaps in collaboration with PPPs or the pharmaceutical industry, as suggested above) in order to establish clear and reliable dossiers of structure&#x02013;activity relationship (SAR) and structure&#x02013;property relationship. These data are essential to consistently improve all the required parameters as a basis for a continuous advancement of lead structures towards the selection of (pre)clinical candidates. Computational methods based on machine learning techniques like profile-quantitative structure&#x02013;activity relationship (pQSAR) can help to build predictive models regarding activity, selectivity, toxicity, MoA and further parameters for specific compound classes, hence, providing valuable in silico input for more effective hit discovery and lead design<sup><xref ref-type="bibr" rid="CR119">119</xref>,<xref ref-type="bibr" rid="CR120">120</xref></sup>.</p></sec></sec><sec id="Sec10"><title>Natural-product-based hit compounds</title><p id="Par59">Historically, microbial natural products have been the most important source of antibiotic&#x000a0;<xref rid="Glos17" ref-type="list">lead compounds</xref>; over the last 40 years, about 60% of all new chemical entities in the field of antibacterials were based on or derived from natural products<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>. Here, to complement the key aspects described above for synthetic hits, we outline the major requirements specific to the identification and prioritization of antibacterial natural product hits. We focus on efficiency and, particularly for the academic sector, achievability in terms of technological and financial demands.</p><sec id="Sec11"><title>Identification of new chemotypes from natural sources</title><p id="Par60">The known antibiotic activity of natural products has, in general, been identified by phenotypic screening campaigns that determine activity against panels of test organisms in standardized assays. These screens, which constitute the basis for bioactivity-guided isolation of natural products from complex mixtures, efficiently retrieve bioactive compounds when libraries of crude extracts are evaluated. However, their ability to reveal useful novelty is limited by both a high rediscovery rate of already known molecules associated with pre-existing resistance mechanisms, as well as a substantial proportion of hits that show significant cytotoxicity or poor ADMET properties.</p><p id="Par61">We emphasize that there is a general lack of efficient tools and strategies to increase the number of new chemotypes and to reduce the rediscovery rates in antibacterial screening approaches. Even on a global scale, the number of newly discovered chemotypes, especially novel scaffolds acting against&#x000a0;Gram-negative bacteria, is consistently low. Several approaches are relevant to improve this situation:</p><p id="Par62">One possibility to enforce the identification of new antibacterial chemistry is to limit screening of already broadly characterized groups of secondary metabolite producers, for example, actinomycetes, and to expand efforts on identifying new types of producers by extensive biodiversity mining. This can be achieved by focusing on the ~99.999% of microbial taxa of the Earth&#x02019;s microbiome that remain undiscovered<sup><xref ref-type="bibr" rid="CR122">122</xref>,<xref ref-type="bibr" rid="CR123">123</xref></sup>, including the as yet underexplored taxa of human and animal microbiomes<sup><xref ref-type="bibr" rid="CR124">124</xref>&#x02013;<xref ref-type="bibr" rid="CR127">127</xref></sup>. Emerging innovative isolation and cultivation techniques such as diffusion bioreactors (also carried out on the microscale as with the iChip<sup><xref ref-type="bibr" rid="CR128">128</xref>&#x02013;<xref ref-type="bibr" rid="CR130">130</xref></sup>), microfluidics<sup><xref ref-type="bibr" rid="CR131">131</xref>&#x02013;<xref ref-type="bibr" rid="CR133">133</xref></sup>, elicitors<sup><xref ref-type="bibr" rid="CR134">134</xref></sup> and various co-cultivations<sup><xref ref-type="bibr" rid="CR135">135</xref>,<xref ref-type="bibr" rid="CR136">136</xref></sup> will help to access and understand the rare and less-studied groups of microorganisms from diverse habitats<sup><xref ref-type="bibr" rid="CR137">137</xref>&#x02013;<xref ref-type="bibr" rid="CR139">139</xref></sup>. Further, molecular (co-)evolution acting to generate novel metabolites for efficient microbial warfare could be exploited<sup><xref ref-type="bibr" rid="CR140">140</xref>,<xref ref-type="bibr" rid="CR141">141</xref></sup>, for example, by sampling from environments heavily contaminated with antibiotics (like sewage in Southeast Asia or South America), which are known to contain highly resistant microbes<sup><xref ref-type="bibr" rid="CR142">142</xref>,<xref ref-type="bibr" rid="CR143">143</xref></sup>. Complementarily, this can be achieved by laboratory exposure of potent producers to subinhibitory antibiotic concentrations<sup><xref ref-type="bibr" rid="CR144">144</xref></sup> or by co-culturing them together with drug-resistant (pathogenic) strains<sup><xref ref-type="bibr" rid="CR145">145</xref></sup>. Beyond microbial producers, a great variety of plants<sup><xref ref-type="bibr" rid="CR146">146</xref>,<xref ref-type="bibr" rid="CR147">147</xref></sup>, macroscopic filamentous fungi (e.g. Basidiomycota)<sup><xref ref-type="bibr" rid="CR148">148</xref></sup> and animals<sup><xref ref-type="bibr" rid="CR149">149</xref></sup> bear the potential to deliver useful compounds as a base for novel antimicrobials. Altogether, the exploration of untapped biological resources, which represent a major reservoir for future therapeutics, should generally be extended within the academic and industrial sector.</p><p id="Par63">After genome mining of novel microbial isolates or metagenome-driven discovery of novel natural products<sup><xref ref-type="bibr" rid="CR150">150</xref>&#x02013;<xref ref-type="bibr" rid="CR153">153</xref></sup>, selected&#x000a0;<xref rid="Glos18" ref-type="list">biosynthetic gene clusters</xref> (BGCs) that potentially produce unknown secondary metabolites should be systematically expressed in specialized heterologous host strains<sup><xref ref-type="bibr" rid="CR154">154</xref>&#x02013;<xref ref-type="bibr" rid="CR156">156</xref></sup>. This helps to facilitate a straightforward detection and isolation of the new compounds, particularly if their BGCs are &#x02018;silent&#x02019; (i.e. not expressed under known conditions) in the native host. Such heterologous hosts or chassis strains can be based on microbial species that commonly produce a large variety of natural products, but have been made devoid of their own secondary metabolite BGCs and/or have been further optimized to efficiently express BGCs originating from &#x02018;non-common&#x02019; sources (for example, rare actinomycetes or fungi)<sup><xref ref-type="bibr" rid="CR154">154</xref>,<xref ref-type="bibr" rid="CR157">157</xref>,<xref ref-type="bibr" rid="CR158">158</xref></sup>. However, only a limited set of such specialized host strains is available so far, and a much more diverse array of microbial chassis needs to be developed to fit the demands of a growing arsenal of BGCs that potentially produce novel chemistry. BGC expression is often most successful in strains closely related to the native producer, and, thus, it is important to develop methods for standardized heterologous expression in selected host strains with desirable properties that have not yet been domesticated for the use as regular chassis<sup><xref ref-type="bibr" rid="CR159">159</xref></sup>.</p><p id="Par64">Chemical space can also be enlarged by using emerging synthetic biology approaches for medium-to-high-throughput genome editing and pathway engineering. These approaches, which are primarily based on <xref rid="Glos19" ref-type="list">CRISPR/Cas9</xref> (refs<sup><xref ref-type="bibr" rid="CR160">160</xref>,<xref ref-type="bibr" rid="CR161">161</xref></sup>) and diverse recombination, assembly and integrase systems<sup><xref ref-type="bibr" rid="CR162">162</xref>&#x02013;<xref ref-type="bibr" rid="CR164">164</xref></sup>, can be followed up with advanced analytics and screening of the potentially modified natural products, which may be produced in only trace quantities. This technology involves the extensive use of information on genome sequences, enzyme activities and compound structures collected by publications, databases and web tools (such as MIBiG<sup><xref ref-type="bibr" rid="CR165">165</xref></sup>, antiSMASH<sup><xref ref-type="bibr" rid="CR166">166</xref></sup> and PRISM<sup><xref ref-type="bibr" rid="CR167">167</xref></sup>) over the past few decades. In many cases, the modularity of the BGC composition, which is found in gene clusters, for example, coding for polyketide synthases or non-ribosomal peptide synthetases, can be used to implement a bioinformatics-supported plug-and-play diversification strategy enabling the exchange and recombination of core units, as well as modifying enzymes<sup><xref ref-type="bibr" rid="CR168">168</xref>&#x02013;<xref ref-type="bibr" rid="CR171">171</xref></sup>. A concomitant refactoring of BGCs, especially from rare microbial sources, often allows high-level heterologous production of the antibiotic compounds in suitable hosts<sup><xref ref-type="bibr" rid="CR172">172</xref>&#x02013;<xref ref-type="bibr" rid="CR175">175</xref></sup>. However, these methods are still in their infancy and require wider testing with different classes of antimicrobials to define general principles of feasibility and scalability, which, furthermore, necessitates an improved understanding of the complex biosynthetic machineries and their modular evolution.</p><p id="Par65">Advances in analytical chemistry techniques, for example, in mass-spectrometry-based metabolomics and its enhancement by molecular networking and the application of machine learning, support the process of dereplication<sup><xref ref-type="bibr" rid="CR176">176</xref></sup> during (secondary) metabolome mining<sup><xref ref-type="bibr" rid="CR177">177</xref>&#x02013;<xref ref-type="bibr" rid="CR181">181</xref></sup>. Known compounds produced in reasonably high yields can be rapidly identified via their high-resolution masses, tandem mass spectrometry fragmentation patterns or structural data in secondary metabolite databases<sup><xref ref-type="bibr" rid="CR138">138</xref>,<xref ref-type="bibr" rid="CR182">182</xref>&#x02013;<xref ref-type="bibr" rid="CR187">187</xref></sup>. However, the remaining bottleneck is to highlight and annotate novel antibiotic compounds, particularly those with low production titres, as early as possible in the discovery process (i.e. from crude extracts if possible, without the need for small-scale fractionation and enrichment). This objective can be supported by innovative extraction methods prior to bioactivity-guided isolation of novel compounds<sup><xref ref-type="bibr" rid="CR188">188</xref></sup>.</p><p id="Par66">In addition, revisiting known potent antibiotics, previously neglected as a result of unacceptable or non-addressable properties such cytotoxicity or lack of stability, can be a valuable strategy to provide novel leads and candidates. The reassessment of such scaffolds can be based on a variety of efforts, including the improvement of production and purification<sup><xref ref-type="bibr" rid="CR189">189</xref></sup>, reconsideration of application and effective dose for natural derivatives<sup><xref ref-type="bibr" rid="CR190">190</xref></sup>, or advantageous scaffold modification by biosynthetic engineering and semi-synthetic approaches<sup><xref ref-type="bibr" rid="CR191">191</xref>,<xref ref-type="bibr" rid="CR192">192</xref></sup> (Box&#x000a0;<xref rid="Sec7" ref-type="sec">4</xref>).</p><p id="Par67">Further opportunities remain to improve the discovery and development of agents for combination therapy as indicated above, i.e. compounds that act synergistically against multidrug-resistant and/or high-priority pathogens<sup><xref ref-type="bibr" rid="CR193">193</xref>,<xref ref-type="bibr" rid="CR194">194</xref></sup>. The discrimination of specific synergistic activities from non-specific antibiotic activities remains a challenge during the discovery process.</p><p id="Par68">Improving bacterial target access, enhancing potency and broadening the antimicrobial spectrum of known and novel antibiotic scaffolds can be achieved by using drug-conjugate strategies, for example, linking of pathogen-specific antibodies<sup><xref ref-type="bibr" rid="CR195">195</xref>,<xref ref-type="bibr" rid="CR196">196</xref></sup>, siderophore moieties<sup><xref ref-type="bibr" rid="CR197">197</xref>,<xref ref-type="bibr" rid="CR198">198</xref></sup> or positively charged peptides<sup><xref ref-type="bibr" rid="CR199">199</xref>,<xref ref-type="bibr" rid="CR200">200</xref></sup> to the antibiotic core scaffold. Though these approaches have been proven effective in a number of cases, some of them may also have unintended effects, such as a spontaneously increasing frequency of resistance, which can be problematic, for example, in the case of the&#x000a0;<xref rid="Glos20" ref-type="list">Trojan Horse approach</xref><sup><xref ref-type="bibr" rid="CR201">201</xref></sup>.</p><p id="Par69">Overall, a variety of innovative and complementary technologies is required to improve access to novel natural product scaffolds. Computational methods can provide powerful assistance at different levels in many of the areas indicated above, as recent efforts show<sup><xref ref-type="bibr" rid="CR202">202</xref>,<xref ref-type="bibr" rid="CR203">203</xref></sup>. In this context, artificial intelligence might play a game-changing role in the future. The general power of neural networks for detecting new antimicrobial candidates has already been demonstrated<sup><xref ref-type="bibr" rid="CR202">202</xref></sup>. By using a computational model that screens hundreds of millions of chemical compounds in a few days, potential antibiotics even with new MoA(s) could be proposed rapidly. Given the recent advances in artificial intelligence, these and other models will likely add to the future identification of new candidate drugs.</p><p id="Par70">Interestingly, when looking at compound properties, it appears that there is often more flexibility in the selection of &#x02018;successful&#x02019; natural product scaffolds compared with synthetics, for example, regarding Lipinski&#x02019;s rule of five<sup><xref ref-type="bibr" rid="CR204">204</xref>&#x02013;<xref ref-type="bibr" rid="CR206">206</xref></sup>, which natural products frequently &#x02018;disobey&#x02019; (such as cyclosporine or macrolides like azithromycin). Thus, antimicrobial drug discovery in &#x02018;beyond rule of five&#x02019; chemical space is an opportunity when using natural compound collections or when assembling libraries of de novo designed compounds<sup><xref ref-type="bibr" rid="CR207">207</xref>&#x02013;<xref ref-type="bibr" rid="CR209">209</xref></sup>, though the general need for optimizing key pharmacological properties of such hits remains beyond question.</p><p id="Par71">Another major challenge for natural products can be the generation of structurally diverse analogues (particularly if they are not accessible through biosynthesis). Many scaffold positions can be difficult to access by means of semi-synthesis and, thus, broad derivatization of natural-product-based hit and lead compounds is often much more labour-intensive, and establishing synthetic access to these scaffolds with a focus on the ability to systematically diversify their chemical space can require large amounts of resources<sup><xref ref-type="bibr" rid="CR210">210</xref></sup>. Nevertheless, the modification of natural scaffolds with substituents that are often easier to incorporate by (semi-)synthetic or chemoenzymatic approaches, such as halogens that allow the modulation of solubility, permeability, selectivity, target affinity etc.<sup><xref ref-type="bibr" rid="CR211">211</xref>,<xref ref-type="bibr" rid="CR212">212</xref></sup>, proves that multiple opportunities arise when combining synthetic and biological chemistry.</p></sec><sec id="Sec12"><title>Required access to biological and chemical material and data</title><p id="Par72">Many scientists frequently experience difficulty in accessing and sharing research material from third parties, including microbial strains, cultivation extracts, pure compounds, genome or gene cluster sequences and further background data (of published or even unpublished results). For example, an interesting BGC is identified in publicly accessible databases, but the strain is not specified or not available from the indicated source. Similarly, access to industrial antibiotic overproducers can be impossible, even when a company no longer has a commercial interest in the resulting molecule. This phenomenon has several origins, including legal restraints (for example, imposed by the Nagoya Protocol<sup><xref ref-type="bibr" rid="CR213">213</xref></sup>) or intellectual property (IP) claims on strains, compounds, biologics or (re)profiling data of already known structures.</p><p id="Par73">In the public interest, standardized procedures are necessary to facilitate access to research materials and to solve IP conflicts, at least within the field of academia, in which it is common practice to share research materials with colleagues by negotiating appropriate cooperation agreements.</p><p id="Par74">Further, the access to in-house compound libraries of pharmaceutical companies (at least subsets of them and especially those that are not intended for antibiotic-related screening) could be very valuable for academic partners who are eager to identify novel antibacterial hits, which could lead to joint drug development programmes. Enabling access to materials can also be extended to strain collections, including clinical isolates representing the diversity of pathogens associated with a certain clinical indication, and advanced compound information based on pre-existing characterization and profiling campaigns. An increased availability of these resources will be of great benefit to the antimicrobial research community worldwide.</p><p id="Par75">Furthermore, comprehensive databases and data-sharing platforms can provide another valuable resource for present and future antibiotic R&#x00026;D projects and, hence, should be implemented and maintained with care<sup><xref ref-type="bibr" rid="CR214">214</xref></sup>. There is a growing body of recently initiated and publicly available web-based tools and archives that support accumulation and exchange of data regarding antibacterial compounds in different stages of discovery or therapeutic development, known or predicted antibiotic targets and the diversity of antimicrobial resistance determinants (Box&#x000a0;<xref rid="Sec13" ref-type="sec">5</xref>). Further connection and integration of such databases is desirable to optimize the output for a specific search request. In addition, initiatives comparable with the European Commission&#x02019;s manifesto to maximize the public accessibility of research results in the fight against COVID-19 (ref.<sup><xref ref-type="bibr" rid="CR215">215</xref></sup>) are also highly recommended to support AMR-related scientific research at all levels, including facilitated access to online resources.</p></sec><sec id="Sec13"><boxed-text><label>Box 5 Examples of public databases and tools related to antimicrobial compounds, targets and resistance</label><p id="Par76">
<list list-type="bullet"><list-item><p id="Par77">
<bold><italic>Discovery of antibacterial compounds and development into (potential) therapeutics:</italic></bold>
</p></list-item></list>
</p><p id="Par78">
<ext-link ext-link-type="uri" xlink:href="https://db.co-add.org/downloads/">https://db.co-add.org/downloads/</ext-link>
</p><p id="Par79">
<ext-link ext-link-type="uri" xlink:href="https://globalamrhub.org/dynamic-dashboard/">https://globalamrhub.org/dynamic-dashboard/</ext-link>
</p><p id="Par80">
<ext-link ext-link-type="uri" xlink:href="https://chemdb.niaid.nih.gov/DrugDevelopmentTB.aspx">https://chemdb.niaid.nih.gov/DrugDevelopmentTB.aspx</ext-link>
</p><p id="Par81">
<ext-link ext-link-type="uri" xlink:href="https://coconut.naturalproducts.net/">https://coconut.naturalproducts.net/</ext-link>
</p><p id="Par82">
<ext-link ext-link-type="uri" xlink:href="https://zinc.docking.org/">https://zinc.docking.org/</ext-link>
</p><p id="Par83">
<ext-link ext-link-type="uri" xlink:href="https://revive.gardp.org/resources/">https://revive.gardp.org/resources/</ext-link>
</p><p id="Par84">
<ext-link ext-link-type="uri" xlink:href="https://go.drugbank.com/">https://go.drugbank.com/</ext-link>
</p><p id="Par85">
<ext-link ext-link-type="uri" xlink:href="https://www.antibioticdb.com/">https://www.antibioticdb.com/</ext-link>
</p><p id="Par86">
<ext-link ext-link-type="uri" xlink:href="https://www.pewtrusts.org/en/research-and-analysis/articles/2018/09/21/the-shared-platform-for-antibiotic-research-and-knowledge">https://www.pewtrusts.org/en/research-and-analysis/articles/2018/09/21/the-shared-platform-for-antibiotic-research-and-knowledge</ext-link>
</p><p id="Par87">
<ext-link ext-link-type="uri" xlink:href="https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2014/antibiotics-currently-in-clinical-development">https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2014/antibiotics-currently-in-clinical-development</ext-link>
</p><p id="Par88">
<ext-link ext-link-type="uri" xlink:href="https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2017/nontraditional-products-for-bacterial-infections-in-clinical-development">https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2017/nontraditional-products-for-bacterial-infections-in-clinical-development</ext-link>
</p><p id="Par89">
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/who-antibacterial-preclinical-pipeline-review">https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/who-antibacterial-preclinical-pipeline-review</ext-link>
</p><p id="Par90">
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens">https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens</ext-link>
</p><p id="Par91">
<list list-type="bullet"><list-item><p id="Par92">
<bold><italic>Antimicrobial target search and prediction:</italic></bold>
</p></list-item></list>
</p><p id="Par93">
<ext-link ext-link-type="uri" xlink:href="https://pypi.org/project/targetDB/">https://pypi.org/project/targetDB/</ext-link>
</p><p id="Par94">
<ext-link ext-link-type="uri" xlink:href="https://platform.opentargets.org/">https://platform.opentargets.org/</ext-link>
</p><p id="Par95">
<ext-link ext-link-type="uri" xlink:href="https://arts.ziemertlab.com/">https://arts.ziemertlab.com/</ext-link>
</p><p id="Par96">
<list list-type="bullet"><list-item><p id="Par97">
<bold><italic>Antimicrobial resistance:</italic></bold>
</p></list-item></list>
</p><p id="Par98">
<ext-link ext-link-type="uri" xlink:href="https://card.mcmaster.ca/">https://card.mcmaster.ca/</ext-link>
</p><p id="Par99">
<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/">https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/</ext-link>
</p><p id="Par100">
<ext-link ext-link-type="uri" xlink:href="https://bench.cs.vt.edu/deeparg">https://bench.cs.vt.edu/deeparg</ext-link>
</p><p id="Par101">
<ext-link ext-link-type="uri" xlink:href="https://github.com/abu034004/PARGT">https://github.com/abu034004/PARGT</ext-link>
</p></boxed-text></sec><sec id="Sec14"><title>Prediction of antimicrobial structure and function from genome sequence data</title><p id="Par102">Driven by breakthroughs in sequencing technologies and genome mining, the identification of BGCs encoding the biosynthesis of natural products has matured to complement the chemistry-driven and bioactivity-driven screening processes for natural product hits. Computational methods are established and continuously improved to identify novel biosynthetic pathways in (meta)genomic sequence data<sup><xref ref-type="bibr" rid="CR150">150</xref>,<xref ref-type="bibr" rid="CR151">151</xref></sup>. Recently, third-generation genome sequencing techniques such as PacBio and Oxford Nanopore have been developed that provide high-quality full genome data even for complex microorganisms like filamentous fungi at reasonable cost, which is an ideal prerequisite for large-scale genome mining approaches<sup><xref ref-type="bibr" rid="CR216">216</xref></sup>.</p><p id="Par103">However, linking the obtained sequence information to possible structural or functional features of the encoded molecules remains a great challenge. Prediction of chemical structures directly from genome data would help to distinguish known from potentially novel scaffolds during a very early stage of dereplication; the training of machine learning algorithms with sufficient quantity of genome data from microbial producers could ultimately lead to fairly accurate predictions of chemical structures linked to specific BGCs and possibly even their biological activities<sup><xref ref-type="bibr" rid="CR167">167</xref></sup>.</p><p id="Par104">A successful strategy to decipher antibacterial targets of new natural products, without the need to isolate them, is a directed search for known resistance factors in the genomes of antibiotic-producing microbes<sup><xref ref-type="bibr" rid="CR217">217</xref>,<xref ref-type="bibr" rid="CR218">218</xref></sup>. These producers may code for resistant variants of the molecular target(s) that interact with the intrinsic antibiotic(s) without damaging the host or conserved class-specific transporters that release the compound(s) into the environment. This approach recently led to the discovery of novel antibiotic scaffolds<sup><xref ref-type="bibr" rid="CR219">219</xref></sup>. However, most BGCs do not contain apparent or specific drug-resistance genes that could straightforwardly indicate a compound&#x02019;s function. In the majority of cases, very limited predictions based on genomic data concerning function and potential target(s) of a natural product are currently possible, although advanced automated tools for target-directed genome mining are available<sup><xref ref-type="bibr" rid="CR220">220</xref></sup>. Thus, there is a high demand for innovative methods to predict the molecular function or target of a natural compound based on genomic data. Such data would be extremely valuable in order to prioritize BGCs for experimental characterization. In the future, artificial intelligence approaches, based on either classical machine learning methods (extracting new knowledge from preprocessed data sets) or on deep learning (drawing conclusions from raw data such as representative examples, often by using multilayer neural networks), may deliver such predictions with increasing accuracy<sup><xref ref-type="bibr" rid="CR221">221</xref></sup>. However, existing algorithms need to be improved, and new ones have to be developed to specifically address the question of how to assign target-based functions to natural products with confidence during the early stages of discovery and prioritization. These approaches also require a huge amount of validated training data<sup><xref ref-type="bibr" rid="CR222">222</xref></sup>.</p></sec></sec><sec id="Sec15"><title>Advancing hits to (pre)clinical status</title><p id="Par105">Regardless of whether antibacterial hits emerge from rationally designed synthetic molecules or from the pool of natural products, the subsequent hit-to-lead and lead-to-candidate optimization phases are very similar for compounds irrespective of origin (&#x02018;Y model&#x02019;, see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). We now discuss the most critical obstacles and requirements for delivering those advanced leads that may eventually become the next generation of (pre)clinical candidates.</p><sec id="Sec16"><title>Drug&#x02013;target interaction studies as a base for hit development</title><p id="Par106">For hits arising from phenotypic assays, cellular MoA(s) or specific molecular target(s) may not be known at the hit-to-lead stage, and, sometimes, the precise MoA is elucidated years after the approval of a drug, as in the case of daptomycin<sup><xref ref-type="bibr" rid="CR223">223</xref></sup>. However, detailed insight into the mechanism(s) by which compounds exert their pharmacological activity is highly desirable for further rational optimization of chemical scaffolds, particularly when structurally enabled approaches can be used, for a convincing presentation of preclinical candidate dossiers and for regulatory requirements. Since universally applicable methods for characterizing the MoA(s) of antibiotics do not exist, a full suite of expertise in genetics, genomics, microbiology, chemical biology and biophysics is required. Identification of the molecular target can be achieved by targeted screens of indicator or mutant strains, whole-genome sequencing upon focused resistance development<sup><xref ref-type="bibr" rid="CR224">224</xref>,<xref ref-type="bibr" rid="CR225">225</xref></sup>, pattern recognition techniques based on transcriptomics<sup><xref ref-type="bibr" rid="CR226">226</xref></sup>, imaging<sup><xref ref-type="bibr" rid="CR227">227</xref>,<xref ref-type="bibr" rid="CR228">228</xref></sup>, metabolomics<sup><xref ref-type="bibr" rid="CR229">229</xref></sup>, macromolecular synthesis<sup><xref ref-type="bibr" rid="CR230">230</xref>,<xref ref-type="bibr" rid="CR231">231</xref></sup> or mutant fitness profiles<sup><xref ref-type="bibr" rid="CR232">232</xref>,<xref ref-type="bibr" rid="CR233">233</xref></sup>, which can be coupled with machine learning approaches for directed predictions<sup><xref ref-type="bibr" rid="CR225">225</xref>,<xref ref-type="bibr" rid="CR233">233</xref></sup>, or chemoproteomics<sup><xref ref-type="bibr" rid="CR234">234</xref>,<xref ref-type="bibr" rid="CR235">235</xref></sup>. The latter is specifically useful in the case of non-essential target inhibitors like pathoblockers, since these may not generate resistant mutants (at least under standard laboratory conditions). Additional techniques for MoA studies may include crystallography, a diverse set of spectroscopic and calorimetric analyses<sup><xref ref-type="bibr" rid="CR236">236</xref>&#x02013;<xref ref-type="bibr" rid="CR240">240</xref></sup>, as well as the use of functionalized derivatives (&#x02018;tool compounds&#x02019;)<sup><xref ref-type="bibr" rid="CR241">241</xref>,<xref ref-type="bibr" rid="CR242">242</xref></sup>, which can support both target identification and validation and may provide in-depth information of drug&#x02013;target interactions to drive the rational hit-to-lead optimization process forward. Alternatively, identification of drug&#x02013;target (or ligand&#x02013;protein) interactions formed under native (unbiased) conditions by using specialized proteomic approaches is becoming increasingly successful<sup><xref ref-type="bibr" rid="CR243">243</xref>&#x02013;<xref ref-type="bibr" rid="CR246">246</xref></sup>. Current bioinformatic tools can also combine genome-mining approaches with the prediction of potentially innovative MoA(s) based on the presence of resistant target genes in BGCs encoding novel antibiotics<sup><xref ref-type="bibr" rid="CR220">220</xref></sup>. These and other examples illustrate how a diverse set of emerging learning methods is steadily enhancing the predictability of drug&#x02013;target interactions<sup><xref ref-type="bibr" rid="CR247">247</xref>,<xref ref-type="bibr" rid="CR248">248</xref></sup>.</p><p id="Par107">In addition to the specific molecular target(s), it is important to understand the impact of the antibiotic compound on the general physiology of the bacterial cell. This includes the sequence of events leading to bacterial death, the time point when killing occurs (based on either individual bacterial cells or their population/colonization level) and the conditions that might enhance or preclude it. Such characterizations may require the application or development of a range of secondary assays. For compounds acting on intracellular bacterial targets (i.e. targets located in the cytoplasm), the processes of compound influx and prevention of efflux (especially so for Gram-negative bacteria as a result of their complex cell envelope and presence of numerous multidrug efflux pumps) are both critical optimization parameters to ensure sufficient target engagement<sup><xref ref-type="bibr" rid="CR249">249</xref>&#x02013;<xref ref-type="bibr" rid="CR253">253</xref></sup>. These factors can be addressed by suitable compound design, which generally remains rather empirical and challenging<sup><xref ref-type="bibr" rid="CR254">254</xref>&#x02013;<xref ref-type="bibr" rid="CR257">257</xref></sup>. Other possibilities to address this key area would be to use these compounds in combination with outer membrane permeabilizing agents<sup><xref ref-type="bibr" rid="CR258">258</xref>,<xref ref-type="bibr" rid="CR259">259</xref></sup> or efflux inhibitors<sup><xref ref-type="bibr" rid="CR93">93</xref>,<xref ref-type="bibr" rid="CR260">260</xref></sup>. Alternative approaches targeting extracellular virulence factors, for example, extracellular lectins required for attachment and biofilm formation or secreted proteolytic enzymes, do not suffer from a possible lack of bacterial uptake<sup><xref ref-type="bibr" rid="CR261">261</xref></sup>. Often, antibiotics, and particularly natural products, have more than one target and disturb bacterial physiology in several different pathways, a phenomenon referred to as polypharmacology<sup><xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR262">262</xref>,<xref ref-type="bibr" rid="CR263">263</xref></sup>, which is beneficial for inflicting severe damage on the bacterial cell and slowing down target-mediated resistance development. Information related to such effects should be acquired for all bacterial species within the spectrum of activity of the potential drug, and it may diverge significantly across phylogenetically distant species.</p><p id="Par108">Apart from the desired biological effects on bacterial pathogens, knowledge about undesired adverse effects on eukaryotic cells (&#x02018;off-target effects&#x02019;<sup><xref ref-type="bibr" rid="CR264">264</xref>&#x02013;<xref ref-type="bibr" rid="CR269">269</xref></sup>) should be acquired early on, since toxicity is a major contributor to attrition in the drug development process. However, whilst in vitro cytotoxicity screens are useful during the early discovery process, they are often not predictive of toxicological effects that can become most significant during in vivo studies. Furthermore, collateral damage to the microbiome needs to be considered<sup><xref ref-type="bibr" rid="CR270">270</xref>&#x02013;<xref ref-type="bibr" rid="CR273">273</xref></sup> and can be modulated by selective drug design<sup><xref ref-type="bibr" rid="CR274">274</xref></sup>. For compounds with a novel or particularly complex MoA, it often takes several years to achieve a detailed molecular understanding and the cellular consequences of exposure. Therefore, acquiring this knowledge as early as possible is a key aspect for further rational drug optimization, including SAR studies and structure-guided hit/lead optimization. We recommend investing resources into expanded MoA studies already during the initial stages of the drug development process and, furthermore, building a network of experts who can provide MoA analyses that fulfil the requirements of a preclinical candidate dossier. While these aspects are standard for drug development projects in the pharmaceutical industry, academia usually suffers from insufficient funding to appropriately address such requirements, and, therefore, additional resources need to be secured.</p></sec><sec id="Sec17"><title>Limited resources to move from hit into lead stage</title><p id="Par109">Once a hit validation has been accomplished, the resources needed to advance the selected compound series into hit-to-lead and lead optimization greatly increase. These stages require a diverse scientific team covering analytical, computational and medicinal chemistry, biochemistry, microbiology, bioinformatics (ideally including machine learning and artificial intelligence methods), drug metabolism and pharmacokinetics, as well as, specifically for natural-product-based compounds, biotechnology and genetic engineering. In industrial projects, typically 5&#x02013;15 medicinal chemists work on the optimization of a hit (depending on how complex the chemistry of a certain compound is) to create promising leads or preclinical candidates, essentially by generating, testing and advancing SAR-based analogue series in an iterative manner. The challenge is to simultaneously optimize all properties necessary for the drug to be most effective and least toxic. This includes potency, selectivity, physicochemical parameters and cytotoxicity, as well as pharmacokinetics and pharmacodynamics (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The multi-parameter optimization can usually be achieved within a time frame of about 2&#x02013;4 years, but remains dependent on the human, technological and financial capacities, as well as the particular challenges represented by the chemical series. Such resources are difficult to acquire through classical academic funding schemes, which usually reward new discoveries in fundamental science, rather than subsequent steps of time-consuming and resource-consuming optimization, where there is no guarantee of success.</p><p id="Par110">Academia must, therefore, find new ways to provide suitable resources for early-stage translational research. Since few academic institutions possess the relevant expertise and facilities to carry out lead optimization, they usually require access to high-quality expertise and/or capacities in cooperation with pharmaceutical companies/SMEs or through contract research organizations (CROs), which can only be achieved through additional funding or partnerships. One possible strategy to acquire appropriate resources in future could be the application of alternative reward schemes for evaluation of academic project funding, which might not only be based on high-impact publications but also on verifiable commitment to health research, such as making dedicated contributions to a global antibacterial portfolio. The emergence of centres for translational science in many countries (for example, the German Center for Infection Research; <ext-link ext-link-type="uri" xlink:href="https://www.dzif.de/en">https://www.dzif.de/en</ext-link>) could be an opportunity to develop and implement such measures, possibly at an international level.</p></sec><sec id="Sec18"><title>The bottleneck of compound supply</title><p id="Par111">The enhanced biological profiling that is mandatory in hit and lead optimization programmes requires a considerable amount of sufficiently pure compounds to be tested. While this can be a problem for chemists in general even with respect to synthetic hits and leads (especially the massive scale-up of typical laboratory test reactions)<sup><xref ref-type="bibr" rid="CR275">275</xref>,<xref ref-type="bibr" rid="CR276">276</xref></sup>, the problem of supplying increasingly large quantities of natural products originating from bacteria, fungi or plants is particularly challenging. Indeed, academic projects are often concluded when natural compounds or biotechnologically generated variants thereof are identified at small scale (often &#x0003c;10&#x02009;mg), with only rudimentary profiling. In many laboratories, there are no additional resources to increase the yields of natural product hits or initial leads, or to scale up production in a pre-pilot plant environment that is capable of carrying out the fermentation (possibly by using heterologous production hosts to achieve attractive yields<sup><xref ref-type="bibr" rid="CR277">277</xref>,<xref ref-type="bibr" rid="CR278">278</xref></sup>). In addition, downstream processing has to be established and optimized for every new compound to ensure satisfactory purity at a sufficient quantity for the following stages, including scaffold optimization by medicinal chemistry or extended biological profiling. The fact that sufficient amounts of compounds (multigram-to-kilogram scale) cannot be produced in many cases severely decreases the chances of developing novel therapeutics from natural products. This is particularly unfortunate in the antibiotics field, because about two-thirds of all antibiotic drugs in therapeutic use are derived from natural products<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR121">121</xref></sup>. Regrettably, fermentation-independent supply, for example, through the total synthesis of complex natural compounds, can only be achieved for a low percentage of novel hits and leads and requires a tremendous amount of additional capacity and resources<sup><xref ref-type="bibr" rid="CR279">279</xref>&#x02013;<xref ref-type="bibr" rid="CR282">282</xref></sup>.</p><p id="Par112">Thus, suitable funding instruments are needed to cover the essential processes of natural compound scale-up and supply based on biotechnological methods, including large-scale fermentation and efficient downstream processing<sup><xref ref-type="bibr" rid="CR283">283</xref>&#x02013;<xref ref-type="bibr" rid="CR285">285</xref></sup>, towards obtaining high-quality source material for semi-synthesis and further studies. In addition, a robust method for large-scale production and downstream processing of the candidate molecule is a prerequisite for process transfer to <xref rid="Glos21" ref-type="list">good manufacturing practice</xref> (GMP) production before entering (pre)clinical stages. Generally, further scientific and technological development is required to make the provision of compound material from various sources a more routine and affordable task, particularly in the non-industrial research environment.</p></sec><sec id="Sec19"><title>Requirements for in vivo studies and project transfer</title><p id="Par113">The primary assays in most discovery programmes usually address biochemical, biophysical and/or microbiological functionality of newly generated compounds. In order to convert a molecule with in vitro activity into a drug, sufficient exposure at the infection site in vivo must be achieved. To analyse this, a full suite of ADMET assays is required<sup><xref ref-type="bibr" rid="CR286">286</xref>,<xref ref-type="bibr" rid="CR287">287</xref></sup>, followed by pharmacokinetics experiments in animals (usually starting with rodent models)<sup><xref ref-type="bibr" rid="CR288">288</xref>,<xref ref-type="bibr" rid="CR289">289</xref></sup>, which can be combined with physiologically based PK modelling and in silico ADMET prediction<sup><xref ref-type="bibr" rid="CR290">290</xref>,<xref ref-type="bibr" rid="CR291">291</xref></sup>.</p><p id="Par114">A sufficient correlation between in vitro and in vivo data, which is not always achievable for all antimicrobial compounds, should generally be pursued as early as possible in the programme, otherwise, continued lead design might be based on irrelevant or misleading data points (for example, see some case studies with&#x000a0;<xref rid="Glos22" ref-type="list">LpxC inhibitors</xref><sup><xref ref-type="bibr" rid="CR292">292</xref>,<xref ref-type="bibr" rid="CR293">293</xref></sup>). Furthermore, the availability of PD models<sup><xref ref-type="bibr" rid="CR294">294</xref>,<xref ref-type="bibr" rid="CR295">295</xref></sup> of high translational relevance, i.e. reliably predicting a minimal efficacious dose in humans, is a critical factor of success in order to generate the optimal drug candidate during lead and lead-to-candidate optimization. In the field of antibiotics, in particular, preclinical PK/PD relationships are generally predictive and have a high relevance for regulatory dossiers<sup><xref ref-type="bibr" rid="CR296">296</xref>,<xref ref-type="bibr" rid="CR297">297</xref></sup>, for example, for human PK/PD target attainment at therapeutic doses and drug formulation development, and, as such, they have to be evaluated carefully at the earliest possible stages<sup><xref ref-type="bibr" rid="CR298">298</xref>&#x02013;<xref ref-type="bibr" rid="CR300">300</xref></sup>. Typically, PK/PD target attainments for antibiotics require relatively high doses compared with other drug classes (particularly to achieve sufficient exposure at the site of infection), limiting the successful application of existing formulation and delivery technologies. This constraint is especially true for oral medications that may present further challenges, for example, to reach an adequate bioavailability of the drug. Hence, a broader array of potential delivery systems should be tested systematically, which may include conventional permeation enhancers<sup><xref ref-type="bibr" rid="CR301">301</xref></sup>, as well as sophisticated nanoformulations, for example, liposome-based drug delivery systems<sup><xref ref-type="bibr" rid="CR302">302</xref>&#x02013;<xref ref-type="bibr" rid="CR305">305</xref></sup>. The latter, however, can only be produced based on expert knowledge and infrastructure, which is, once again, not often available in academia, and, thus, specialized CROs or SMEs may be approached based on available funding.</p><p id="Par115">A further obstacle is the need to perform (initially) rather extensive studies in laboratory animals to understand the PK/PD relationship of a novel compound, which, at subsequent stages, allows the number of animal experiments to be minimized according to <xref rid="Glos23" ref-type="list">the 3Rs principle</xref><sup><xref ref-type="bibr" rid="CR306">306</xref></sup>. However, these studies are generally associated with ethical concerns, high costs and administrative burden. Likewise, these matters are relevant for the in vivo evaluation of toxicology, toxicokinetics and safety pharmacology to cover safety aspects before entering clinical trials<sup><xref ref-type="bibr" rid="CR307">307</xref>,<xref ref-type="bibr" rid="CR308">308</xref></sup>. Here, exploratory or early-stage predictive assays using computational models, as well as in vivo systems with minimal ethical concerns, for example, in vertebrates like <italic>Danio rerio</italic> (zebrafish), insects like <italic>Galleria mellonella</italic> (the greater wax moth) or worms like <italic>Caenorhabditis elegans</italic> (a soil-dwelling nematode), are an opportunity to estimate both efficacy and potential toxicity risks before considering standard in vivo experiments in rodents and other mammals<sup><xref ref-type="bibr" rid="CR309">309</xref>&#x02013;<xref ref-type="bibr" rid="CR311">311</xref></sup>.</p><p id="Par116">Ultimately, the demonstration of efficacy in a relevant animal model, associated with convincing exposure at the site of infection and a rough estimation of a reasonable safety margin, is often a prerequisite to attract an investor&#x02019;s interest; typical minimum requirements are a tolerance/dose range finding study in one or two animal species, as well as human dose prediction based on a solid set of PK/PD data, for example, by testing efficacy in the neutropenic thigh infection model in mice<sup><xref ref-type="bibr" rid="CR312">312</xref></sup>.</p><p id="Par117">Generally, TPPs and the corresponding TCPs should continue to be the base for all further optimization attempts, especially when including in vivo studies, and, hence, should be thoroughly compiled before the development programme starts, with the help of subject matter experts. These data will guide the strategies and decisions for all chemical and biological development processes during the optimization phases, mainly with respect to one (or more) clinical indication(s). In order to specify robust finishing lines, these documents should outline sets of minimum acceptable criteria for each phase, for example, for biochemical assays during early stages and (pre)clinical endpoints at later stages. Such compound progression criteria should be defined for a validated hit, entry into lead optimization, a late lead and a preclinical candidate. There are different TPPs for different bacterial infections. As projects evolve, they may encounter serendipitous discoveries, unsurmountable hurdles or important findings from other groups or competitors, which may affect the TPP that they target. Therefore, the TPP can be critically reviewed and possibly refined or adapted throughout the project, for example, at each transition into the next development stage. Ideally, a pool of commonly accepted TPPs (i.e. approved by the pharmaceutical industry as well as the public health sector) should be available for the multitude of clinical indications to serve as a base for each discovery and development programme of novel therapeutics. The WHO and the GARDP have already started to produce such TPPs for public health concerns, for example, in the field of sexually transmitted infections<sup><xref ref-type="bibr" rid="CR313">313</xref></sup>. These TPPs need to be regularly reviewed, and, where necessary, updated, to make sure that they reflect the current clinical situation; for example, TPPs addressing indications caused by bacterial infections may be affected by the latest emerging (or anticipated) drug-resistant pathogens of critical relevance. It is important to note that only convincing TPPs together with comprehensive preclinical candidate dossiers (highly informative TCPs) and reliable SOPs for scalable compound supply will allow early partnering and a smooth transfer of the project to an industrial stakeholder to move into (pre)clinical development (Box&#x000a0;<xref rid="Sec20" ref-type="sec">6</xref>).</p></sec><sec id="Sec20"><boxed-text><label>Box 6 Late preclinical development of corallopyronin A to first-in-human trial</label><p id="Par118">The bacterial DNA-dependent RNA polymerase inhibitor corallopyronin A (CorA), produced by the soil-dwelling myxobacterium <italic>Corallococcus coralloides</italic>, is active against Gram-negative and Gram-positive bacteria, including methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA)<sup><xref ref-type="bibr" rid="CR341">341</xref>,<xref ref-type="bibr" rid="CR342">342</xref></sup>, by targeting the hinge (switch) region of the holoenzyme<sup><xref ref-type="bibr" rid="CR343">343</xref></sup>. Structure&#x02013;activity relationships demonstrated that the initial natural product hit was the most effective compound<sup><xref ref-type="bibr" rid="CR344">344</xref></sup>, allowing for its development without extensive medicinal chemistry. The essential intracellular <italic>Wolbachia</italic> symbionts (Gram-negative) of human filarial nematodes, which cause the neglected tropical diseases lymphatic filariasis and onchocerciasis (river blindness), are also targets of CorA<sup><xref ref-type="bibr" rid="CR345">345</xref></sup>. Currently, the compound is being developed to clinical phase I to support elimination of these nematode infections<sup><xref ref-type="bibr" rid="CR346">346</xref>&#x02013;<xref ref-type="bibr" rid="CR348">348</xref></sup>, an aim of the United Nations&#x02019; Sustainable Development Goal 3 (UN-SDG)<sup><xref ref-type="bibr" rid="CR349">349</xref></sup>. CorA also has activity against the human pathogenic bacteria <italic>Chlamydia trachomatis</italic>, <italic>Neisseria gonorrhoeae</italic>, <italic>Rickettsia</italic> spp. and <italic>Orientia tsutsugamushi</italic><sup><xref ref-type="bibr" rid="CR350">350</xref>&#x02013;<xref ref-type="bibr" rid="CR352">352</xref></sup>, which are included in the UN-SDG or World Health Organization/Centers for Disease Control and Prevention (WHO/CDC) lists for priority antibiotic discovery and development. Heterologous expression of the CorA biosynthetic cluster in <italic>Myxococcus xanthus</italic>, yielding &#x0003e;100&#x02009;mg&#x02009;l<sup>&#x02212;1</sup> (refs<sup><xref ref-type="bibr" rid="CR277">277</xref>,<xref ref-type="bibr" rid="CR278">278</xref>,<xref ref-type="bibr" rid="CR353">353</xref></sup>), allow consistent multi-gram-scale production with a purity of 90&#x02013;95%. This preliminary product specification has been formally accepted by the German Federal Institute for Drugs and Medical Devices (BfArM). Most standard in vitro and in vivo non-GLP (good laboratory practice) absorption, distribution, metabolism, excretion and toxicity studies have been successfully completed. Compared with rifampicin, the expression of CYP450s is not altered and CYP3A4 induction is eightfold lower. CorA is stable in plasma &#x0003e;240&#x02009;min. Its metabolism in human and dog microsomes is <italic>T</italic><sub>1/2</sub>&#x02009;&#x0003e;&#x02009;45&#x02009;min, resulting in oxidation metabolites and minimal glucuronidation. Off-target profiling resulted in three hits (inhibition/activation), but the half maximal effective concentration (EC<sub>50</sub>) are 170&#x02013;1,500-fold higher than the in vitro EC<sub>50</sub> against <italic>Wolbachia</italic>. CorA does not inhibit hERG, and no genotoxicity was observed. These results indicate that CorA is non-toxic and pharmacologically safe (awaiting further in vivo validation). The project is publicly funded to finalize preclinical studies, including formulation development and in vivo toxicity in rodents and dogs (see Acknowledgements). In parallel, the manufacturing protocol for heterologous production and optimized, upscalable downstream processing (DSP) has been recently transferred to a good manufacturing practice (GMP)-certified contract manufacturing organization (CMO) to produce cGMP-grade material for the GLP and phase I studies. Completing the clinical studies will require a product development partnership. Provision of CorA to countries endemic for filarial infections is envisaged via public&#x02013;private partnerships to achieve the United Nations&#x02019; Sustainable Development Goal 3. After regulatory approval, provision of CorA for treating sexually transmitted infections and as a reserve antibiotic for MRSA shall be achieved through licensing.</p><p id="Par119">ADME, absorption, distribution, metabolism and excretion; m&#x020ac;, million euros; PK/PD, pharmacokinetics/pharmacodynamics.<graphic position="anchor" xlink:href="41570_2021_313_Figf_HTML" id="d32e3059"/></p></boxed-text></sec><sec id="Sec21"><title>The management challenge in hit and lead optimization programmes</title><p id="Par120">As the development of antibacterials requires a multidisciplinary approach, knowledge of a diverse set of techniques and domains (for example, assay development, high-throughput screening, medicinal and computational chemistry, ADMET, PK/PD, drug delivery, clinical background of disease processes etc.) is required in order to develop a compound to the level of a preclinical candidate. Single principal investigators (PIs) will usually not possess the broad base of expertise that is necessary, since academia largely focuses on early-stage discovery and compound optimization at the laboratory scale. Hence, research groups that do not possess the extensive skill set for drug development in its various stages should pursue a team approach by collaborating with organizations that have the relevant experience, be it within the academic or the industrial sector. There is also the possibility of calling on specialized consultancy or outsourcing packages of work (for example, ADMET) to CROs that possess relevant expertise and experimental capabilities. However, in addition to the relatively high costs of such services, PIs often struggle with remaining questions once a CRO assignment ends, and sufficient resources for tailor-made optimizations are often lacking. Moreover, the need to interpret results and devise a clear path forward towards the TPP from multiple data packages remains with the project teams. Hence, partnerships and collaborations are essential if relevant in-house expertise or infrastructure is missing. Therefore, we propose the following solutions for efficient translational project management:</p><p id="Par121">Aligning and collaborating with suitable partners from various sectors or disciplines is crucial for groups with limited know-how in drug discovery and development. Generally, larger project teams can provide or identify expertise much more quickly to sufficiently resolve emerging knowledge gaps. Additionally, project consultants or CROs can be approached at different levels to fulfil remaining tasks, for example, data evaluation or processing defined and highly specific work packages, for example in PK and toxicological studies.</p><p id="Par122">Databases of experts should be available for relevant research areas or services, and the various technical and IP-related aspects need to be elaborated on a case-by-case basis. Unbiased partners have to be identified to host and curate such databases on a regular basis, which could fall into the remit of non-profit health organizations such as the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) or the GARDP.</p><p id="Par123">Training of PIs on a frequent basis is required to broaden their knowledge and to ensure a high-level understanding of potential barriers and pitfalls at least until projects reach the (pre)clinical stages. A number of renowned institutions already offer regular workshops and seminars (often as interactive webinars, for example, GARDP REVIVE; <ext-link ext-link-type="uri" xlink:href="https://revive.gardp.org/">https://revive.gardp.org/</ext-link>), as well as extended training programmes (for example, the Interdisciplinary Course on Antibiotics and Resistance; <ext-link ext-link-type="uri" xlink:href="https://www.icarecourse.org/">https://www.icarecourse.org/</ext-link>, hosted by Institut Pasteur, France), and these are increasingly popular. In addition to PIs from academia, non-academic experts from industry, health and political sectors should share their perspectives on current research and funding aspects more regularly within interdisciplinary settings.</p><p id="Par124">Overall, it is important that the necessary financial and legal frameworks for efficiency-oriented project management are established as early as possible during the course of a development programme to avoid loss of time and resources. The required settings can be implemented either individually at a particular project level or existing management models (for example, available in the industrial sector or in translational research centres) could be used or adapted for the specific purpose.</p></sec></sec><sec id="Sec22"><title>Conclusions and outlook</title><p id="Par125">To ensure a healthy and vibrant antimicrobial pipeline, considerable efforts are needed not only to develop the next generation of antibacterial drugs but also to safeguard and foster profound expertise in antibiotic drug discovery and development. In the short and medium term, such capacity-building must be performed as a collaborative and iterative process between academia and industry to ensure that the necessary skills are available to translate validated hits into potential drug products. The development of joint initiatives for education in translational sciences will require specific funding, as they are not part of most universities&#x02019; standard curricula. Many experienced scientists in the pharmaceutical industry are eager to share their translational and regulatory knowledge, often after retirement or due to change of operations. Thus, pharmaceutical companies could serve as a valuable training ground for acquiring and developing specific skills in the antimicrobial sector. However, limited funding (especially for SMEs) and economic uncertainties negatively affect this premise because it leads to business closures, high employee turnover rates, prevents the recruitment and training of inexperienced staff and deters scientists from embarking on a career in SMEs. In order to achieve transfer of vital expertise, workshops, symposiums and exchanges that foster academic&#x02013;industrial interactions between students and advanced researchers are required and need financial support. Unfortunately, there are very few market-driven initiatives for such events and, therefore, a connection to already existing education and training programmes, for example, those supported by IMI, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) or British Society for Antimicrobial Chemotherapy (BSAC), can be a valuable option as long as the transition into an era of mutually sustained knowledge transfer between industry and academia continues.</p><p id="Par126">Another critical aspect for all future antibiotic R&#x00026;D projects is the implementation of a legal framework for IP ownership at project commencement. The multidisciplinary and collaborative nature of antibiotic drug discovery often results in collaborations between different institutions on a national or international level. This creates challenging ownership structures with increasing complexity of such consortia, especially when an antibacterial programme is out-licensed, for example, to an SME. Negotiating ownership agreements among inventor institutions can be lengthy and may discourage industry from in-licensing valuable assets for further development. The increased collaboration between academia and industry requires fair and justifiable guidelines for knowledge and compound transfer outlined in appropriate agreements. The creation of such guidelines should be supported, for example, in the form of templates to settle ownership agreements between project partners or third parties, to facilitate processes for the benefit of researchers with limited experience in these matters. Such a framework will accelerate potential technology and compound transfer towards industrial drug developers, will make the relative commitment for each participant clearer and, thus, their gains more attractive.</p><p id="Par127">Finally, we believe that AMR research requires diligent lobbying at the national and international levels to create entry points for large funders. Many scientists working on antimicrobials in either academia or SMEs are outside the few existing networks that involve decision makers within commercial funding sources, such as venture capitalists, including the newly announced AMR Action Fund, philanthropic organizations, national or regional governments or international bodies. This situation has resulted in an environment in which the challenges of antimicrobial drug developers are either not heard or are even ignored, even as public awareness of AMR steadily increases. It is evident that a strong lobbying position will lead to changes, which has recently been shown by the BEAM Alliance and their interaction and negotiations with diverse political bodies in Europe, leading to increased recognition of the challenges for antibacterial drug developers by the European Commission and Europe&#x02019;s national governments<sup><xref ref-type="bibr" rid="CR314">314</xref>&#x02013;<xref ref-type="bibr" rid="CR316">316</xref></sup>.</p><p id="Par128">For the above reasons, we recommend that an international group of experienced AMR lobbyists should be formed that, together, can campaign for funding of early antibacterial drug discovery research along the principles set out in this article. Such a group should include national, regional and global scientific and industry associations that have practice in interacting with relevant stakeholders connected with national parliaments, EC, G7, G20 and further decision-making entities<sup><xref ref-type="bibr" rid="CR317">317</xref></sup>. The Global AMR R&#x00026;D Hub (<ext-link ext-link-type="uri" xlink:href="https://globalamrhub.org/">https://globalamrhub.org/</ext-link>) could be a crystallization point to pioneer such developments, which can be supported by various consortia, including the authors of this article: The International Research Alliance for Antibiotic Discovery and Development (IRAADD; <ext-link ext-link-type="uri" xlink:href="https://www.iraadd.eu/">https://www.iraadd.eu/</ext-link>), which we have recently established with the support of the JPIAMR Virtual Research Institute (JPIAMR-VRI; <ext-link ext-link-type="uri" xlink:href="https://www.jpiamr.eu/jpiamr-vri/">https://www.jpiamr.eu/jpiamr-vri/</ext-link>), identifies itself as a part of the mission that is addressed by the current roadmap. The IRAADD aims to improve the situation of novel antibiotic discovery and development by bringing together experts for early drug research from the academic and industrial sectors, who can provide knowledge and advice for diverse projects in the field. A recent example of our activities is the support of the JPIAMR-VRI to create a new online resource (the JPIAMR-VRI Digital Platform &#x02018;DISQOVER&#x02019;; <ext-link ext-link-type="uri" xlink:href="https://www.jpiamr.eu/activities/jpiamr-vri/digital-platform/">https://www.jpiamr.eu/activities/jpiamr-vri/digital-platform/</ext-link>), serving as a comprehensive and interlinked database for AMR-related research at multiple levels. Although the IRAADD currently has only a short-term funding perspective, it is one of our main goals to help define and implement interdisciplinary innovative antibiotic development programmes based on sustainable research funding, in order to refill the translational pipeline with new drug candidates in the foreseeable future. In this respect, and as a possible long-term vision, the creation of internationally operating antibiotic research hubs, which may emerge from already existing pre-stage platforms such as the IRAADD, can be a major step forward to engage as many members as possible from academia, industry and public health organizations in antimicrobial R&#x00026;D collaborations, and to create a strong and path-breaking position that cannot be overlooked. Only a responsible connection of thought leaders and dedicated experts from all relevant sectors of society, joining together now and for the future, will allow suitable rapid responses to globally emerging pathogens. Therefore, taking corrective and preventive action now through concerted and innovative approaches in the field of novel antibiotic drug discovery and development is the essential path forward to be prepared for future pandemics caused by multi-to-pan drug-resistant (so-called superbug) bacteria, which is an aim that deserves our undivided attention.</p></sec></body><back><fn-group><fn><p><bold>Peer review information</bold></p><p><italic>Nature Reviews Chemistry</italic> thanks U. Theuretzbacher, G. Wright and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.</p></fn><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are grateful to &#x000c9;dith Brochu (JPIAMR-VRI, Canada) for helpful discussion and comments during manuscript preparation. Coordination of the IRAADD consortium is funded by the JPIAMR-VRI, including the publication of this article. The project on PqsR pathoblocker development acknowledges funding through the German Center for Infection Research (DZIF; projects TTU09.908 and TTU09.916), the Helmholtz Association (Helmholtz Validation Fund) and additional contributions by the associated academic institutes (HZI and HIPS). The development of chelocardins is supported by the DZIF (TTU09.814/09.821), the Helmholtz Innovation Fund (Pre-4D), by the Slovenian Research Agency, ARRS, grant no. J4-8226, and in collaboration with AciesBio, Slovenia. The corallopyronin project is funded by the DZIF (TTU09.807/09.816, TTU09.914), the German Federal Ministry of Education and Research (BMBF), the federal state of North Rhine-Westphalia (EFRE.NRW) and EU Horizon 2020. Eriko Takano was funded by the European Union&#x02019;s Horizon 2020 research and innovation programme under grant agreement no. 720793 &#x0201c;TOPCAPI: Thoroughly Optimised Production Chassis for Advanced Pharmaceutical Ingredients&#x0201d;.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to researching data, discussion of content, writing of the article, as well as reviewing and editing the article.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par129">M. H. Medema is a co-founder of Design Pharmaceuticals and a member of the scientific advisory board of Hexagon Bio, and S. Donadio is a co-founder and shareholder of NAICONS, owning intellectual property on antibacterial compounds. The remaining authors do not declare any competing interests.</p></notes><glossary><title>Glossary</title><def-list><def-item id="Glos1"><term>ESKAPE</term><def><p>Acronym of highly virulent and often (mainly in hospitals) multidrug-resistant bacterial priority pathogens, including <italic>Enterococcus faecium</italic>, <italic>Staphylococcus aureus</italic>, <italic>Klebsiella pneumoniae</italic>, <italic>Acinetobacter baumannii</italic>, <italic>Pseudomonas aeruginosa</italic> and <italic>Enterobacter</italic> spp.</p></def></def-item><def-item id="Glos2"><term>Push</term><def><p>Push incentives (for example, grants for the different phases of drug discovery or development) aim to generate and push a product (such as a new antibiotic) into the market.</p></def></def-item><def-item id="Glos3"><term>Pull</term><def><p>Pull incentives ensure that a product is established at the market (for example, by defined payments to the manufacturer for a certain time after market release).</p></def></def-item><def-item id="Glos4"><term>Subscription models</term><def><p>These models constitute that fixed prices will be paid at regular intervals for a certain period (for example, by governments) to the provider of a product to trigger (&#x02018;pull&#x02019;) the development of therapeutics, such as novel antibiotics.</p></def></def-item><def-item id="Glos5"><term>Delinkage models</term><def><p>These models combine expanded government funding for drug development with cash reward incentives to drug developers in order to delink high innovation costs from high sales prices.</p></def></def-item><def-item id="Glos6"><term>Hit compounds</term><def><p>Molecules that show a desired type of activity in initial screening assay(s).</p></def></def-item><def-item id="Glos7"><term>ADMET studies</term><def><p>Absorption, distribution, metabolism, excretion and toxicity. A collection of experimental studies that determines the fate of a pharmaceutical compound in an organism.</p></def></def-item><def-item id="Glos8"><term>Mode of action</term><def><p>A change in cellular function (referring to the bacterial cell throughout the article) that results from exposure to a drug.</p></def></def-item><def-item id="Glos9"><term>Pathoblockers</term><def><p>Anti-virulence drugs, i.e. drugs acting against factors (usually non-essential targets) that are involved in the development of bacterial virulence, often combined with a regular antibiotic to provide a synergistic effect.</p></def></def-item><def-item id="Glos10"><term>Gram-positive bacteria</term><def><p>Bacteria that stain positive with Gram&#x02019;s method by retaining the crystal violet dye in the thick peptidoglycan layer that composes their cell wall, together with the inner cytoplasmic cell membrane; the absence of an outer membrane often makes them more susceptible to cell wall targeting antibiotics and to influx of antibiotics into the cytoplasm.</p></def></def-item><def-item id="Glos11"><term>Gram-negative bacteria</term><def><p>Bacteria that stain negative (do not retain the crystal violet dye) when using Gram&#x02019;s method for bacterial differentiation; their cell envelopes are composed of an inner cytoplasmic cell membrane and an outer membrane (containing amphiphilic lipopolysaccharides at the outer leaflet), which enclose the periplasmic space containing a thin peptidoglycan layer.</p></def></def-item><def-item id="Glos12"><term>Minimum inhibitory concentrations</term><def><p>The minimum concentrations, usually expressed in units of mass per litre, that prevent visible growth of bacteria. Complementary to minimum bactericidal concentration.</p></def></def-item><def-item id="Glos13"><term>Minimum bactericidal concentrations</term><def><p>The minimum concentrations, usually expressed in units of mass per litre, that result in death for &#x02265;99.9% of bacteria. Complementary to minimum inhibitory concentration.</p></def></def-item><def-item id="Glos14"><term>Target candidate profile</term><def><p>(TCP). Reflects how the chemical matter of an identified compound is optimized towards the target product profile by summarizing the desired chemical, physicochemical and biological characteristics of a preclinical drug candidate.</p></def></def-item><def-item id="Glos15"><term>Target product profile</term><def><p>(TPP). Summarizes the key requirements for a new therapeutic that fulfils a priority medical need; thus, it identifies and outlines the critical attributes and (pre)clinical endpoints of a product as a guidance before development begins.</p></def></def-item><def-item id="Glos16"><term>Mechanism of resistance</term><def><p>Native or acquired, this is the route by which a microorganism resists the action of a particular drug. This may include, for example, decreased influx, enhanced efflux, modification of the drug target and modification/inactivation of the drug.</p></def></def-item><def-item id="Glos17"><term>Lead compounds</term><def><p>Molecules with validated activity that serve as a basis for the development of a drug candidate.</p></def></def-item><def-item id="Glos18"><term>Biosynthetic gene clusters</term><def><p>(BGCs). Sets of genes, typically found close to one another in the genome, that code for the enzymes responsible for the synthesis of a particular secondary metabolite.</p></def></def-item><def-item id="Glos19"><term>CRISPR/Cas9</term><def><p>Clustered regularly interspaced short palindromic repeats&#x02013;CRISPR-associated protein 9. Components of the immunological defence of certain bacteria against viruses and plasmids; used in molecular biology not only for genetic engineering of bacterial genomes.</p></def></def-item><def-item id="Glos20"><term>Trojan Horse approach</term><def><p>Describes the addition of another chemical moiety (e.g. a siderophore) to a drug scaffold in order to facilitate the bacterial uptake of this drug conjugate (for example, by exploiting bacterial siderophore transporters).</p></def></def-item><def-item id="Glos21"><term>Good manufacturing practice</term><def><p>(GMP). The set of minimum requirements that must be followed in manufacturing in order to satisfy the agencies responsible for licensing.</p></def></def-item><def-item id="Glos22"><term>LpxC inhibitors</term><def><p>Inhibitors targeting the enzyme LpxC that catalyses the initial step in the biosynthesis of lipid A &#x02014; a structural component of the lipopolysaccharide molecules in Gram-negative bacteria.</p></def></def-item><def-item id="Glos23"><term>The 3Rs principle</term><def><p>&#x02018;Replacement, reduction and refinement&#x02019;; guiding principles defined for a more ethical approach to animal research.</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventola</surname><given-names>CL</given-names></name></person-group><article-title>The antibiotic resistance crisis: part 1: causes and threats</article-title><source>Pharm. Ther.</source><year>2015</year><volume>40</volume><fpage>277</fpage><lpage>283</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>MK</given-names></name><etal/></person-group><article-title>The drivers of antibiotic use and misuse: the development and investigation of a theory driven community measure</article-title><source>BMC Public. Health</source><year>2019</year><volume>19</volume><fpage>1425</fpage><pub-id pub-id-type="doi">10.1186/s12889-019-7796-8</pub-id><?supplied-pmid 31666056?><pub-id pub-id-type="pmid">31666056</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadimpalli</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Urban informal settlements as hotspots of antimicrobial resistance and the need to curb environmental transmission</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>787</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0722-0</pub-id><?supplied-pmid 32467623?><pub-id pub-id-type="pmid">32467623</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">World Health Organization (WHO). WHO report on surveillance of antibiotic consumption 2016&#x02013;2018 early implementation (WHO, 2018) <ext-link ext-link-type="uri" xlink:href="https://www.who.int/medicines/areas/rational_use/oms-amr-amc-report-2016-2018/en/">https://www.who.int/medicines/areas/rational_use/oms-amr-amc-report-2016-2018/en/</ext-link></mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrader</surname><given-names>SM</given-names></name><name><surname>Vaubourgeix</surname><given-names>J</given-names></name><name><surname>Nathan</surname><given-names>C</given-names></name></person-group><article-title>Biology of antimicrobial resistance and approaches to combat it</article-title><source>Sci. Trans. Med.</source><year>2020</year><volume>12</volume><fpage>eaaz6992</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaz6992</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conlon</surname><given-names>BP</given-names></name><etal/></person-group><article-title>Persister formation in <italic>Staphylococcus aureus</italic> is associated with ATP depletion</article-title><source>Nat. Microbiol.</source><year>2016</year><volume>1</volume><fpage>16051</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.51</pub-id><?supplied-pmid 27572649?><pub-id pub-id-type="pmid">27572649</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>A</given-names></name><name><surname>Maisonneuve</surname><given-names>E</given-names></name><name><surname>Gerdes</surname><given-names>K</given-names></name></person-group><article-title>Mechanisms of bacterial persistence during stress and antibiotic exposure</article-title><source>Science</source><year>2016</year><volume>354</volume><fpage>aaf4268</fpage><pub-id pub-id-type="doi">10.1126/science.aaf4268</pub-id><?supplied-pmid 27980159?><pub-id pub-id-type="pmid">27980159</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaskovich</surname><given-names>MAT</given-names></name></person-group><article-title>Antibiotics special issue: challenges and opportunities in antibiotic discovery and development</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>1286</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00331</pub-id><pub-id pub-id-type="pmid">32527093</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">O&#x02019;Neill, J. Tackling drug-resistant infections globally: final report and recommendations. <italic>The Review on Antimicrobial Resistance</italic><ext-link ext-link-type="uri" xlink:href="https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf">https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf</ext-link> (2016). <bold>Ground-breaking report and action plan to tackle present and future threats imposed by drug-resistant infections on a global scale</bold>.</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other"><italic>AMR Industry Alliance.</italic> 2020 progress report (AMR Industry Alliance, 2020) <ext-link ext-link-type="uri" xlink:href="https://www.amrindustryalliance.org/wp-content/uploads/2020/01/AMR-2020-Progress-Report.pdf">https://www.amrindustryalliance.org/wp-content/uploads/2020/01/AMR-2020-Progress-Report.pdf</ext-link></mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><etal/></person-group><article-title>Bacterial and fungal infections in COVID-19 patients: A matter of concern</article-title><source>Infect. Control Hospital Epidemiol.</source><year>2020</year><volume>41</volume><fpage>1124</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1017/ice.2020.156</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>The microbial coinfection in COVID-19</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2020</year><volume>104</volume><fpage>7777</fpage><lpage>7785</lpage><pub-id pub-id-type="doi">10.1007/s00253-020-10814-6</pub-id><?supplied-pmid 32780290?><pub-id pub-id-type="pmid">32780290</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><etal/></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><?supplied-pmid 32171076?><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nori</surname><given-names>P</given-names></name><etal/></person-group><article-title>Emerging co-pathogens: New Delhi metallo-beta-lactamase producing Enterobacterales infections in New York City COVID-19 patients</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><volume>56</volume><fpage>106179</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106179</pub-id><?supplied-pmid 32987104?><pub-id pub-id-type="pmid">32987104</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Getahun</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Trivedi</surname><given-names>K</given-names></name><name><surname>Paulin</surname><given-names>S</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name></person-group><article-title>Tackling antimicrobial resistance in the COVID-19 pandemic</article-title><source>Bull. World Health Organ.</source><year>2020</year><volume>98</volume><fpage>442</fpage><lpage>442A</lpage><pub-id pub-id-type="doi">10.2471/BLT.20.268573</pub-id><?supplied-pmid 32742026?><pub-id pub-id-type="pmid">32742026</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldenburg</surname><given-names>CE</given-names></name><name><surname>Doan</surname><given-names>T</given-names></name></person-group><article-title>Azithromycin for severe COVID-19</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>936</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31863-8</pub-id><?supplied-pmid 32896293?><pub-id pub-id-type="pmid">32896293</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease</article-title><source>Ther. Adv. Respir. Dis.</source><year>2020</year><volume>14</volume><fpage>1753466620951053</fpage><pub-id pub-id-type="doi">10.1177/1753466620951053</pub-id><?supplied-pmid 32873175?><pub-id pub-id-type="pmid">32873175</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodhi</surname><given-names>M</given-names></name><name><surname>Etminan</surname><given-names>M</given-names></name></person-group><article-title>Therapeutic potential for tetracyclines in the treatment of COVID-19</article-title><source>Pharmacotherapy</source><year>2020</year><volume>40</volume><fpage>487</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1002/phar.2395</pub-id><?supplied-pmid 32267566?><pub-id pub-id-type="pmid">32267566</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>SA</given-names></name><name><surname>Devaux</surname><given-names>C</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name><name><surname>Rolain</surname><given-names>J-M</given-names></name></person-group><article-title>Teicoplanin: an alternative drug for the treatment of COVID-19?</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><volume>55</volume><fpage>105944</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105944</pub-id><?supplied-pmid 32179150?><pub-id pub-id-type="pmid">32179150</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contou</surname><given-names>D</given-names></name><etal/></person-group><article-title>Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU</article-title><source>Ann. Intensive Care</source><year>2020</year><volume>10</volume><fpage>119</fpage><pub-id pub-id-type="doi">10.1186/s13613-020-00736-x</pub-id><?supplied-pmid 32894364?><pub-id pub-id-type="pmid">32894364</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifipour</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU</article-title><source>BMC Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>646</fpage><pub-id pub-id-type="doi">10.1186/s12879-020-05374-z</pub-id><?supplied-pmid 32873235?><pub-id pub-id-type="pmid">32873235</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langford</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><volume>26</volume><fpage>1622</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.07.016</pub-id><?supplied-pmid 32711058?><pub-id pub-id-type="pmid">32711058</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawson</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>71</volume><fpage>2459</fpage><lpage>2468</lpage><?supplied-pmid 32358954?><pub-id pub-id-type="pmid">32358954</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughn</surname><given-names>VM</given-names></name><etal/></person-group><article-title>Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>72</volume><fpage>e533</fpage><lpage>e541</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1239</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>J</given-names></name></person-group><article-title>How covid-19 is accelerating the threat of antimicrobial resistance</article-title><source>BMJ</source><year>2020</year><volume>369</volume><fpage>m1983</fpage><pub-id pub-id-type="doi">10.1136/bmj.m1983</pub-id><?supplied-pmid 32423901?><pub-id pub-id-type="pmid">32423901</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawson</surname><given-names>TM</given-names></name><name><surname>Ming</surname><given-names>D</given-names></name><name><surname>Ahmad</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>LSP</given-names></name><name><surname>Holmes</surname><given-names>AH</given-names></name></person-group><article-title>Antimicrobial use, drug-resistant infections and COVID-19</article-title><source>Nat. Rev. Microbiol.</source><year>2020</year><volume>18</volume><fpage>409</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-0395-y</pub-id><?supplied-pmid 32488173?><pub-id pub-id-type="pmid">32488173</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengoechea</surname><given-names>JA</given-names></name><name><surname>Bamford</surname><given-names>CG</given-names></name></person-group><article-title>SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19?</article-title><source>EMBO Mol. Med.</source><year>2020</year><volume>12</volume><fpage>e12560</fpage><pub-id pub-id-type="doi">10.15252/emmm.202012560</pub-id><?supplied-pmid 32453917?><pub-id pub-id-type="pmid">32453917</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huttner</surname><given-names>BD</given-names></name><name><surname>Catho</surname><given-names>G</given-names></name><name><surname>Pano-Pardo</surname><given-names>JR</given-names></name><name><surname>Pulcini</surname><given-names>C</given-names></name><name><surname>Schouten</surname><given-names>J</given-names></name></person-group><article-title>COVID-19: don&#x02019;t neglect antimicrobial stewardship principles!</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><volume>26</volume><fpage>808</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.04.024</pub-id><?supplied-pmid 32360446?><pub-id pub-id-type="pmid">32360446</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buehrle</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Antibiotic consumption and stewardship at a hospital outside of an early coronavirus disease 2019 epicenter</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e01011</fpage><lpage>e01020</lpage><pub-id pub-id-type="doi">10.1128/AAC.01011-20</pub-id><?supplied-pmid 32816693?><pub-id pub-id-type="pmid">32816693</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieuwlaat</surname><given-names>R</given-names></name><etal/></person-group><article-title>COVID-19 and antimicrobial resistance: parallel and interacting health emergencies</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>72</volume><fpage>1657</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa773</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Giacobbe</surname><given-names>DR</given-names></name></person-group><article-title>A look at the clinical, economic, and societal impact of antimicrobial resistance in 2020</article-title><source>Expert Opin. Pharmacother.</source><year>2020</year><volume>21</volume><fpage>2067</fpage><lpage>2071</lpage><pub-id pub-id-type="doi">10.1080/14656566.2020.1802427</pub-id><?supplied-pmid 32749893?><pub-id pub-id-type="pmid">32749893</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magiorakos</surname><given-names>A-P</given-names></name><etal/></person-group><article-title>Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance</article-title><source>Clin. Microbiol. Infect.</source><year>2012</year><volume>18</volume><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id><?supplied-pmid 21793988?><pub-id pub-id-type="pmid">21793988</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin Yu</surname><given-names>J</given-names></name><name><surname>Hubbard-Lucey</surname><given-names>VM</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><article-title>Immuno-oncology drug development goes global</article-title><source>Nat. Rev. Drug Discov.</source><year>2019</year><volume>18</volume><fpage>899</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1038/d41573-019-00167-9</pub-id><?supplied-pmid 31780841?><pub-id pub-id-type="pmid">31780841</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other"><italic>The Pew Charitable Trusts</italic>. Tracking the global pipeline of antibiotics in development, April 2020 (The Pew Charitable Trusts, 2020) <ext-link ext-link-type="uri" xlink:href="https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2020/04/tracking-the-global-pipeline-of-antibiotics-in-development">https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2020/04/tracking-the-global-pipeline-of-antibiotics-in-development</ext-link></mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>P</given-names></name><name><surname>Paulin</surname><given-names>S</given-names></name></person-group><article-title>The antibacterial research and development pipeline needs urgent solutions</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>1289</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00044</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other"><italic>World Health Organization (WHO)</italic>. 2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. (WHO, 2019) <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf</ext-link></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other"><italic>The Pew Charitable Trusts. A scientific roadmap for antibiotic discovery.</italic> (The Pew Charitable Trusts, 2016) <ext-link ext-link-type="uri" xlink:href="https://www.pewtrusts.org/en/research-and-analysis/reports/2016/05/a-scientific-roadmap-for-antibiotic-discovery">https://www.pewtrusts.org/en/research-and-analysis/reports/2016/05/a-scientific-roadmap-for-antibiotic-discovery</ext-link></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other"><italic>OECD Publishing</italic>. Stemming the superbug tide: Just a few dollars more. (OECD, 2018) <ext-link ext-link-type="uri" xlink:href="https://www.oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm">https://www.oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm</ext-link></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">&#x000c5;rdal, C. et al. DRIVE-AB report: revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access. (DRIVE AB, 2018) <ext-link ext-link-type="uri" xlink:href="http://drive-ab.eu/wp-content/uploads/2018/01/CHHJ5467-Drive-AB-Main-Report-180319-WEB.pdf">http://drive-ab.eu/wp-content/uploads/2018/01/CHHJ5467-Drive-AB-Main-Report-180319-WEB.pdf</ext-link></mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Prosen</surname><given-names>KR</given-names></name><name><surname>Lepore</surname><given-names>CJ</given-names></name><name><surname>Coukell</surname><given-names>A</given-names></name></person-group><article-title>On the road to discovering urgently needed antibiotics: so close yet so far away</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>1292</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00100</pub-id><?supplied-pmid 32527096?><pub-id pub-id-type="pmid">32527096</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theuretzbacher</surname><given-names>U</given-names></name><name><surname>Outterson</surname><given-names>K</given-names></name><name><surname>Engel</surname><given-names>A</given-names></name><name><surname>Karl&#x000e9;n</surname><given-names>A</given-names></name></person-group><article-title>The global preclinical antibacterial pipeline</article-title><source>Nat. Rev. Microbiol.</source><year>2020</year><volume>18</volume><fpage>275</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0288-0</pub-id><?supplied-pmid 31745331?><pub-id pub-id-type="pmid">31745331</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">O&#x02019;Neill, J. Securing new drugs for future generations: the pipeline of antibiotics. (The Review on Antimicrobial Resistance, 2015) <ext-link ext-link-type="uri" xlink:href="https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf">https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf</ext-link></mixed-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>MI</given-names></name><name><surname>Truman</surname><given-names>AW</given-names></name><name><surname>Wilkinson</surname><given-names>B</given-names></name></person-group><article-title>Antibiotics: past, present and future</article-title><source>Curr. Opin. Microbiol.</source><year>2019</year><volume>51</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2019.10.008</pub-id><?supplied-pmid 31733401?><pub-id pub-id-type="pmid">31733401</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>K</given-names></name></person-group><article-title>The science of antibiotic discovery</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>29</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.056</pub-id><?supplied-pmid 32197064?><pub-id pub-id-type="pmid">32197064</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname><given-names>ARM</given-names></name><name><surname>Halls</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group><article-title>Novel classes of antibiotics or more of the same?</article-title><source>Br. J. Pharmacol.</source><year>2011</year><volume>163</volume><fpage>184</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01250.x</pub-id><?supplied-pmid 21323894?><pub-id pub-id-type="pmid">21323894</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>D</given-names></name><name><surname>Karl&#x000e9;n</surname><given-names>A</given-names></name></person-group><article-title>Discovery and preclinical development of new antibiotics</article-title><source>Upsala J. Med. Sci.</source><year>2014</year><volume>119</volume><fpage>162</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.3109/03009734.2014.896437</pub-id><?supplied-pmid 24646082?><pub-id pub-id-type="pmid">24646082</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>N</given-names></name><name><surname>Czaplewski</surname><given-names>L</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><article-title>Discovery and development of new antibacterial drugs: learning from experience?</article-title><source>J. Antimicrob. Chemother.</source><year>2018</year><volume>73</volume><fpage>1452</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1093/jac/dky019</pub-id><?supplied-pmid 29438542?><pub-id pub-id-type="pmid">29438542</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>DJ</given-names></name><name><surname>Gwynn</surname><given-names>MN</given-names></name><name><surname>Holmes</surname><given-names>DJ</given-names></name><name><surname>Pompliano</surname><given-names>DL</given-names></name></person-group><article-title>Drugs for bad bugs: confronting the challenges of antibacterial discovery</article-title><source>Nat. Rev. Drug Discov.</source><year>2007</year><volume>6</volume><fpage>29</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/nrd2201</pub-id><?supplied-pmid 17159923?><pub-id pub-id-type="pmid">17159923</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other"><italic>BEAM Alliance</italic>. Supporting financial investments on R&#x00026;D to de-risk antimicrobial development. (BEAM Alliance, 2019) <ext-link ext-link-type="uri" xlink:href="https://beam-alliance.eu/wp-content/uploads/2019/10/the-beam-push-memo.pdf">https://beam-alliance.eu/wp-content/uploads/2019/10/the-beam-push-memo.pdf</ext-link></mixed-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlaes</surname><given-names>DM</given-names></name></person-group><article-title>Antibacterial drugs: the last frontier</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>1313</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00057</pub-id><?supplied-pmid 32527094?><pub-id pub-id-type="pmid">32527094</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rex</surname><given-names>JH</given-names></name><name><surname>Outterson</surname><given-names>K</given-names></name></person-group><article-title>Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach</article-title><source>Lancet Infect. Dis.</source><year>2016</year><volume>16</volume><fpage>500</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)00500-9</pub-id><?supplied-pmid 27036356?><pub-id pub-id-type="pmid">27036356</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Outterson</surname><given-names>K</given-names></name></person-group><article-title>A shot in the arm for new antibiotics</article-title><source>Nat. Biotechnol.</source><year>2019</year><volume>37</volume><fpage>1110</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0279-8</pub-id><?supplied-pmid 31578512?><pub-id pub-id-type="pmid">31578512</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rex</surname><given-names>JH</given-names></name><name><surname>Fernandez Lynch</surname><given-names>H</given-names></name><name><surname>Cohen</surname><given-names>IG</given-names></name><name><surname>Darrow</surname><given-names>JJ</given-names></name><name><surname>Outterson</surname><given-names>K</given-names></name></person-group><article-title>Designing development programs for non-traditional antibacterial agents</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>3416</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11303-9</pub-id><?supplied-pmid 31366924?><pub-id pub-id-type="pmid">31366924</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c5;rdal</surname><given-names>C</given-names></name><etal/></person-group><article-title>Antibiotic development - economic, regulatory and societal challenges</article-title><source>Nat. Rev. Microbiol.</source><year>2020</year><volume>18</volume><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0293-3</pub-id><?supplied-pmid 31745330?><pub-id pub-id-type="pmid">31745330</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other"><italic>International Federation of Pharmaceutical Manufacturers &#x00026; Associations</italic> (IFPMA) New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion. (IFPMA, 2020) <ext-link ext-link-type="uri" xlink:href="https://www.ifpma.org/resource-centre/new-amr-action-fund-steps-in-to-save-collapsing-antibiotic-pipeline/">https://www.ifpma.org/resource-centre/new-amr-action-fund-steps-in-to-save-collapsing-antibiotic-pipeline/</ext-link></mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other"><italic>The Public Health Agency of Sweden</italic>. Availability of antibiotics: Reporting of Government Commission. (The Public Health Agency of Sweden, 2017) <ext-link ext-link-type="uri" xlink:href="https://www.folkhalsomyndigheten.se/contentassets/ab79066a80c7477ca5611ccfb211828e/availability-antibiotics-01229-2017-1.pdf">https://www.folkhalsomyndigheten.se/contentassets/ab79066a80c7477ca5611ccfb211828e/availability-antibiotics-01229-2017-1.pdf</ext-link></mixed-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullard</surname><given-names>A</given-names></name></person-group><article-title>UK outlines its antibiotic pull incentive plan</article-title><source>Nat. Rev. Drug Discov.</source><year>2020</year><volume>19</volume><fpage>298</fpage><lpage>299</lpage><?supplied-pmid 32269311?><pub-id pub-id-type="pmid">32269311</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahase</surname><given-names>E</given-names></name></person-group><article-title>UK launches subscription style model for antibiotics to encourage new development</article-title><source>BMJ</source><year>2020</year><volume>369</volume><fpage>m2468</fpage><pub-id pub-id-type="doi">10.1136/bmj.m2468</pub-id><?supplied-pmid 32554429?><pub-id pub-id-type="pmid">32554429</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Bennet, S. M. &#x00026; Young, S. T. The Pioneering Antimicrobial Subscriptions to End Up Surging Resistance Act of 2020. (The PASTEUR Act. Michael Bennet, U.S. Senator for Colorado); <ext-link ext-link-type="uri" xlink:href="https://www.bennet.senate.gov/public/_cache/files/b/5/b5032465-bf79-4dca-beba-50fb9b0f4aee/C1FD8B8C4143F1332DC6A5E5EC09C83B.bon20468.pdf">https://www.bennet.senate.gov/public/_cache/files/b/5/b5032465-bf79-4dca-beba-50fb9b0f4aee/C1FD8B8C4143F1332DC6A5E5EC09C83B.bon20468.pdf</ext-link> (2020).</mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Davis, D. K. Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019. DISARM Act of 2019. (Congress.gov, 2019) <ext-link ext-link-type="uri" xlink:href="https://www.congress.gov/116/bills/hr4100/BILLS-116hr4100ih.pdf">https://www.congress.gov/116/bills/hr4100/BILLS-116hr4100ih.pdf</ext-link> (2019).</mixed-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasegaram</surname><given-names>M</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><article-title>The Global Antibiotic Research and Development Partnership (GARDP) not-for-profit model of antibiotic development</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>1295</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00101</pub-id><?supplied-pmid 32406675?><pub-id pub-id-type="pmid">32406675</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alm</surname><given-names>RA</given-names></name><name><surname>Gallant</surname><given-names>K</given-names></name></person-group><article-title>Innovation in antimicrobial resistance: the CARB-X perspective</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>1317</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00026</pub-id><?supplied-pmid 32202756?><pub-id pub-id-type="pmid">32202756</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other"><italic>Innovative Medicines Initiative (IMI) AMR Accelerator Programme</italic>. Collaboration for prevention and treatment of multi-drug resistant bacterial infections (COMBINE, 2019). <ext-link ext-link-type="uri" xlink:href="https://amr-accelerator.eu/project/combine/">https://amr-accelerator.eu/project/combine/</ext-link></mixed-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other"><italic>BEAM Alliance</italic>. BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics. (BEAM Alliance, 2020) <ext-link ext-link-type="uri" xlink:href="https://beam-alliance.eu/wp-content/uploads/2020/09/post-amr-conference-paper.pdf">https://beam-alliance.eu/wp-content/uploads/2020/09/post-amr-conference-paper.pdf</ext-link></mixed-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>A</given-names></name></person-group><article-title>Fostering antibiotic development through impact funding</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>1311</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00069</pub-id><?supplied-pmid 32527099?><pub-id pub-id-type="pmid">32527099</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuegg</surname><given-names>J</given-names></name><name><surname>Hansford</surname><given-names>KA</given-names></name><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name></person-group><article-title>How to stimulate and facilitate early stage antibiotic discovery</article-title><source>ACS Infect. Dis.</source><year>2020</year><volume>6</volume><fpage>1302</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00163</pub-id><?supplied-pmid 32527097?><pub-id pub-id-type="pmid">32527097</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Hengel</surname><given-names>AJ</given-names></name><name><surname>Marin</surname><given-names>L</given-names></name></person-group><article-title>Research, innovation, and policy: an alliance combating antimicrobial resistance</article-title><source>Trends Microbiol.</source><year>2019</year><volume>27</volume><fpage>287</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.12.005</pub-id><?supplied-pmid 30638776?><pub-id pub-id-type="pmid">30638776</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpkin</surname><given-names>VL</given-names></name><name><surname>Renwick</surname><given-names>MJ</given-names></name><name><surname>Kelly</surname><given-names>R</given-names></name><name><surname>Mossialos</surname><given-names>E</given-names></name></person-group><article-title>Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps</article-title><source>J. Antibiot.</source><year>2017</year><volume>70</volume><fpage>1087</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1038/ja.2017.124</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><mixed-citation publication-type="other"><italic>BEAM Alliance</italic>. Incentivising a sustainable response to the threat of AMR. (BEAM Alliance, 2019) <ext-link ext-link-type="uri" xlink:href="https://beam-alliance.eu/wp-content/uploads/2019/11/the-beam-pull-memo.pdf">https://beam-alliance.eu/wp-content/uploads/2019/11/the-beam-pull-memo.pdf</ext-link></mixed-citation></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="other"><italic>European Commission</italic>. A European One Health Action Plan against Antimicrobial Resistance. (AMR). (European Commission, 2017) <ext-link ext-link-type="uri" xlink:href="https://ec.europa.eu/health/sites/default/files/antimicrobial_resistance/docs/amr_2017_action-plan.pdf">https://ec.europa.eu/health/sites/default/files/antimicrobial_resistance/docs/amr_2017_action-plan.pdf</ext-link></mixed-citation></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other"><italic>World Health Organization</italic> (WHO). Global action plan on antimicrobial resistance. (WHO, 2015) <ext-link ext-link-type="uri" xlink:href="https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/">https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/</ext-link></mixed-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>JP</given-names></name><name><surname>Rees</surname><given-names>S</given-names></name><name><surname>Kalindjian</surname><given-names>SB</given-names></name><name><surname>Philpott</surname><given-names>KL</given-names></name></person-group><article-title>Principles of early drug discovery</article-title><source>Br. J. Pharmacol.</source><year>2011</year><volume>162</volume><fpage>1239</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01127.x</pub-id><?supplied-pmid 21091654?><pub-id pub-id-type="pmid">21091654</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>AS</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>Polypharmacology: drug discovery for the future</article-title><source>Expert Rev. Clin. Pharmacol.</source><year>2013</year><volume>6</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1586/ecp.12.74</pub-id><?supplied-pmid 23272792?><pub-id pub-id-type="pmid">23272792</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyers</surname><given-names>M</given-names></name><name><surname>Wright</surname><given-names>GD</given-names></name></person-group><article-title>Drug combinations: a strategy to extend the life of antibiotics in the 21st century</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>141</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0141-x</pub-id><?supplied-pmid 30683887?><pub-id pub-id-type="pmid">30683887</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Shea</surname><given-names>R</given-names></name><name><surname>Moser</surname><given-names>HE</given-names></name></person-group><article-title>Physicochemical properties of antibacterial compounds: implications for drug discovery</article-title><source>J. Med. Chem.</source><year>2008</year><volume>51</volume><fpage>2871</fpage><lpage>2878</lpage><pub-id pub-id-type="doi">10.1021/jm700967e</pub-id><?supplied-pmid 18260614?><pub-id pub-id-type="pmid">18260614</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reck</surname><given-names>F</given-names></name><name><surname>Jansen</surname><given-names>JM</given-names></name><name><surname>Moser</surname><given-names>HE</given-names></name></person-group><article-title>Challenges of antibacterial drug discovery</article-title><source>Arkivoc</source><year>2020</year><volume>2019</volume><fpage>227</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.24820/ark.5550190.p010.955</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="other"><italic>AMR Industry Alliance</italic>. Declaration by the pharmaceutical, biotechnology and diagnostics industries on combating antimicrobial resistance. (AMR Industry Alliance, 2016) <ext-link ext-link-type="uri" xlink:href="https://www.amrindustryalliance.org/wp-content/uploads/2017/12/AMR-Industry-Declaration.pdf">https://www.amrindustryalliance.org/wp-content/uploads/2017/12/AMR-Industry-Declaration.pdf</ext-link></mixed-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karawajczyk</surname><given-names>A</given-names></name><name><surname>Orrling</surname><given-names>KM</given-names></name><name><surname>Vlieger</surname><given-names>JSB</given-names></name><name><surname>de, Rijnders</surname><given-names>T</given-names></name><name><surname>Tzalis</surname><given-names>D</given-names></name></person-group><article-title>The European lead factory: a blueprint for public-private partnerships in early drug discovery</article-title><source>Front. Med.</source><year>2016</year><volume>3</volume><fpage>75</fpage></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgentin</surname><given-names>R</given-names></name><etal/></person-group><article-title>Translation of innovative chemistry into screening libraries: an exemplar partnership from the European Lead Factory</article-title><source>Drug Discov. Today</source><year>2018</year><volume>23</volume><fpage>1578</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2018.05.007</pub-id><?supplied-pmid 29753124?><pub-id pub-id-type="pmid">29753124</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besnard</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>PS</given-names></name><name><surname>Hopkins</surname><given-names>AL</given-names></name><name><surname>Pannifer</surname><given-names>AD</given-names></name></person-group><article-title>The Joint European Compound Library: boosting precompetitive research</article-title><source>Drug Discov. Today</source><year>2015</year><volume>20</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2014.08.014</pub-id><?supplied-pmid 25205347?><pub-id pub-id-type="pmid">25205347</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theuretzbacher</surname><given-names>U</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><article-title>Non-traditional antibacterial therapeutic options and challenges</article-title><source>Cell Host Microbe</source><year>2019</year><volume>26</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.06.004</pub-id><?supplied-pmid 31295426?><pub-id pub-id-type="pmid">31295426</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleitas Mart&#x000ed;nez</surname><given-names>O</given-names></name><name><surname>Cardoso</surname><given-names>MH</given-names></name><name><surname>Ribeiro</surname><given-names>SM</given-names></name><name><surname>Franco</surname><given-names>OL</given-names></name></person-group><article-title>Recent advances in anti-virulence therapeutic strategies with a focus on dismantling bacterial membrane microdomains, toxin neutralization, quorum-sensing interference and biofilm inhibition</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2019</year><volume>9</volume><fpage>74</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2019.00074</pub-id><?supplied-pmid 31001485?><pub-id pub-id-type="pmid">31001485</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Ellermann</surname><given-names>M</given-names></name><name><surname>Sperandio</surname><given-names>V</given-names></name></person-group><article-title>Taming the beast: Interplay between gut small molecules and enteric pathogens</article-title><source>Infect. Immun.</source><year>2019</year><volume>87</volume><fpage>e00131-19</fpage><pub-id pub-id-type="doi">10.1128/IAI.00131-19</pub-id><?supplied-pmid 31262983?><pub-id pub-id-type="pmid">31262983</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laws</surname><given-names>M</given-names></name><name><surname>Shaaban</surname><given-names>A</given-names></name><name><surname>Rahman</surname><given-names>KM</given-names></name></person-group><article-title>Antibiotic resistance breakers: current approaches and future directions</article-title><source>FEMS Microbiol. Rev.</source><year>2019</year><volume>43</volume><fpage>490</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuz014</pub-id><?supplied-pmid 31150547?><pub-id pub-id-type="pmid">31150547</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annunziato</surname><given-names>G</given-names></name></person-group><article-title>Strategies to overcome antimicrobial resistance (AMR) making use of non-essential target inhibitors: a review</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><fpage>5844</fpage><pub-id pub-id-type="doi">10.3390/ijms20235844</pub-id><pub-id pub-id-type="pmid">31766441</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvert</surname><given-names>MB</given-names></name><name><surname>Jumde</surname><given-names>VR</given-names></name><name><surname>Titz</surname><given-names>A</given-names></name></person-group><article-title>Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections</article-title><source>Beilstein J. Org. Chem.</source><year>2018</year><volume>14</volume><fpage>2607</fpage><lpage>2617</lpage><pub-id pub-id-type="doi">10.3762/bjoc.14.239</pub-id><?supplied-pmid 30410623?><pub-id pub-id-type="pmid">30410623</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000fc;tz</surname><given-names>C</given-names></name><name><surname>Empting</surname><given-names>M</given-names></name></person-group><article-title>Targeting the <italic>Pseudomonas</italic> quinolone signal quorum sensing system for the discovery of novel anti-infective pathoblockers</article-title><source>Beilstein J. Org. Chem.</source><year>2018</year><volume>14</volume><fpage>2627</fpage><lpage>2645</lpage><pub-id pub-id-type="doi">10.3762/bjoc.14.241</pub-id><?supplied-pmid 30410625?><pub-id pub-id-type="pmid">30410625</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Glycomimetic, orally bioavailable LecB inhibitors block biofilm formation of pseudomonas aeruginosa</article-title><source>J. Am. Chem. Soc.</source><year>2018</year><volume>140</volume><fpage>2537</fpage><lpage>2545</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b11133</pub-id><?supplied-pmid 29272578?><pub-id pub-id-type="pmid">29272578</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudaher</surname><given-names>E</given-names></name><name><surname>Shaffer</surname><given-names>CL</given-names></name></person-group><article-title>Inhibiting bacterial secretion systems in the fight against antibiotic resistance</article-title><source>MedChemComm</source><year>2019</year><volume>10</volume><fpage>682</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1039/C9MD00076C</pub-id><?supplied-pmid 31741728?><pub-id pub-id-type="pmid">31741728</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>MC</given-names></name><name><surname>Linington</surname><given-names>RG</given-names></name><name><surname>Auerbuch</surname><given-names>V</given-names></name></person-group><article-title>Chemical inhibitors of the type three secretion system: disarming bacterial pathogens</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>5433</fpage><lpage>5441</lpage><pub-id pub-id-type="doi">10.1128/AAC.00975-12</pub-id><?supplied-pmid 22850518?><pub-id pub-id-type="pmid">22850518</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;nauer</surname><given-names>E</given-names></name><etal/></person-group><article-title>Discovery of a potent inhibitor class with high selectivity toward clostridial collagenases</article-title><source>J. Am. Chem. Soc.</source><year>2017</year><volume>139</volume><fpage>12696</fpage><lpage>12703</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b06935</pub-id><?supplied-pmid 28820255?><pub-id pub-id-type="pmid">28820255</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paolino</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of potent inhibitors of the <italic>Mycobacterium tuberculosis</italic> virulence factor Zmp1 and evaluation of their effect on mycobacterial survival inside macrophages</article-title><source>ChemMedChem</source><year>2018</year><volume>13</volume><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201700759</pub-id><?supplied-pmid 29334428?><pub-id pub-id-type="pmid">29334428</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>RL</given-names></name><etal/></person-group><article-title>New multidrug efflux inhibitors for Gram-negative bacteria</article-title><source>mBio</source><year>2020</year><volume>11</volume><fpage>e01340-20</fpage><pub-id pub-id-type="doi">10.1128/mBio.01340-20</pub-id><?supplied-pmid 32665275?><pub-id pub-id-type="pmid">32665275</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>K</given-names></name><name><surname>Bradford</surname><given-names>PA</given-names></name></person-group><article-title>Interplay between &#x003b2;-lactamases and new &#x003b2;-lactamase inhibitors</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>295</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0159-8</pub-id><?supplied-pmid 30837684?><pub-id pub-id-type="pmid">30837684</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tooke</surname><given-names>CL</given-names></name><etal/></person-group><article-title>&#x003b2;-Lactamases and &#x003b2;-lactamase inhibitors in the 21st century</article-title><source>J. Mol. Biol.</source><year>2019</year><volume>431</volume><fpage>3472</fpage><lpage>3500</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.04.002</pub-id><?supplied-pmid 30959050?><pub-id pub-id-type="pmid">30959050</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smirnova</surname><given-names>GV</given-names></name><name><surname>Oktyabrsky</surname><given-names>ON</given-names></name></person-group><article-title>Glutathione in bacteria</article-title><source>Biochemistry</source><year>2005</year><volume>70</volume><fpage>1199</fpage><lpage>1211</lpage><?supplied-pmid 16336178?><pub-id pub-id-type="pmid">16336178</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>NH</given-names></name><etal/></person-group><article-title>A glutathione-dependent detoxification system is required for formaldehyde resistance and optimal survival of <italic>Neisseria meningitidis</italic> in biofilms</article-title><source>Antioxid. Redox Signal.</source><year>2013</year><volume>18</volume><fpage>743</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1089/ars.2012.4749</pub-id><?supplied-pmid 22937752?><pub-id pub-id-type="pmid">22937752</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>P</given-names></name><etal/></person-group><article-title>The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>2625</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-20989-8</pub-id><?supplied-pmid 29422632?><pub-id pub-id-type="pmid">29422632</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>IK</given-names></name><name><surname>Bajeli</surname><given-names>S</given-names></name><name><surname>Akela</surname><given-names>AK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Bioenergetics of <italic>Mycobacterium</italic>: an emerging landscape for drug discovery</article-title><source>Pathogens</source><year>2018</year><volume>7</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.3390/pathogens7010024</pub-id><pub-id pub-id-type="pmid">29473841</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fol</surname><given-names>M</given-names></name><name><surname>W&#x00142;odarczyk</surname><given-names>M</given-names></name><name><surname>Druszczy&#x00144;ska</surname><given-names>M</given-names></name></person-group><article-title>Host epigenetics in intracellular pathogen infections</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><fpage>4573</fpage><pub-id pub-id-type="doi">10.3390/ijms21134573</pub-id><pub-id pub-id-type="pmid">32605029</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>D</given-names></name><name><surname>Veeraraghavan</surname><given-names>B</given-names></name><name><surname>Elangovan</surname><given-names>R</given-names></name><name><surname>Vivekanandan</surname><given-names>P</given-names></name></person-group><article-title>Antibiotic resistance and epigenetics: more to it than meets the eye</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e02225-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.02225-19</pub-id><?supplied-pmid 31740560?><pub-id pub-id-type="pmid">31740560</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venter</surname><given-names>H</given-names></name></person-group><article-title>Reversing resistance to counter antimicrobial resistance in the World Health Organisation&#x02019;s critical priority of most dangerous pathogens</article-title><source>Biosci. Rep.</source><year>2019</year><volume>39</volume><fpage>BSR20180474</fpage><pub-id pub-id-type="doi">10.1042/BSR20180474</pub-id><?supplied-pmid 30910848?><pub-id pub-id-type="pmid">30910848</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezzoagli</surname><given-names>C</given-names></name><name><surname>Archetti</surname><given-names>M</given-names></name><name><surname>Mignot</surname><given-names>I</given-names></name><name><surname>Baumgartner</surname><given-names>M</given-names></name><name><surname>K&#x000fc;mmerli</surname><given-names>R</given-names></name></person-group><article-title>Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in <italic>Pseudomonas aeruginosa</italic></article-title><source>PLoS Biol.</source><year>2020</year><volume>18</volume><fpage>e3000805</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.3000805</pub-id><?supplied-pmid 32810152?><pub-id pub-id-type="pmid">32810152</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strich</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>1172</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30153-5</pub-id><?supplied-pmid 32505231?><pub-id pub-id-type="pmid">32505231</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakemeyer</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Mandl</surname><given-names>FA</given-names></name><name><surname>Hammann</surname><given-names>P</given-names></name><name><surname>Sieber</surname><given-names>SA</given-names></name></person-group><article-title>Thinking outside the box &#x02014; novel antibacterials to tackle the resistance crisis</article-title><source>Angew. Chem. Int. Ed.</source><year>2018</year><volume>57</volume><fpage>14440</fpage><lpage>14475</lpage><pub-id pub-id-type="doi">10.1002/anie.201804971</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennessen</surname><given-names>F</given-names></name><etal/></person-group><article-title>Amidochelocardin overcomes resistance mechanisms exerted on tetracyclines and natural chelocardin</article-title><source>Antibiotics</source><year>2020</year><volume>9</volume><fpage>619</fpage><pub-id pub-id-type="doi">10.3390/antibiotics9090619</pub-id><pub-id pub-id-type="pmid">32962088</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarigul</surname><given-names>N</given-names></name><name><surname>Korkmaz</surname><given-names>F</given-names></name><name><surname>Kurultak</surname><given-names>&#x00130;</given-names></name></person-group><article-title>A new artificial urine protocol to better imitate human urine</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>20159</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-56693-4</pub-id><?supplied-pmid 31882896?><pub-id pub-id-type="pmid">31882896</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name></person-group><article-title>Iron homeostasis in host defence and inflammation</article-title><source>Nat. Rev. Immunol.</source><year>2015</year><volume>15</volume><fpage>500</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1038/nri3863</pub-id><?supplied-pmid 26160612?><pub-id pub-id-type="pmid">26160612</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>AC</given-names></name><name><surname>Almeida</surname><given-names>JI</given-names></name><name><surname>Lima</surname><given-names>IS</given-names></name><name><surname>Kapit&#x000e3;o</surname><given-names>AS</given-names></name><name><surname>Gozzelino</surname><given-names>R</given-names></name></person-group><article-title>Iron metabolism and the inflammatory response</article-title><source>IUBMB Life</source><year>2017</year><volume>69</volume><fpage>442</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1002/iub.1635</pub-id><?supplied-pmid 28474474?><pub-id pub-id-type="pmid">28474474</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krismer</surname><given-names>B</given-names></name><name><surname>Weidenmaier</surname><given-names>C</given-names></name><name><surname>Zipperer</surname><given-names>A</given-names></name><name><surname>Peschel</surname><given-names>A</given-names></name></person-group><article-title>The commensal lifestyle of <italic>Staphylococcus aureus</italic> and its interactions with the nasal microbiota</article-title><source>Nat. Rev. Microbiol.</source><year>2017</year><volume>15</volume><fpage>675</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.104</pub-id><?supplied-pmid 29021598?><pub-id pub-id-type="pmid">29021598</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayaz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Synergistic interactions of phytochemicals with antimicrobial agents: Potential strategy to counteract drug resistance</article-title><source>Chem. Biol. Interact.</source><year>2019</year><volume>308</volume><fpage>294</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2019.05.050</pub-id><?supplied-pmid 31158333?><pub-id pub-id-type="pmid">31158333</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahomoodally</surname><given-names>MF</given-names></name><name><surname>Sadeer</surname><given-names>NB</given-names></name></person-group><article-title>Antibiotic potentiation of natural products: A promising target to fight pathogenic bacteria</article-title><source>Curr. Drug Targets</source><year>2020</year><volume>22</volume><fpage>555</fpage><lpage>572</lpage></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkinson</surname><given-names>EI</given-names></name><etal/></person-group><article-title>Deoxynybomycins inhibit mutant DNA gyrase and rescue mice infected with fluoroquinolone-resistant bacteria</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>6947</fpage><pub-id pub-id-type="doi">10.1038/ncomms7947</pub-id><?supplied-pmid 25907309?><pub-id pub-id-type="pmid">25907309</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Aspergillomarasmine A overcomes metallo-&#x003b2;-lactamase antibiotic resistance</article-title><source>Nature</source><year>2014</year><volume>510</volume><fpage>503</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/nature13445</pub-id><?supplied-pmid 24965651?><pub-id pub-id-type="pmid">24965651</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Target-based identification of whole-cell active inhibitors of biotin biosynthesis in <italic>Mycobacterium tuberculosis</italic></article-title><source>Chem. Biol.</source><year>2015</year><volume>22</volume><fpage>76</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2014.11.012</pub-id><?supplied-pmid 25556942?><pub-id pub-id-type="pmid">25556942</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Prabhakar</surname><given-names>YS</given-names></name></person-group><article-title>Target based drug design - a reality in virtual sphere</article-title><source>Curr. Med. Chem.</source><year>2015</year><volume>22</volume><fpage>1603</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.2174/0929867322666150209151209</pub-id><?supplied-pmid 25666805?><pub-id pub-id-type="pmid">25666805</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graef</surname><given-names>F</given-names></name><etal/></person-group><article-title><italic>In vitro</italic> model of the Gram-negative bacterial cell envelope for investigation of anti-infective permeation kinetics</article-title><source>ACS Infect. Dis.</source><year>2018</year><volume>4</volume><fpage>1188</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00165</pub-id><?supplied-pmid 29750862?><pub-id pub-id-type="pmid">29750862</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>R</given-names></name><etal/></person-group><article-title>A hydrogel-based in vitro assay for the fast prediction of antibiotic accumulation in Gram-negative bacteria</article-title><source>Mater. Today Bio</source><year>2020</year><volume>8</volume><fpage>100084</fpage><pub-id pub-id-type="doi">10.1016/j.mtbio.2020.100084</pub-id><?supplied-pmid 33313504?><pub-id pub-id-type="pmid">33313504</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>All-Assay-Max2 pQSAR: activity predictions as accurate as four-concentration IC<sub>50</sub>s for 8558 Novartis assays</article-title><source>J. Chem. Inf. Model.</source><year>2019</year><volume>59</volume><fpage>4450</fpage><lpage>4459</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.9b00375</pub-id><?supplied-pmid 31518124?><pub-id pub-id-type="pmid">31518124</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durrant</surname><given-names>JD</given-names></name><name><surname>Amaro</surname><given-names>RE</given-names></name></person-group><article-title>Machine-learning techniques applied to antibacterial drug discovery</article-title><source>Chem. Biol. Drug Des.</source><year>2015</year><volume>85</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/cbdd.12423</pub-id><?supplied-pmid 25521642?><pub-id pub-id-type="pmid">25521642</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>DJ</given-names></name><name><surname>Cragg</surname><given-names>GM</given-names></name></person-group><article-title>Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019</article-title><source>J. Nat. Prod.</source><year>2020</year><volume>83</volume><fpage>770</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b01285</pub-id><?supplied-pmid 32162523?><pub-id pub-id-type="pmid">32162523</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locey</surname><given-names>KJ</given-names></name><name><surname>Lennon</surname><given-names>JT</given-names></name></person-group><article-title>Scaling laws predict global microbial diversity</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>5970</fpage><lpage>5975</lpage><pub-id pub-id-type="doi">10.1073/pnas.1521291113</pub-id><?supplied-pmid 27140646?><pub-id pub-id-type="pmid">27140646</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>LR</given-names></name><etal/></person-group><article-title>A communal catalogue reveals Earth&#x02019;s multiscale microbial diversity</article-title><source>Nature</source><year>2017</year><volume>551</volume><fpage>457</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1038/nature24621</pub-id><?supplied-pmid 29088705?><pub-id pub-id-type="pmid">29088705</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mousa</surname><given-names>WK</given-names></name><name><surname>Athar</surname><given-names>B</given-names></name><name><surname>Merwin</surname><given-names>NJ</given-names></name><name><surname>Magarvey</surname><given-names>NA</given-names></name></person-group><article-title>Antibiotics and specialized metabolites from the human microbiota</article-title><source>Nat. Prod. Rep.</source><year>2017</year><volume>34</volume><fpage>1302</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1039/C7NP00021A</pub-id><?supplied-pmid 29018846?><pub-id pub-id-type="pmid">29018846</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zipperer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Human commensals producing a novel antibiotic impair pathogen colonization</article-title><source>Nature</source><year>2016</year><volume>535</volume><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1038/nature18634</pub-id><?supplied-pmid 27466123?><pub-id pub-id-type="pmid">27466123</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A new antibiotic selectively kills Gram-negative pathogens</article-title><source>Nature</source><year>2019</year><volume>576</volume><fpage>459</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1791-1</pub-id><?supplied-pmid 31747680?><pub-id pub-id-type="pmid">31747680</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adnani</surname><given-names>N</given-names></name><name><surname>Rajski</surname><given-names>SR</given-names></name><name><surname>Bugni</surname><given-names>TS</given-names></name></person-group><article-title>Symbiosis-inspired approaches to antibiotic discovery</article-title><source>Nat. Prod. Rep.</source><year>2017</year><volume>34</volume><fpage>784</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1039/C7NP00009J</pub-id><?supplied-pmid 28561849?><pub-id pub-id-type="pmid">28561849</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodhi</surname><given-names>AF</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Adil</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name></person-group><article-title>Antibiotic discovery: combining isolation chip (iChip) technology and co-culture technique</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>7333</fpage><lpage>7341</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-9193-0</pub-id><?supplied-pmid 29974183?><pub-id pub-id-type="pmid">29974183</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kealey</surname><given-names>C</given-names></name><name><surname>Creaven</surname><given-names>CA</given-names></name><name><surname>Murphy</surname><given-names>CD</given-names></name><name><surname>Brady</surname><given-names>CB</given-names></name></person-group><article-title>New approaches to antibiotic discovery</article-title><source>Biotechnol. Lett.</source><year>2017</year><volume>39</volume><fpage>805</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1007/s10529-017-2311-8</pub-id><?supplied-pmid 28275884?><pub-id pub-id-type="pmid">28275884</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>LL</given-names></name><etal/></person-group><article-title>A new antibiotic kills pathogens without detectable resistance</article-title><source>Nature</source><year>2015</year><volume>517</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1038/nature14098</pub-id><?supplied-pmid 25561178?><pub-id pub-id-type="pmid">25561178</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><etal/></person-group><article-title>Gene-targeted microfluidic cultivation validated by isolation of a gut bacterium listed in Human Microbiome Project&#x02019;s Most Wanted taxa</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>9768</fpage><lpage>9773</lpage><pub-id pub-id-type="doi">10.1073/pnas.1404753111</pub-id><?supplied-pmid 24965364?><pub-id pub-id-type="pmid">24965364</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>L</given-names></name><etal/></person-group><article-title>Highly parallelized microfluidic droplet cultivation and prioritization on antibiotic producers from complex natural microbial communities</article-title><source>eLife</source><year>2021</year><volume>10</volume><fpage>e64774</fpage><pub-id pub-id-type="doi">10.7554/eLife.64774</pub-id><?supplied-pmid 33764297?><pub-id pub-id-type="pmid">33764297</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>High-throughput single-cell cultivation on microfluidic streak plates</article-title><source>Appl. Environ. Microbiol.</source><year>2016</year><volume>82</volume><fpage>2210</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1128/AEM.03588-15</pub-id><?supplied-pmid 26850294?><pub-id pub-id-type="pmid">26850294</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seyedsayamdost</surname><given-names>MR</given-names></name></person-group><article-title>High-throughput platform for the discovery of elicitors of silent bacterial gene clusters</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>7266</fpage><lpage>7271</lpage><pub-id pub-id-type="doi">10.1073/pnas.1400019111</pub-id><?supplied-pmid 24808135?><pub-id pub-id-type="pmid">24808135</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pishchany</surname><given-names>G</given-names></name><etal/></person-group><article-title>Amycomicin is a potent and specific antibiotic discovered with a targeted interaction screen</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>10124</fpage><lpage>10129</lpage><pub-id pub-id-type="doi">10.1073/pnas.1807613115</pub-id><?supplied-pmid 30228116?><pub-id pub-id-type="pmid">30228116</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>DK</given-names></name><name><surname>Khulan</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name></person-group><article-title>Development of a novel cultivation technique for uncultured soil bacteria</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>6666</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-43182-x</pub-id><?supplied-pmid 31040339?><pub-id pub-id-type="pmid">31040339</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masschelein</surname><given-names>J</given-names></name><name><surname>Jenner</surname><given-names>M</given-names></name><name><surname>Challis</surname><given-names>GL</given-names></name></person-group><article-title>Antibiotics from Gram-negative bacteria: a comprehensive overview and selected biosynthetic highlights</article-title><source>Nat. Prod. Rep.</source><year>2017</year><volume>34</volume><fpage>712</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1039/C7NP00010C</pub-id><?supplied-pmid 28650032?><pub-id pub-id-type="pmid">28650032</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Correlating chemical diversity with taxonomic distance for discovery of natural products in myxobacteria</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>803</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03184-1</pub-id><?supplied-pmid 29476047?><pub-id pub-id-type="pmid">29476047</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>CC</given-names></name><name><surname>Fenical</surname><given-names>W</given-names></name></person-group><article-title>Antibacterials from the sea</article-title><source>Chem. Eur. J.</source><year>2010</year><volume>16</volume><fpage>12512</fpage><lpage>12525</lpage><pub-id pub-id-type="doi">10.1002/chem.201001279</pub-id><?supplied-pmid 20845412?><pub-id pub-id-type="pmid">20845412</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrudan</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Socially mediated induction and suppression of antibiosis during bacterial coexistence</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>11054</fpage><lpage>11059</lpage><pub-id pub-id-type="doi">10.1073/pnas.1504076112</pub-id><?supplied-pmid 26216986?><pub-id pub-id-type="pmid">26216986</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granato</surname><given-names>ET</given-names></name><name><surname>Meiller-Legrand</surname><given-names>TA</given-names></name><name><surname>Foster</surname><given-names>KR</given-names></name></person-group><article-title>The evolution and ecology of bacterial warfare</article-title><source>Curr. Biol.</source><year>2019</year><volume>29</volume><fpage>R521</fpage><lpage>R537</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2019.04.024</pub-id><?supplied-pmid 31163166?><pub-id pub-id-type="pmid">31163166</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>SA</given-names></name><name><surname>Ramachandran</surname><given-names>A</given-names></name><name><surname>Perron</surname><given-names>GG</given-names></name></person-group><article-title>Antibiotic pollution in the environment: from microbial ecology to public policy</article-title><source>Microorganisms</source><year>2019</year><volume>7</volume><fpage>180</fpage><pub-id pub-id-type="doi">10.3390/microorganisms7060180</pub-id><pub-id pub-id-type="pmid">31234491</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>F</given-names></name><etal/></person-group><article-title>Wastewater treatment plant resistomes are shaped by bacterial composition, genetic exchange, and upregulated expression in the effluent microbiomes</article-title><source>ISME J.</source><year>2019</year><volume>13</volume><fpage>346</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/s41396-018-0277-8</pub-id><?supplied-pmid 30250051?><pub-id pub-id-type="pmid">30250051</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra-Zapata</surname><given-names>L</given-names></name><etal/></person-group><article-title>Inducible antibacterial activity in the bacillales by triphenyl tetrazolium chloride</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>5563</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-62236-z</pub-id><?supplied-pmid 32221330?><pub-id pub-id-type="pmid">32221330</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charusanti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Exploiting adaptive laboratory evolution of <italic>Streptomyces clavuligerus</italic> for antibiotic discovery and overproduction</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e33727</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0033727</pub-id><?supplied-pmid 22470465?><pub-id pub-id-type="pmid">22470465</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan</surname><given-names>MM</given-names></name></person-group><article-title>Plant products as antimicrobial agents</article-title><source>Clin. Microbiol. Rev.</source><year>1999</year><volume>12</volume><fpage>564</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1128/CMR.12.4.564</pub-id><?supplied-pmid 10515903?><pub-id pub-id-type="pmid">10515903</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>DJ</given-names></name><name><surname>Cragg</surname><given-names>GM</given-names></name></person-group><article-title>Plant endophytes and epiphytes: Burgeoning sources of known and &#x0201c;unknown&#x0201d; cytotoxic and antibiotic agents?</article-title><source>Planta Medica</source><year>2020</year><volume>86</volume><fpage>891</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1055/a-1095-1111</pub-id><?supplied-pmid 32023633?><pub-id pub-id-type="pmid">32023633</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyde</surname><given-names>KD</given-names></name><etal/></person-group><article-title>The amazing potential of fungi: 50 ways we can exploit fungi industrially</article-title><source>Fungal Divers.</source><year>2019</year><volume>97</volume><fpage>1</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1007/s13225-019-00430-9</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>ON</given-names></name><etal/></person-group><article-title>Repurposing a peptide toxin from wasp venom into antiinfectives with dual antimicrobial and immunomodulatory properties</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>26936</fpage><lpage>26945</lpage><pub-id pub-id-type="doi">10.1073/pnas.2012379117</pub-id><?supplied-pmid 33046640?><pub-id pub-id-type="pmid">33046640</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medema</surname><given-names>MH</given-names></name><name><surname>Fischbach</surname><given-names>MA</given-names></name></person-group><article-title>Computational approaches to natural product discovery</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>639</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1884</pub-id><?supplied-pmid 26284671?><pub-id pub-id-type="pmid">26284671</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>Hover</surname><given-names>BM</given-names></name><name><surname>Brady</surname><given-names>SF</given-names></name></person-group><article-title>Culture-independent discovery of natural products from soil metagenomes</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2016</year><volume>43</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1007/s10295-015-1706-6</pub-id><?supplied-pmid 26586404?><pub-id pub-id-type="pmid">26586404</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crits-Christoph</surname><given-names>A</given-names></name><name><surname>Diamond</surname><given-names>S</given-names></name><name><surname>Butterfield</surname><given-names>CN</given-names></name><name><surname>Thomas</surname><given-names>BC</given-names></name><name><surname>Banfield</surname><given-names>JF</given-names></name></person-group><article-title>Novel soil bacteria possess diverse genes for secondary metabolite biosynthesis</article-title><source>Nature</source><year>2018</year><volume>558</volume><fpage>440</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0207-y</pub-id><?supplied-pmid 29899444?><pub-id pub-id-type="pmid">29899444</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milshteyn</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>JS</given-names></name><name><surname>Brady</surname><given-names>SF</given-names></name></person-group><article-title>Mining the metabiome: identifying novel natural products from microbial communities</article-title><source>Chem. Biol.</source><year>2014</year><volume>21</volume><fpage>1211</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2014.08.006</pub-id><?supplied-pmid 25237864?><pub-id pub-id-type="pmid">25237864</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myronovskyi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Generation of a cluster-free <italic>Streptomyces albus</italic> chassis strains for improved heterologous expression of secondary metabolite clusters</article-title><source>Metab. Eng.</source><year>2018</year><volume>49</volume><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2018.09.004</pub-id><?supplied-pmid 30196100?><pub-id pub-id-type="pmid">30196100</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Escribano</surname><given-names>JP</given-names></name><name><surname>Bibb</surname><given-names>MJ</given-names></name></person-group><article-title>Engineering <italic>Streptomyces coelicolor</italic> for heterologous expression of secondary metabolite gene clusters</article-title><source>Microb. Biotechnol.</source><year>2011</year><volume>4</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7915.2010.00219.x</pub-id><?supplied-pmid 21342466?><pub-id pub-id-type="pmid">21342466</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komatsu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Engineered <italic>Streptomyces avermitilis</italic> host for heterologous expression of biosynthetic gene cluster for secondary metabolites</article-title><source>ACS Synth. Biol.</source><year>2013</year><volume>2</volume><fpage>384</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1021/sb3001003</pub-id><?supplied-pmid 23654282?><pub-id pub-id-type="pmid">23654282</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherwood</surname><given-names>EJ</given-names></name><name><surname>Hesketh</surname><given-names>AR</given-names></name><name><surname>Bibb</surname><given-names>MJ</given-names></name></person-group><article-title>Cloning and analysis of the planosporicin lantibiotic biosynthetic gene cluster of <italic>Planomonospora alba</italic></article-title><source>J. Bacteriol.</source><year>2013</year><volume>195</volume><fpage>2309</fpage><lpage>2321</lpage><pub-id pub-id-type="doi">10.1128/JB.02291-12</pub-id><?supplied-pmid 23475977?><pub-id pub-id-type="pmid">23475977</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Engineering of <italic>Streptomyces lividans</italic> for heterologous expression of secondary metabolite gene clusters</article-title><source>Microb. Cell Fact.</source><year>2020</year><volume>19</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/s12934-020-1277-8</pub-id><?supplied-pmid 31918711?><pub-id pub-id-type="pmid">31918711</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>CRAGE enables rapid activation of biosynthetic gene clusters in undomesticated bacteria</article-title><source>Nat. Microbiol.</source><year>2019</year><volume>4</volume><fpage>2498</fpage><lpage>2510</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0573-8</pub-id><?supplied-pmid 31611640?><pub-id pub-id-type="pmid">31611640</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Weber</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name></person-group><article-title>CRISPR/Cas-based genome engineering in natural product discovery</article-title><source>Nat. Prod. Rep.</source><year>2019</year><volume>36</volume><fpage>1262</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1039/C8NP00089A</pub-id><?supplied-pmid 30548045?><pub-id pub-id-type="pmid">30548045</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Fuente-N&#x000fa;&#x000f1;ez</surname><given-names>Cde</given-names></name><name><surname>Lu</surname><given-names>TK</given-names></name></person-group><article-title>CRISPR-Cas9 technology: applications in genome engineering, development of sequence-specific antimicrobials, and future prospects</article-title><source>Integr. Biol.</source><year>2017</year><volume>9</volume><fpage>109</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1039/c6ib00140h</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>ExoCET: exonuclease in vitro assembly combined with RecET recombination for highly efficient direct DNA cloning from complex genomes</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>e28</fpage><pub-id pub-id-type="doi">10.1093/nar/gkx1249</pub-id><?supplied-pmid 29240926?><pub-id pub-id-type="pmid">29240926</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>F</given-names></name><etal/></person-group><article-title>AFEAP cloning: a precise and efficient method for large DNA sequence assembly</article-title><source>BMC Biotechnol.</source><year>2017</year><volume>17</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/s12896-017-0394-x</pub-id><?supplied-pmid 29137618?><pub-id pub-id-type="pmid">29137618</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snoeck</surname><given-names>N</given-names></name><etal/></person-group><article-title>Serine integrase recombinational engineering (SIRE): A versatile toolbox for genome editing</article-title><source>Biotechnol. Bioeng.</source><year>2019</year><volume>116</volume><fpage>364</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1002/bit.26854</pub-id><?supplied-pmid 30345503?><pub-id pub-id-type="pmid">30345503</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kautsar</surname><given-names>SA</given-names></name><etal/></person-group><article-title>MIBiG 2.0: a repository for biosynthetic gene clusters of known function</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>D454</fpage><lpage>D458</lpage><?supplied-pmid 31612915?><pub-id pub-id-type="pmid">31612915</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blin</surname><given-names>K</given-names></name><etal/></person-group><article-title>antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>W81</fpage><lpage>W87</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz310</pub-id><?supplied-pmid 31032519?><pub-id pub-id-type="pmid">31032519</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skinnider</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Comprehensive prediction of secondary metabolite structure and biological activity from microbial genome sequences</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>6058</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-19986-1</pub-id><?supplied-pmid 33247171?><pub-id pub-id-type="pmid">33247171</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alanjary</surname><given-names>M</given-names></name><name><surname>Cano-Prieto</surname><given-names>C</given-names></name><name><surname>Gross</surname><given-names>H</given-names></name><name><surname>Medema</surname><given-names>MH</given-names></name></person-group><article-title>Computer-aided re-engineering of nonribosomal peptide and polyketide biosynthetic assembly lines</article-title><source>Nat. Prod. Rep.</source><year>2019</year><volume>36</volume><fpage>1249</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1039/C9NP00021F</pub-id><?supplied-pmid 31259995?><pub-id pub-id-type="pmid">31259995</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assembling a plug-and-play production line for combinatorial biosynthesis of aromatic polyketides in <italic>Escherichia coli</italic></article-title><source>PLoS Biol.</source><year>2019</year><volume>17</volume><fpage>e3000347</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.3000347</pub-id><?supplied-pmid 31318855?><pub-id pub-id-type="pmid">31318855</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Palsson</surname><given-names>B</given-names></name><name><surname>Cho</surname><given-names>B-K</given-names></name></person-group><article-title>Repurposing modular polyketide synthases and non-ribosomal peptide synthetases for novel chemical biosynthesis</article-title><source>Front. Mol. Biosci.</source><year>2020</year><volume>7</volume><fpage>87</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2020.00087</pub-id><?supplied-pmid 32500080?><pub-id pub-id-type="pmid">32500080</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozh&#x000fc;y&#x000fc;k</surname><given-names>KAJ</given-names></name><etal/></person-group><article-title>Modification and de novo design of non-ribosomal peptide synthetases using specific assembly points within condensation domains</article-title><source>Nat. Chem.</source><year>2019</year><volume>11</volume><fpage>653</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1038/s41557-019-0276-z</pub-id><?supplied-pmid 31182822?><pub-id pub-id-type="pmid">31182822</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Enghiad</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name></person-group><article-title>New tools for reconstruction and heterologous expression of natural product biosynthetic gene clusters</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1039/C5NP00085H</pub-id><?supplied-pmid 26647833?><pub-id pub-id-type="pmid">26647833</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>G-Y</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name></person-group><article-title>Rational synthetic pathway refactoring of natural products biosynthesis in actinobacteria</article-title><source>Metab. Eng.</source><year>2017</year><volume>39</volume><fpage>228</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2016.12.006</pub-id><?supplied-pmid 28013086?><pub-id pub-id-type="pmid">28013086</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JJ</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Moore</surname><given-names>BS</given-names></name></person-group><article-title>Genetic platforms for heterologous expression of microbial natural products</article-title><source>Nat. Prod. Rep.</source><year>2019</year><volume>36</volume><fpage>1313</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.1039/C9NP00025A</pub-id><?supplied-pmid 31197291?><pub-id pub-id-type="pmid">31197291</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Heterologous expression of bacterial natural product biosynthetic pathways</article-title><source>Nat. Prod. Rep.</source><year>2019</year><volume>36</volume><fpage>1412</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1039/C8NP00091C</pub-id><?supplied-pmid 30620035?><pub-id pub-id-type="pmid">30620035</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Masubuchi</surname><given-names>M</given-names></name></person-group><article-title>Dereplication of microbial extracts and related analytical technologies</article-title><source>J. Antibiot.</source><year>2014</year><volume>67</volume><fpage>353</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/ja.2014.12</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Molecular networking as a drug discovery, drug metabolism, and precision medicine strategy</article-title><source>Trends Pharmacol. Sci.</source><year>2017</year><volume>38</volume><fpage>143</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2016.10.011</pub-id><?supplied-pmid 27842887?><pub-id pub-id-type="pmid">27842887</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>M</given-names></name><etal/></person-group><article-title>MolNetEnhancer: Enhanced molecular networks by integrating metabolome mining and annotation tools</article-title><source>Metabolites</source><year>2019</year><volume>9</volume><fpage>144</fpage><pub-id pub-id-type="doi">10.3390/metabo9070144</pub-id><pub-id pub-id-type="pmid">31315242</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebal</surname><given-names>UW</given-names></name><name><surname>Phan</surname><given-names>ANT</given-names></name><name><surname>Sudhakar</surname><given-names>M</given-names></name><name><surname>Raman</surname><given-names>K</given-names></name><name><surname>Blank</surname><given-names>LM</given-names></name></person-group><article-title>Machine learning applications for mass spectrometry-based metabolomics</article-title><source>Metabolites</source><year>2020</year><volume>10</volume><fpage>243</fpage><pub-id pub-id-type="doi">10.3390/metabo10060243</pub-id><pub-id pub-id-type="pmid">32545768</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubert</surname><given-names>J</given-names></name><name><surname>Nuzillard</surname><given-names>J-M</given-names></name><name><surname>Renault</surname><given-names>J-H</given-names></name></person-group><article-title>Dereplication strategies in natural product research: How many tools and methodologies behind the same concept?</article-title><source>Phytochem. Rev.</source><year>2017</year><volume>16</volume><fpage>55</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s11101-015-9448-7</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Gavin</surname><given-names>A-C</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name></person-group><article-title>Identification of metabolites from tandem mass spectra with a machine learning approach utilizing structural features</article-title><source>Bioinformatics</source><year>2020</year><volume>36</volume><fpage>1213</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz736</pub-id><?supplied-pmid 31605112?><pub-id pub-id-type="pmid">31605112</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zani</surname><given-names>CL</given-names></name><name><surname>Carroll</surname><given-names>AR</given-names></name></person-group><article-title>Database for rapid dereplication of known natural products using data from MS and Fast NMR experiments</article-title><source>J. Nat. Prod.</source><year>2017</year><volume>80</volume><fpage>1758</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.6b01093</pub-id><?supplied-pmid 28616931?><pub-id pub-id-type="pmid">28616931</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Santen</surname><given-names>JA</given-names></name><etal/></person-group><article-title>The natural products atlas: an open access knowledge base for microbial natural products discovery</article-title><source>ACS Cent. Sci.</source><year>2019</year><volume>5</volume><fpage>1824</fpage><lpage>1833</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.9b00806</pub-id><?supplied-pmid 31807684?><pub-id pub-id-type="pmid">31807684</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sharing and community curation of mass spectrometry data with global natural products social molecular networking</article-title><source>Nat. Biotechnol.</source><year>2016</year><volume>34</volume><fpage>828</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1038/nbt.3597</pub-id><?supplied-pmid 27504778?><pub-id pub-id-type="pmid">27504778</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guijas</surname><given-names>C</given-names></name><etal/></person-group><article-title>METLIN: a technology platform for identifying knowns and unknowns</article-title><source>Anal. Chem.</source><year>2018</year><volume>90</volume><fpage>3156</fpage><lpage>3164</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.7b04424</pub-id><?supplied-pmid 29381867?><pub-id pub-id-type="pmid">29381867</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>S</given-names></name><name><surname>Schl&#x000f6;rer</surname><given-names>NE</given-names></name></person-group><article-title>Facilitating quality control for spectra assignments of small organic molecules: nmrshiftdb2&#x02013;a free in-house NMR database with integrated LIMS for academic service laboratories</article-title><source>Magn. Reson. Chem.</source><year>2015</year><volume>53</volume><fpage>582</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1002/mrc.4263</pub-id><?supplied-pmid 25998807?><pub-id pub-id-type="pmid">25998807</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-P&#x000e9;rez</surname><given-names>JL</given-names></name><name><surname>Ther&#x000f3;n</surname><given-names>R</given-names></name><name><surname>del Olmo</surname><given-names>E</given-names></name><name><surname>D&#x000ed;az</surname><given-names>D</given-names></name></person-group><article-title>NAPROC-13: a database for the dereplication of natural product mixtures in bioassay-guided protocols</article-title><source>Bioinformatics</source><year>2007</year><volume>23</volume><fpage>3256</fpage><lpage>3257</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btm516</pub-id><?supplied-pmid 17956876?><pub-id pub-id-type="pmid">17956876</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>CD</given-names></name><name><surname>Neuber</surname><given-names>M</given-names></name><name><surname>Panter</surname><given-names>F</given-names></name><name><surname>Krug</surname><given-names>D</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R</given-names></name></person-group><article-title>Supercritical fluid extraction enhances discovery of secondary metabolites from myxobacteria</article-title><source>Anal. Chem.</source><year>2020</year><volume>92</volume><fpage>15403</fpage><lpage>15411</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.0c02995</pub-id><?supplied-pmid 33171050?><pub-id pub-id-type="pmid">33171050</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nass</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of &#x003b3;-actinorhodin</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>17419</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17232-1</pub-id><?supplied-pmid 29234001?><pub-id pub-id-type="pmid">29234001</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>2410</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-38634-3</pub-id><?supplied-pmid 30787404?><pub-id pub-id-type="pmid">30787404</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le&#x00161;nik</surname><given-names>U</given-names></name><etal/></person-group><article-title>Construction of a new class of tetracycline lead structures with potent antibacterial activity through biosynthetic engineering</article-title><source>Angew. Chem. Int. Ed.</source><year>2015</year><volume>54</volume><fpage>3937</fpage><lpage>3940</lpage><pub-id pub-id-type="doi">10.1002/anie.201411028</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandclaudon</surname><given-names>C</given-names></name><etal/></person-group><article-title>Semisynthesis and biological evaluation of amidochelocardin derivatives as broad-spectrum antibiotics</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>188</volume><fpage>112005</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.112005</pub-id><?supplied-pmid 31911294?><pub-id pub-id-type="pmid">31911294</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omollo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant <italic>Mycobacterium tuberculosis</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2021</year><volume>65</volume><fpage>e02554-20</fpage><pub-id pub-id-type="doi">10.1128/AAC.02554-20</pub-id><pub-id pub-id-type="pmid">33619062</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>JH</given-names></name><etal/></person-group><article-title>In vitro and in vivo efficacy of an LpxC inhibitor, CHIR-090, alone or combined with colistin against <italic>Pseudomonas aeruginosa</italic> biofilm</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e02223-16</fpage><pub-id pub-id-type="doi">10.1128/AAC.02223-16</pub-id><?supplied-pmid 28461320?><pub-id pub-id-type="pmid">28461320</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariathasan</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>M-W</given-names></name></person-group><article-title>Antibody&#x02013;antibiotic conjugates: a novel therapeutic platform against bacterial infections</article-title><source>Trends Mol. Med.</source><year>2017</year><volume>23</volume><fpage>135</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2016.12.008</pub-id><?supplied-pmid 28126271?><pub-id pub-id-type="pmid">28126271</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><mixed-citation publication-type="other">Koenig, S. G. &#x00026; Pillow, T. H. in <italic>Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2</italic> Vol. 1332 (eds Pesti, J. A., Abdel-Magid, A. F. &#x00026; Vaidyanathan, R.) 85&#x02013;105 (American Chemical Society, 2019).</mixed-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negash</surname><given-names>KH</given-names></name><name><surname>Norris</surname><given-names>JKS</given-names></name><name><surname>Hodgkinson</surname><given-names>JT</given-names></name></person-group><article-title>Siderophore&#x02013;antibiotic conjugate design: New drugs for bad bugs?</article-title><source>Molecules</source><year>2019</year><volume>24</volume><fpage>3314</fpage><pub-id pub-id-type="doi">10.3390/molecules24183314</pub-id><pub-id pub-id-type="pmid">31514464</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schalk</surname><given-names>IJ</given-names></name></person-group><article-title>Siderophore&#x02013;antibiotic conjugates: exploiting iron uptake to deliver drugs into bacteria</article-title><source>Clin. Microbiol. Infect.</source><year>2018</year><volume>24</volume><fpage>801</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2018.03.037</pub-id><?supplied-pmid 29649600?><pub-id pub-id-type="pmid">29649600</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><etal/></person-group><article-title>Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02123-w</pub-id><?supplied-pmid 29295973?><pub-id pub-id-type="pmid">29295973</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umst&#x000e4;tter</surname><given-names>F</given-names></name><etal/></person-group><article-title>Vancomycin resistance is overcome by conjugation of polycationic peptides</article-title><source>Angew. Chem. Int. Ed.</source><year>2020</year><volume>59</volume><fpage>8823</fpage><lpage>8827</lpage><pub-id pub-id-type="doi">10.1002/anie.202002727</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pharmacodynamic profiling of a siderophore-conjugated monocarbam in <italic>Pseudomonas aeruginosa</italic>: assessing the risk for resistance and attenuated efficacy</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>7743</fpage><lpage>7752</lpage><pub-id pub-id-type="doi">10.1128/AAC.00831-15</pub-id><?supplied-pmid 26438502?><pub-id pub-id-type="pmid">26438502</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>JM</given-names></name><etal/></person-group><article-title>A deep learning approach to antibiotic discovery</article-title><source>Cell</source><year>2020</year><volume>180</volume><fpage>688</fpage><lpage>702.e13</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.01.021</pub-id><?supplied-pmid 32084340?><pub-id pub-id-type="pmid">32084340</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Fuente-Nunez</surname><given-names>C</given-names></name></person-group><article-title>Toward autonomous antibiotic discovery</article-title><source>mSystems</source><year>2019</year><volume>4</volume><fpage>e00151-19</fpage><pub-id pub-id-type="doi">10.1128/mSystems.00151-19</pub-id><?supplied-pmid 31186311?><pub-id pub-id-type="pmid">31186311</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>CA</given-names></name><name><surname>Lombardo</surname><given-names>F</given-names></name><name><surname>Dominy</surname><given-names>BW</given-names></name><name><surname>Feeney</surname><given-names>PJ</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source>Adv. Drug Deliv. Rev.</source><year>1997</year><volume>23</volume><fpage>3</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(96)00423-1</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>CA</given-names></name></person-group><article-title>Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions</article-title><source>Adv. Drug Deliv. Rev.</source><year>2016</year><volume>101</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2016.04.029</pub-id><?supplied-pmid 27154268?><pub-id pub-id-type="pmid">27154268</pub-id></element-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benet</surname><given-names>LZ</given-names></name><name><surname>Hosey</surname><given-names>CM</given-names></name><name><surname>Ursu</surname><given-names>O</given-names></name><name><surname>Oprea</surname><given-names>TI</given-names></name></person-group><article-title>BDDCS, the Rule of 5 and drugability</article-title><source>Adv. Drug Deliv. Rev.</source><year>2016</year><volume>101</volume><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2016.05.007</pub-id><?supplied-pmid 27182629?><pub-id pub-id-type="pmid">27182629</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeGoey</surname><given-names>DA</given-names></name><name><surname>Chen</surname><given-names>H-J</given-names></name><name><surname>Cox</surname><given-names>PB</given-names></name><name><surname>Wendt</surname><given-names>MD</given-names></name></person-group><article-title>Beyond the rule of 5: lessons learned from AbbVie&#x02019;s drugs and compound collection</article-title><source>J. Med. Chem.</source><year>2018</year><volume>61</volume><fpage>2636</fpage><lpage>2651</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00717</pub-id><?supplied-pmid 28926247?><pub-id pub-id-type="pmid">28926247</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doak</surname><given-names>BC</given-names></name><name><surname>Over</surname><given-names>B</given-names></name><name><surname>Giordanetto</surname><given-names>F</given-names></name><name><surname>Kihlberg</surname><given-names>J</given-names></name></person-group><article-title>Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates</article-title><source>Chem. Biol.</source><year>2014</year><volume>21</volume><fpage>1115</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2014.08.013</pub-id><?supplied-pmid 25237858?><pub-id pub-id-type="pmid">25237858</pub-id></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>M</given-names></name><name><surname>Begnini</surname><given-names>F</given-names></name><name><surname>Poongavanam</surname><given-names>V</given-names></name><name><surname>Doak</surname><given-names>BC</given-names></name><name><surname>Kihlberg</surname><given-names>J</given-names></name></person-group><article-title>Drug syntheses beyond the rule of 5</article-title><source>Chem. Eur. J.</source><year>2020</year><volume>26</volume><fpage>49</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1002/chem.201902716</pub-id><?supplied-pmid 31483909?><pub-id pub-id-type="pmid">31483909</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>PM</given-names></name><name><surname>Seiple</surname><given-names>IB</given-names></name><name><surname>Myers</surname><given-names>AG</given-names></name></person-group><article-title>The evolving role of chemical synthesis in antibacterial drug discovery</article-title><source>Angew. Chem. Int. Ed.</source><year>2014</year><volume>53</volume><fpage>8840</fpage><lpage>8869</lpage><pub-id pub-id-type="doi">10.1002/anie.201310843</pub-id></element-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>V</given-names></name><etal/></person-group><article-title>Enzymatic halogenation and dehalogenation reactions: pervasive and mechanistically diverse</article-title><source>Chem. Rev.</source><year>2017</year><volume>117</volume><fpage>5619</fpage><lpage>5674</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.6b00571</pub-id><?supplied-pmid 28106994?><pub-id pub-id-type="pmid">28106994</pub-id></element-citation></ref><ref id="CR212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcken</surname><given-names>R</given-names></name><name><surname>Zimmermann</surname><given-names>MO</given-names></name><name><surname>Lange</surname><given-names>A</given-names></name><name><surname>Joerger</surname><given-names>AC</given-names></name><name><surname>Boeckler</surname><given-names>FM</given-names></name></person-group><article-title>Principles and applications of halogen bonding in medicinal chemistry and chemical biology</article-title><source>J. Med. Chem.</source><year>2013</year><volume>56</volume><fpage>1363</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1021/jm3012068</pub-id><?supplied-pmid 23145854?><pub-id pub-id-type="pmid">23145854</pub-id></element-citation></ref><ref id="CR213"><label>213.</label><mixed-citation publication-type="other"><italic>Convention on Biological Diversity United Nations</italic>. Nagoya Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the Convention on Biological Diversity. (Convention on Biological Diversity, 2011) <ext-link ext-link-type="uri" xlink:href="https://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf">https://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf</ext-link></mixed-citation></ref><ref id="CR214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorokina</surname><given-names>M</given-names></name><name><surname>Steinbeck</surname><given-names>C</given-names></name></person-group><article-title>Review on natural products databases: where to find data in 2020</article-title><source>J. Cheminform.</source><year>2020</year><volume>12</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s13321-020-00424-9</pub-id><?supplied-pmid 33431011?><pub-id pub-id-type="pmid">33431011</pub-id></element-citation></ref><ref id="CR215"><label>215.</label><mixed-citation publication-type="other"><italic>European Commission</italic>. Manifesto for EU COVID-19 research: maximising the accessibility of research results in the fight against COVID-19. (European Commission, 2020) <ext-link ext-link-type="uri" xlink:href="https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research-and-innovation/covid-research-manifesto_en">https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research-and-innovation/covid-research-manifesto_en</ext-link></mixed-citation></ref><ref id="CR216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wibberg</surname><given-names>D</given-names></name><etal/></person-group><article-title>High quality genome sequences of thirteen Hypoxylaceae (Ascomycota) strengthen the phylogenetic family backbone and enable the discovery of new taxa</article-title><source>Fungal Divers.</source><year>2021</year><volume>106</volume><fpage>7</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s13225-020-00447-5</pub-id></element-citation></ref><ref id="CR217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kling</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antibiotics. targeting DnaN for tuberculosis therapy using novel griselimycins</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>1106</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4690</pub-id><?supplied-pmid 26045430?><pub-id pub-id-type="pmid">26045430</pub-id></element-citation></ref><ref id="CR218"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Assembly and clustering of natural antibiotics guides target identification</article-title><source>Nat. Chem. Biol.</source><year>2016</year><volume>12</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2018</pub-id><?supplied-pmid 26829473?><pub-id pub-id-type="pmid">26829473</pub-id></element-citation></ref><ref id="CR219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panter</surname><given-names>F</given-names></name><name><surname>Krug</surname><given-names>D</given-names></name><name><surname>Baumann</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R</given-names></name></person-group><article-title>Self-resistance guided genome mining uncovers new topoisomerase inhibitors from myxobacteria</article-title><source>Chem. Sci.</source><year>2018</year><volume>9</volume><fpage>4898</fpage><lpage>4908</lpage><pub-id pub-id-type="doi">10.1039/C8SC01325J</pub-id><?supplied-pmid 29910943?><pub-id pub-id-type="pmid">29910943</pub-id></element-citation></ref><ref id="CR220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mungan</surname><given-names>MD</given-names></name><etal/></person-group><article-title>ARTS 2.0: feature updates and expansion of the Antibiotic Resistant Target Seeker for comparative genome mining</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>W546</fpage><lpage>W552</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa374</pub-id><?supplied-pmid 32427317?><pub-id pub-id-type="pmid">32427317</pub-id></element-citation></ref><ref id="CR221"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emmert-Streib</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Tripathi</surname><given-names>S</given-names></name><name><surname>Dehmer</surname><given-names>M</given-names></name></person-group><article-title>An introductory review of deep learning for prediction models with big data</article-title><source>Front. Artif. Intell.</source><year>2020</year><volume>3</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.3389/frai.2020.00004</pub-id><?supplied-pmid 33733124?><pub-id pub-id-type="pmid">33733124</pub-id></element-citation></ref><ref id="CR222"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>P</given-names></name><etal/></person-group><article-title>Rethinking drug design in the artificial intelligence era</article-title><source>Nat. Rev. Drug. Discov.</source><year>2020</year><volume>19</volume><fpage>353</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0050-3</pub-id><?supplied-pmid 31801986?><pub-id pub-id-type="pmid">31801986</pub-id></element-citation></ref><ref id="CR223"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grein</surname><given-names>F</given-names></name><etal/></person-group><article-title>Ca<sup>2+</sup>-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1455</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15257-1</pub-id><?supplied-pmid 32193379?><pub-id pub-id-type="pmid">32193379</pub-id></element-citation></ref><ref id="CR224"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardona</surname><given-names>ST</given-names></name><name><surname>Selin</surname><given-names>C</given-names></name><name><surname>Gislason</surname><given-names>AS</given-names></name></person-group><article-title>Genomic tools to profile antibiotic mode of action</article-title><source>Crit. Rev. Microbiol.</source><year>2015</year><volume>41</volume><fpage>465</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.3109/1040841X.2013.866073</pub-id><?supplied-pmid 24617440?><pub-id pub-id-type="pmid">24617440</pub-id></element-citation></ref><ref id="CR225"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Camp</surname><given-names>P-J</given-names></name><name><surname>Haslam</surname><given-names>DB</given-names></name><name><surname>Porollo</surname><given-names>A</given-names></name></person-group><article-title>Bioinformatics approaches to the understanding of molecular mechanisms in antimicrobial resistance</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><fpage>1363</fpage><pub-id pub-id-type="doi">10.3390/ijms21041363</pub-id><pub-id pub-id-type="pmid">32085478</pub-id></element-citation></ref><ref id="CR226"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Rourke</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mechanism-of-action classification of antibiotics by global transcriptome profiling</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e01207</fpage><lpage>e01219</lpage><pub-id pub-id-type="doi">10.1128/AAC.01207-19</pub-id><?supplied-pmid 31907190?><pub-id pub-id-type="pmid">31907190</pub-id></element-citation></ref><ref id="CR227"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonejuie</surname><given-names>P</given-names></name><name><surname>Burkart</surname><given-names>M</given-names></name><name><surname>Pogliano</surname><given-names>K</given-names></name><name><surname>Pogliano</surname><given-names>J</given-names></name></person-group><article-title>Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>16169</fpage><lpage>16174</lpage><pub-id pub-id-type="doi">10.1073/pnas.1311066110</pub-id><?supplied-pmid 24046367?><pub-id pub-id-type="pmid">24046367</pub-id></element-citation></ref><ref id="CR228"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamsa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Rapid inhibition profiling in <italic>Bacillus subtilis</italic> to identify the mechanism of action of new antimicrobials</article-title><source>ACS Chem. Biol.</source><year>2016</year><volume>11</volume><fpage>2222</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.1021/acschembio.5b01050</pub-id><?supplied-pmid 27193499?><pub-id pub-id-type="pmid">27193499</pub-id></element-citation></ref><ref id="CR229"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro da Cunha</surname><given-names>B</given-names></name><name><surname>Fonseca</surname><given-names>LP</given-names></name><name><surname>Calado</surname><given-names>CRC</given-names></name></person-group><article-title>Metabolic fingerprinting with fourier-transform infrared (FTIR) spectroscopy: towards a high-throughput screening assay for antibiotic discovery and mechanism-of-action elucidation</article-title><source>Metabolites</source><year>2020</year><volume>10</volume><fpage>145</fpage><pub-id pub-id-type="doi">10.3390/metabo10040145</pub-id><pub-id pub-id-type="pmid">32283661</pub-id></element-citation></ref><ref id="CR230"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eustice</surname><given-names>DC</given-names></name><name><surname>Feldman</surname><given-names>PA</given-names></name><name><surname>Slee</surname><given-names>AM</given-names></name></person-group><article-title>The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1988</year><volume>150</volume><fpage>965</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(88)90723-1</pub-id><?supplied-pmid 2449210?><pub-id pub-id-type="pmid">2449210</pub-id></element-citation></ref><ref id="CR231"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>A</given-names></name><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Itto</surname><given-names>K</given-names></name><name><surname>Arimoto</surname><given-names>H</given-names></name></person-group><article-title>Deciphering the mode of action of cell wall-inhibiting antibiotics using metabolic labeling of growing peptidoglycan in <italic>Streptococcus pyogenes</italic></article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>1129</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-01267-5</pub-id><?supplied-pmid 28442740?><pub-id pub-id-type="pmid">28442740</pub-id></element-citation></ref><ref id="CR232"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacace</surname><given-names>E</given-names></name><name><surname>Kritikos</surname><given-names>G</given-names></name><name><surname>Typas</surname><given-names>A</given-names></name></person-group><article-title>Chemical genetics in drug discovery</article-title><source>Curr. Opin. Syst. Biol.</source><year>2017</year><volume>4</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.coisb.2017.05.020</pub-id><?supplied-pmid 32715163?><pub-id pub-id-type="pmid">32715163</pub-id></element-citation></ref><ref id="CR233"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genome-wide mutant profiling predicts the mechanism of a Lipid II binding antibiotic</article-title><source>Nat. Chem. Biol.</source><year>2018</year><volume>14</volume><fpage>601</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0041-4</pub-id><?supplied-pmid 29662210?><pub-id pub-id-type="pmid">29662210</pub-id></element-citation></ref><ref id="CR234"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>MH</given-names></name><name><surname>Sieber</surname><given-names>SA</given-names></name></person-group><article-title>Chemical proteomics approaches for identifying the cellular targets of natural products</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>681</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1039/C6NP00001K</pub-id><?supplied-pmid 27098809?><pub-id pub-id-type="pmid">27098809</pub-id></element-citation></ref><ref id="CR235"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drewes</surname><given-names>G</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name></person-group><article-title>Chemoproteomics and chemical probes for target discovery</article-title><source>Trends Biotechnol.</source><year>2018</year><volume>36</volume><fpage>1275</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2018.06.008</pub-id><?supplied-pmid 30017093?><pub-id pub-id-type="pmid">30017093</pub-id></element-citation></ref><ref id="CR236"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoerr</surname><given-names>V</given-names></name><etal/></person-group><article-title>Characterization and prediction of the mechanism of action of antibiotics through NMR metabolomics</article-title><source>BMC Microbiol.</source><year>2016</year><volume>16</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.1186/s12866-016-0696-5</pub-id><?supplied-pmid 27159970?><pub-id pub-id-type="pmid">27159970</pub-id></element-citation></ref><ref id="CR237"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medeiros-Silva</surname><given-names>J</given-names></name><etal/></person-group><article-title>High-resolution NMR studies of antibiotics in cellular membranes</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>3963</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06314-x</pub-id><?supplied-pmid 30262913?><pub-id pub-id-type="pmid">30262913</pub-id></element-citation></ref><ref id="CR238"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tietze</surname><given-names>LF</given-names></name><name><surname>Krewer</surname><given-names>B</given-names></name><name><surname>Major</surname><given-names>F</given-names></name><name><surname>Schuberth</surname><given-names>I</given-names></name></person-group><article-title>CD-spectroscopy as a powerful tool for investigating the mode of action of unmodified drugs in live cells</article-title><source>J. Am. Chem. Soc.</source><year>2009</year><volume>131</volume><fpage>13031</fpage><lpage>13036</lpage><pub-id pub-id-type="doi">10.1021/ja902767f</pub-id><?supplied-pmid 19697908?><pub-id pub-id-type="pmid">19697908</pub-id></element-citation></ref><ref id="CR239"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altharawi</surname><given-names>A</given-names></name><name><surname>Rahman</surname><given-names>KM</given-names></name><name><surname>Chan</surname><given-names>KLA</given-names></name></person-group><article-title>Towards identifying the mode of action of drugs using live-cell FTIR spectroscopy</article-title><source>Analyst</source><year>2019</year><volume>144</volume><fpage>2725</fpage><lpage>2735</lpage><pub-id pub-id-type="doi">10.1039/C8AN02218F</pub-id><?supplied-pmid 30865733?><pub-id pub-id-type="pmid">30865733</pub-id></element-citation></ref><ref id="CR240"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirnski</surname><given-names>K</given-names></name><name><surname>Coetzee</surname><given-names>J</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R</given-names></name></person-group><article-title>Metabolic profiling to determine bactericidal or bacteriostatic effects of new natural products using isothermal microcalorimetry</article-title><source>J. Vis. Exp.</source><year>2020</year><volume>164</volume><fpage>e61703</fpage></element-citation></ref><ref id="CR241"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrowsmith</surname><given-names>CH</given-names></name><etal/></person-group><article-title>The promise and peril of chemical probes</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>536</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1867</pub-id><?supplied-pmid 26196764?><pub-id pub-id-type="pmid">26196764</pub-id></element-citation></ref><ref id="CR242"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Evidence-based and quantitative prioritization of tool compounds in phenotypic drug discovery</article-title><source>Cell Chem. Biol.</source><year>2016</year><volume>23</volume><fpage>862</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2016.05.016</pub-id><?supplied-pmid 27427232?><pub-id pub-id-type="pmid">27427232</pub-id></element-citation></ref><ref id="CR243"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franken</surname><given-names>H</given-names></name><etal/></person-group><article-title>Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry</article-title><source>Nat. Protoc.</source><year>2015</year><volume>10</volume><fpage>1567</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1038/nprot.2015.101</pub-id><?supplied-pmid 26379230?><pub-id pub-id-type="pmid">26379230</pub-id></element-citation></ref><ref id="CR244"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schopper</surname><given-names>S</given-names></name><etal/></person-group><article-title>Measuring protein structural changes on a proteome-wide scale using limited proteolysis-coupled mass spectrometry</article-title><source>Nat. Protoc.</source><year>2017</year><volume>12</volume><fpage>2391</fpage><lpage>2410</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.100</pub-id><?supplied-pmid 29072706?><pub-id pub-id-type="pmid">29072706</pub-id></element-citation></ref><ref id="CR245"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piazza</surname><given-names>I</given-names></name><etal/></person-group><article-title>A map of protein-metabolite interactions reveals principles of chemical communication</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>358</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.006</pub-id><?supplied-pmid 29307493?><pub-id pub-id-type="pmid">29307493</pub-id></element-citation></ref><ref id="CR246"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Horizontal cell biology: monitoring global changes of protein interaction states with the proteome-wide cellular thermal shift assay (CETSA)</article-title><source>Ann. Rev. Biochem.</source><year>2019</year><volume>88</volume><fpage>383</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-062917-012837</pub-id><?supplied-pmid 30939043?><pub-id pub-id-type="pmid">30939043</pub-id></element-citation></ref><ref id="CR247"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagherian</surname><given-names>M</given-names></name><etal/></person-group><article-title>Machine learning approaches and databases for prediction of drug&#x02013;target interaction: a survey paper</article-title><source>Brief. Bioinform.</source><year>2021</year><volume>22</volume><fpage>247</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1093/bib/bbz157</pub-id><?supplied-pmid 31950972?><pub-id pub-id-type="pmid">31950972</pub-id></element-citation></ref><ref id="CR248"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pliakos</surname><given-names>K</given-names></name><name><surname>Vens</surname><given-names>C</given-names></name></person-group><article-title>Drug-target interaction prediction with tree-ensemble learning and output space reconstruction</article-title><source>BMC Bioinform.</source><year>2020</year><volume>21</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s12859-020-3379-z</pub-id></element-citation></ref><ref id="CR249"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davin-Regli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Membrane permeability and regulation of drug &#x0201c;influx and efflux&#x0201d; in enterobacterial pathogens</article-title><source>Curr. Drug Targets</source><year>2008</year><volume>9</volume><fpage>750</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.2174/138945008785747824</pub-id><?supplied-pmid 18781921?><pub-id pub-id-type="pmid">18781921</pub-id></element-citation></ref><ref id="CR250"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louw</surname><given-names>GE</given-names></name><etal/></person-group><article-title>A balancing act: efflux/influx in mycobacterial drug resistance</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>3181</fpage><lpage>3189</lpage><pub-id pub-id-type="doi">10.1128/AAC.01577-08</pub-id><?supplied-pmid 19451293?><pub-id pub-id-type="pmid">19451293</pub-id></element-citation></ref><ref id="CR251"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chitsaz</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>MH</given-names></name></person-group><article-title>The role played by drug efflux pumps in bacterial multidrug resistance</article-title><source>Essays Biochem.</source><year>2017</year><volume>61</volume><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1042/EBC20160064</pub-id><?supplied-pmid 28258236?><pub-id pub-id-type="pmid">28258236</pub-id></element-citation></ref><ref id="CR252"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weston</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Ricci</surname><given-names>V</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><article-title>Regulation of the AcrAB-TolC efflux pump in Enterobacteriaceae</article-title><source>Res. Microbiol.</source><year>2018</year><volume>169</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/j.resmic.2017.10.005</pub-id><?supplied-pmid 29128373?><pub-id pub-id-type="pmid">29128373</pub-id></element-citation></ref><ref id="CR253"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ropponen</surname><given-names>H-K</given-names></name><name><surname>Richter</surname><given-names>R</given-names></name><name><surname>Hirsch</surname><given-names>AKH</given-names></name><name><surname>Lehr</surname><given-names>C-M</given-names></name></person-group><article-title>Mastering the Gram-negative bacterial barrier &#x02013; Chemical approaches to increase bacterial bioavailability of antibiotics</article-title><source>Adv. Drug Deliv. Rev.</source><year>2021</year><volume>172</volume><fpage>339</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.02.014</pub-id><?supplied-pmid 33705882?><pub-id pub-id-type="pmid">33705882</pub-id></element-citation></ref><ref id="CR254"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Predictive compound accumulation rules yield a broad-spectrum antibiotic</article-title><source>Nature</source><year>2017</year><volume>545</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/nature22308</pub-id><?supplied-pmid 28489819?><pub-id pub-id-type="pmid">28489819</pub-id></element-citation></ref><ref id="CR255"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juki&#x0010d;</surname><given-names>M</given-names></name><name><surname>Gobec</surname><given-names>S</given-names></name><name><surname>Sova</surname><given-names>M</given-names></name></person-group><article-title>Reaching toward underexplored targets in antibacterial drug design</article-title><source>Drug Dev. Res.</source><year>2019</year><volume>80</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1002/ddr.21465</pub-id><?supplied-pmid 30312991?><pub-id pub-id-type="pmid">30312991</pub-id></element-citation></ref><ref id="CR256"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manchester</surname><given-names>JI</given-names></name><name><surname>Buurman</surname><given-names>ET</given-names></name><name><surname>Bisacchi</surname><given-names>GS</given-names></name><name><surname>McLaughlin</surname><given-names>RE</given-names></name></person-group><article-title>Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery</article-title><source>J. Med. Chem.</source><year>2012</year><volume>55</volume><fpage>2532</fpage><lpage>2537</lpage><pub-id pub-id-type="doi">10.1021/jm201275d</pub-id><?supplied-pmid 22224562?><pub-id pub-id-type="pmid">22224562</pub-id></element-citation></ref><ref id="CR257"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hevener</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Chapter Eighteen-Special challenges to the rational design of antibacterial agents</article-title><source>Ann. Rep. Med. Chem.</source><year>2013</year><volume>48</volume><fpage>283</fpage><lpage>298</lpage></element-citation></ref><ref id="CR258"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavascki</surname><given-names>AP</given-names></name><name><surname>Goldani</surname><given-names>LZ</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Nation</surname><given-names>RL</given-names></name></person-group><article-title>Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review</article-title><source>J. Antimicrob. Chemother.</source><year>2007</year><volume>60</volume><fpage>1206</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1093/jac/dkm357</pub-id><?supplied-pmid 17878146?><pub-id pub-id-type="pmid">17878146</pub-id></element-citation></ref><ref id="CR259"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrer-Espada</surname><given-names>R</given-names></name><etal/></person-group><article-title>A permeability-increasing drug synergizes with bacterial efflux pump inhibitors and restores susceptibility to antibiotics in multi-drug resistant <italic>Pseudomonas aeruginosa</italic> strains</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>3452</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-39659-4</pub-id><?supplied-pmid 30837499?><pub-id pub-id-type="pmid">30837499</pub-id></element-citation></ref><ref id="CR260"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweizer</surname><given-names>HP</given-names></name></person-group><article-title>Understanding efflux in Gram-negative bacteria: opportunities for drug discovery</article-title><source>Exp. Opin. Drug Discov.</source><year>2012</year><volume>7</volume><fpage>633</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1517/17460441.2012.688949</pub-id></element-citation></ref><ref id="CR261"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>S</given-names></name><etal/></person-group><article-title>Novel strategies for the treatment of <italic>Pseudomonas aeruginosa</italic> infections</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>5929</fpage><lpage>5969</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01698</pub-id><?supplied-pmid 26804741?><pub-id pub-id-type="pmid">26804741</pub-id></element-citation></ref><ref id="CR262"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name></person-group><article-title>Polypharmacology in drug discovery: a review from systems pharmacology perspective</article-title><source>Curr. Pharm. Des.</source><year>2016</year><volume>22</volume><fpage>3171</fpage><lpage>3181</lpage><pub-id pub-id-type="doi">10.2174/1381612822666160224142812</pub-id><?supplied-pmid 26907941?><pub-id pub-id-type="pmid">26907941</pub-id></element-citation></ref><ref id="CR263"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proschak</surname><given-names>E</given-names></name><name><surname>Stark</surname><given-names>H</given-names></name><name><surname>Merk</surname><given-names>D</given-names></name></person-group><article-title>Polypharmacology by design: a medicinal chemist&#x02019;s perspective on multitargeting compounds</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>420</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00760</pub-id><?supplied-pmid 30035545?><pub-id pub-id-type="pmid">30035545</pub-id></element-citation></ref><ref id="CR264"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>ML</given-names></name><name><surname>Kwan</surname><given-names>BP</given-names></name><name><surname>Nelson</surname><given-names>KJ</given-names></name><name><surname>Bensen</surname><given-names>DC</given-names></name><name><surname>Shaw</surname><given-names>KJ</given-names></name></person-group><article-title>Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay</article-title><source>J. Biomol. Screen.</source><year>2013</year><volume>18</volume><fpage>1018</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1177/1087057113487208</pub-id><?supplied-pmid 23686103?><pub-id pub-id-type="pmid">23686103</pub-id></element-citation></ref><ref id="CR265"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Sripada</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name></person-group><article-title>Side effects of antibiotics during bacterial infection: mitochondria, the main target in host cell</article-title><source>Mitochondrion</source><year>2014</year><volume>16</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2013.10.005</pub-id><?supplied-pmid 24246912?><pub-id pub-id-type="pmid">24246912</pub-id></element-citation></ref><ref id="CR266"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>MJ</given-names></name></person-group><article-title>Off-target effects of drugs that disrupt human mitochondrial DNA maintenance</article-title><source>Front. Mol. Biosci.</source><year>2017</year><volume>4</volume><fpage>74</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2017.00074</pub-id><?supplied-pmid 29214156?><pub-id pub-id-type="pmid">29214156</pub-id></element-citation></ref><ref id="CR267"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moullan</surname><given-names>N</given-names></name><etal/></person-group><article-title>Tetracyclines disturb mitochondrial function across eukaryotic models: a call for caution in biomedical research</article-title><source>Cell Rep.</source><year>2015</year><volume>10</volume><fpage>1681</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.02.034</pub-id><?supplied-pmid 25772356?><pub-id pub-id-type="pmid">25772356</pub-id></element-citation></ref><ref id="CR268"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname><given-names>B</given-names></name><name><surname>Inghammar</surname><given-names>M</given-names></name><name><surname>Svanstr&#x000f6;m</surname><given-names>H</given-names></name></person-group><article-title>Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study</article-title><source>BMJ</source><year>2018</year><volume>360</volume><fpage>k678</fpage><pub-id pub-id-type="doi">10.1136/bmj.k678</pub-id><?supplied-pmid 29519881?><pub-id pub-id-type="pmid">29519881</pub-id></element-citation></ref><ref id="CR269"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fief</surname><given-names>CA</given-names></name><name><surname>Hoang</surname><given-names>KG</given-names></name><name><surname>Phipps</surname><given-names>SD</given-names></name><name><surname>Wallace</surname><given-names>JL</given-names></name><name><surname>Deweese</surname><given-names>JE</given-names></name></person-group><article-title>Examining the impact of antimicrobial fluoroquinolones on human DNA topoisomerase II&#x003b1; and II&#x003b2;</article-title><source>ACS Omega</source><year>2019</year><volume>4</volume><fpage>4049</fpage><lpage>4055</lpage><pub-id pub-id-type="doi">10.1021/acsomega.8b03428</pub-id><?supplied-pmid 31459613?><pub-id pub-id-type="pmid">31459613</pub-id></element-citation></ref><ref id="CR270"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becattini</surname><given-names>S</given-names></name><name><surname>Taur</surname><given-names>Y</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name></person-group><article-title>Antibiotic-induced changes in the intestinal microbiota and disease</article-title><source>Trends Mol. Med.</source><year>2016</year><volume>22</volume><fpage>458</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2016.04.003</pub-id><?supplied-pmid 27178527?><pub-id pub-id-type="pmid">27178527</pub-id></element-citation></ref><ref id="CR271"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhalodi</surname><given-names>AA</given-names></name><name><surname>van Engelen</surname><given-names>TSR</given-names></name><name><surname>Virk</surname><given-names>HS</given-names></name><name><surname>Wiersinga</surname><given-names>WJ</given-names></name></person-group><article-title>Impact of antimicrobial therapy on the gut microbiome</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>i6</fpage><lpage>i15</lpage><pub-id pub-id-type="doi">10.1093/jac/dky530</pub-id><?supplied-pmid 30690540?><pub-id pub-id-type="pmid">30690540</pub-id></element-citation></ref><ref id="CR272"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wipperman</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>10767</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-10346-6</pub-id><?supplied-pmid 28883399?><pub-id pub-id-type="pmid">28883399</pub-id></element-citation></ref><ref id="CR273"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>The effect of antibiotics on the gut microbiome: a metagenomics analysis of microbial shift and gut antibiotic resistance in antibiotic treated mice</article-title><source>BMC Genomics</source><year>2020</year><volume>21</volume><fpage>263</fpage><pub-id pub-id-type="doi">10.1186/s12864-020-6665-2</pub-id><?supplied-pmid 32228448?><pub-id pub-id-type="pmid">32228448</pub-id></element-citation></ref><ref id="CR274"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Exploitation of antibiotic resistance as a novel drug target: development of a &#x003b2;-lactamase-activated antibacterial prodrug</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>4411</fpage><lpage>4425</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01923</pub-id><?supplied-pmid 31009558?><pub-id pub-id-type="pmid">31009558</pub-id></element-citation></ref><ref id="CR275"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J</given-names></name></person-group><article-title>Natural product synthesis at the interface of chemistry and biology</article-title><source>Chem. Eur. J.</source><year>2014</year><volume>20</volume><fpage>10204</fpage><lpage>10212</lpage><pub-id pub-id-type="doi">10.1002/chem.201402804</pub-id><?supplied-pmid 25043880?><pub-id pub-id-type="pmid">25043880</pub-id></element-citation></ref><ref id="CR276"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Br&#x000f6;nstrup</surname><given-names>M</given-names></name></person-group><article-title>Industrial natural product chemistry for drug discovery and development</article-title><source>Nat. Prod. Rep.</source><year>2014</year><volume>31</volume><fpage>35</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1039/C3NP70058E</pub-id><?supplied-pmid 24142193?><pub-id pub-id-type="pmid">24142193</pub-id></element-citation></ref><ref id="CR277"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sucipto</surname><given-names>H</given-names></name><name><surname>Pogorevc</surname><given-names>D</given-names></name><name><surname>Luxenburger</surname><given-names>E</given-names></name><name><surname>Wenzel</surname><given-names>SC</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R</given-names></name></person-group><article-title>Heterologous production of myxobacterial &#x003b1;-pyrone antibiotics in <italic>Myxococcus xanthus</italic></article-title><source>Metab. Eng.</source><year>2017</year><volume>44</volume><fpage>160</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2017.10.004</pub-id><?supplied-pmid 29030273?><pub-id pub-id-type="pmid">29030273</pub-id></element-citation></ref><ref id="CR278"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorevc</surname><given-names>D</given-names></name><etal/></person-group><article-title>Production optimization and biosynthesis revision of corallopyronin A, a potent anti-filarial antibiotic</article-title><source>Metab. Eng.</source><year>2019</year><volume>55</volume><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2019.07.010</pub-id><?supplied-pmid 31340171?><pub-id pub-id-type="pmid">31340171</pub-id></element-citation></ref><ref id="CR279"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><etal/></person-group><article-title>A robust platform for the synthesis of new tetracycline antibiotics</article-title><source>J. Am. Chem. Soc.</source><year>2008</year><volume>130</volume><fpage>17913</fpage><lpage>17927</lpage><pub-id pub-id-type="doi">10.1021/ja806629e</pub-id><?supplied-pmid 19053822?><pub-id pub-id-type="pmid">19053822</pub-id></element-citation></ref><ref id="CR280"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Large-scale preparation of key building blocks for the manufacture of fully synthetic macrolide antibiotics</article-title><source>J. Antibiot.</source><year>2018</year><volume>71</volume><fpage>318</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1038/ja.2017.116</pub-id></element-citation></ref><ref id="CR281"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000fc;ttel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Discovery and total synthesis of natural cystobactamid derivatives with superior activity against Gram-negative pathogens</article-title><source>Angew. Chem. Int. Ed.</source><year>2017</year><volume>56</volume><fpage>12760</fpage><lpage>12764</lpage><pub-id pub-id-type="doi">10.1002/anie.201705913</pub-id></element-citation></ref><ref id="CR282"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gram-scale total synthesis of teixobactin promoting binding mode study and discovery of more potent antibiotics</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>3268</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11211-y</pub-id><?supplied-pmid 31332172?><pub-id pub-id-type="pmid">31332172</pub-id></element-citation></ref><ref id="CR283"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crater</surname><given-names>JS</given-names></name><name><surname>Lievense</surname><given-names>JC</given-names></name></person-group><article-title>Scale-up of industrial microbial processes</article-title><source>FEMS Microbiol. Lett.</source><year>2018</year><volume>365</volume><fpage>fny138</fpage><pub-id pub-id-type="doi">10.1093/femsle/fny138</pub-id><pub-id pub-id-type="pmid">29860483</pub-id></element-citation></ref><ref id="CR284"><label>284.</label><mixed-citation publication-type="other">Nielsen, J. et al. (eds) <italic>Metabolic Engineering. Advances in Biochemical Engineering/Biotechnology</italic> Vol 73 (Springer, 2001).</mixed-citation></ref><ref id="CR285"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>JV</given-names></name><etal/></person-group><article-title>A review of the microbial production of bioactive natural products and biologics</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>1404</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.01404</pub-id><?supplied-pmid 31281299?><pub-id pub-id-type="pmid">31281299</pub-id></element-citation></ref><ref id="CR286"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balani</surname><given-names>SK</given-names></name><name><surname>Miwa</surname><given-names>GT</given-names></name><name><surname>Gan</surname><given-names>L-S</given-names></name><name><surname>Wu</surname><given-names>J-T</given-names></name><name><surname>Lee</surname><given-names>FW</given-names></name></person-group><article-title>Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection</article-title><source>Curr. Top. Med. Chem.</source><year>2005</year><volume>5</volume><fpage>1033</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.2174/156802605774297038</pub-id><?supplied-pmid 16181128?><pub-id pub-id-type="pmid">16181128</pub-id></element-citation></ref><ref id="CR287"><label>287.</label><mixed-citation publication-type="other">Chung, T. D. Y., Terry, D. B. &#x00026; Smith, L. H. in <italic>Assay Guidance Manual</italic> (eds Markossian, S. et al.) (Eli Lilly &#x00026; Company and the National Center for Advancing Translational Sciences, 2015).</mixed-citation></ref><ref id="CR288"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichel</surname><given-names>A</given-names></name><name><surname>Lienau</surname><given-names>P</given-names></name></person-group><article-title>Pharmacokinetics in drug discovery: an exposure-centred approach to optimising and predicting drug efficacy and safety</article-title><source>Handb. Exp. Pharmacol.</source><year>2016</year><volume>232</volume><fpage>235</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1007/164_2015_26</pub-id><?supplied-pmid 26330260?><pub-id pub-id-type="pmid">26330260</pub-id></element-citation></ref><ref id="CR289"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SS</given-names></name></person-group><article-title>Preclinical pharmacokinetics: an approach towards safer and efficacious drugs</article-title><source>Curr. Drug Metab.</source><year>2006</year><volume>7</volume><fpage>165</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.2174/138920006775541552</pub-id><?supplied-pmid 16472106?><pub-id pub-id-type="pmid">16472106</pub-id></element-citation></ref><ref id="CR290"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zha</surname><given-names>W</given-names></name></person-group><article-title>Predicting human pharmacokinetics: physiologically based pharmacokinetic modeling and in silico ADME prediction in early drug discovery</article-title><source>Eur. J. Drug. Metab. Pharmacokinet.</source><year>2019</year><volume>44</volume><fpage>135</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1007/s13318-018-0503-9</pub-id><?supplied-pmid 30136219?><pub-id pub-id-type="pmid">30136219</pub-id></element-citation></ref><ref id="CR291"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>G</given-names></name><etal/></person-group><article-title>ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>W5</fpage><lpage>W14</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab255</pub-id><?supplied-pmid 33893803?><pub-id pub-id-type="pmid">33893803</pub-id></element-citation></ref><ref id="CR292"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Potent LpxC inhibitors with <italic>in vitro</italic> activity against multidrug-resistant <italic>Pseudomonas aeruginosa</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e00977-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.00977-19</pub-id><?supplied-pmid 31451507?><pub-id pub-id-type="pmid">31451507</pub-id></element-citation></ref><ref id="CR293"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>F</given-names></name><etal/></person-group><article-title>Optimization of LpxC inhibitors for antibacterial activity and cardiovascular safety</article-title><source>ChemMedChem</source><year>2019</year><volume>14</volume><fpage>1560</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201900287</pub-id><?supplied-pmid 31283109?><pub-id pub-id-type="pmid">31283109</pub-id></element-citation></ref><ref id="CR294"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felmlee</surname><given-names>MA</given-names></name><name><surname>Morris</surname><given-names>ME</given-names></name><name><surname>Mager</surname><given-names>DE</given-names></name></person-group><article-title>Mechanism-based pharmacodynamic modeling</article-title><source>Meth. Mol. Biol.</source><year>2012</year><volume>929</volume><fpage>583</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-050-2_21</pub-id></element-citation></ref><ref id="CR295"><label>295.</label><mixed-citation publication-type="other">Lepak, A. J. &#x00026; Andes, D. R. in <italic>Antibiotic Pharmacodynamics</italic> Vol. 191 (eds Rotschafer, J. C., Andes, D. R. &#x00026; Rodvold, K. A.) 59&#x02013;87 (Springer, 2016).</mixed-citation></ref><ref id="CR296"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Peer</surname><given-names>A</given-names></name><name><surname>Snoeck</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>ML</given-names></name><name><surname>Heykants</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development</article-title><source>Eur. J. Drug Metab. Pharmacokinet.</source><year>1993</year><volume>18</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1007/BF03220008</pub-id><?supplied-pmid 8335039?><pub-id pub-id-type="pmid">8335039</pub-id></element-citation></ref><ref id="CR297"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Lepak</surname><given-names>AJ</given-names></name><name><surname>Andes</surname><given-names>DR</given-names></name></person-group><article-title>Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents</article-title><source>Bioorg. Med. Chem.</source><year>2016</year><volume>24</volume><fpage>6390</fpage><lpage>6400</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2016.11.008</pub-id><?supplied-pmid 27887963?><pub-id pub-id-type="pmid">27887963</pub-id></element-citation></ref><ref id="CR298"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGinnity</surname><given-names>DF</given-names></name><name><surname>Collington</surname><given-names>J</given-names></name><name><surname>Austin</surname><given-names>RP</given-names></name><name><surname>Riley</surname><given-names>RJ</given-names></name></person-group><article-title>Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs</article-title><source>Curr. Drug Metab.</source><year>2007</year><volume>8</volume><fpage>463</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.2174/138920007780866799</pub-id><?supplied-pmid 17584017?><pub-id pub-id-type="pmid">17584017</pub-id></element-citation></ref><ref id="CR299"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>P</given-names></name><etal/></person-group><article-title>Applications of human pharmacokinetic prediction in first-in-human dose estimation</article-title><source>AAPS J.</source><year>2012</year><volume>14</volume><fpage>262</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1208/s12248-012-9332-y</pub-id><?supplied-pmid 22407287?><pub-id pub-id-type="pmid">22407287</pub-id></element-citation></ref><ref id="CR300"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>KM</given-names></name></person-group><article-title>Validation of early human dose prediction: a key metric for compound progression in drug discovery</article-title><source>Mol. Pharmaceutics</source><year>2016</year><volume>13</volume><fpage>609</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00840</pub-id></element-citation></ref><ref id="CR301"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>S</given-names></name><name><surname>Brayden</surname><given-names>DJ</given-names></name><name><surname>Casettari</surname><given-names>L</given-names></name><name><surname>Illum</surname><given-names>L</given-names></name></person-group><article-title>Application of permeation enhancers in oral delivery of macromolecules: an update</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics11010041</pub-id><pub-id pub-id-type="pmid">30669434</pub-id></element-citation></ref><ref id="CR302"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Williams</surname><given-names>RO</given-names></name></person-group><article-title>Polymeric nanomedicines for poorly soluble drugs in oral delivery systems: an update</article-title><source>J. Pharm. Invest.</source><year>2018</year><volume>48</volume><fpage>61</fpage><lpage>75</lpage></element-citation></ref><ref id="CR303"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pridgen</surname><given-names>EM</given-names></name><name><surname>Alexis</surname><given-names>F</given-names></name><name><surname>Farokhzad</surname><given-names>OC</given-names></name></person-group><article-title>Polymeric nanoparticle technologies for oral drug delivery</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2014</year><volume>12</volume><fpage>1605</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2014.06.018</pub-id><?supplied-pmid 24981782?><pub-id pub-id-type="pmid">24981782</pub-id></element-citation></ref><ref id="CR304"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Vena</surname><given-names>A</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Peghin</surname><given-names>M</given-names></name></person-group><article-title>Inhaled liposomal antimicrobial delivery in lung infections</article-title><source>Drugs</source><year>2020</year><volume>80</volume><fpage>1309</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1007/s40265-020-01359-z</pub-id><?supplied-pmid 32691293?><pub-id pub-id-type="pmid">32691293</pub-id></element-citation></ref><ref id="CR305"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulbake</surname><given-names>U</given-names></name><name><surname>Doppalapudi</surname><given-names>S</given-names></name><name><surname>Kommineni</surname><given-names>N</given-names></name><name><surname>Khan</surname><given-names>W</given-names></name></person-group><article-title>Liposomal formulations in clinical use: an updated review</article-title><source>Pharmaceutics</source><year>2017</year><volume>9</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics9020012</pub-id><pub-id pub-id-type="pmid">28346375</pub-id></element-citation></ref><ref id="CR306"><label>306.</label><mixed-citation publication-type="other">Russell, W. M. S. &#x00026; Burch, R. L. <italic>The Principles of Humane Experimental Technique</italic> (Methuen &#x00026; Co. Limited, 1959). <bold>This work defines, for the first time, the 3Rs principle as the present ethical standard in animal research</bold>.</mixed-citation></ref><ref id="CR307"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaeger</surname><given-names>A</given-names></name><name><surname>Sauder</surname><given-names>P</given-names></name><name><surname>Kopferschmitt</surname></name><name><surname>Dahlet</surname><given-names>M</given-names></name></person-group><article-title>Toxicokinetics in clinical toxicology</article-title><source>Acta Clin. Belg.</source><year>1990</year><volume>45</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1080/17843286.1990.11718122</pub-id><pub-id pub-id-type="pmid">2161599</pub-id></element-citation></ref><ref id="CR308"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goehl</surname><given-names>TJ</given-names></name></person-group><article-title>Toxicokinetics in the national toxicology program</article-title><source>NIDA Res. Monogr.</source><year>1997</year><volume>173</volume><fpage>273</fpage><lpage>304</lpage><?supplied-pmid 9260193?><pub-id pub-id-type="pmid">9260193</pub-id></element-citation></ref><ref id="CR309"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>YS</given-names></name><name><surname>Sedykh</surname><given-names>AY</given-names></name><name><surname>Rusyn</surname><given-names>I</given-names></name><name><surname>Tropsha</surname><given-names>A</given-names></name></person-group><article-title>Integrative approaches for predicting in vivo effects of chemicals from their structural descriptors and the results of short-term biological assays</article-title><source>Curr. Top. Med. Chem.</source><year>2014</year><volume>14</volume><fpage>1356</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.2174/1568026614666140506121116</pub-id><?supplied-pmid 24805064?><pub-id pub-id-type="pmid">24805064</pub-id></element-citation></ref><ref id="CR310"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>LAT</given-names></name><name><surname>Popken</surname><given-names>DA</given-names></name><name><surname>Kaplan</surname><given-names>AM</given-names></name><name><surname>Plunkett</surname><given-names>LM</given-names></name><name><surname>Becker</surname><given-names>RA</given-names></name></person-group><article-title>How well can <italic>in vitro</italic> data predict <italic>in vivo</italic> effects of chemicals? Rodent carcinogenicity as a case study</article-title><source>Regul. Toxicol. Pharmacol.</source><year>2016</year><volume>77</volume><fpage>54</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2016.02.005</pub-id><pub-id pub-id-type="pmid">26879462</pub-id></element-citation></ref><ref id="CR311"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Zebrafish and <italic>Galleria mellonella</italic>: Models to identify the subsequent infection and evaluate the immunological differences in different <italic>Klebsiella pneumoniae</italic> intestinal colonization strains</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>2750</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.02750</pub-id><?supplied-pmid 31849893?><pub-id pub-id-type="pmid">31849893</pub-id></element-citation></ref><ref id="CR312"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herlich</surname><given-names>JA</given-names></name><etal/></person-group><article-title>The non-GLP toleration/dose range finding study: design and methodology used in an early toxicology screening program</article-title><source>Proc. West. Pharmacol. Soc.</source><year>2009</year><volume>52</volume><fpage>94</fpage><lpage>98</lpage><?supplied-pmid 22128433?><pub-id pub-id-type="pmid">22128433</pub-id></element-citation></ref><ref id="CR313"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alirol</surname><given-names>E</given-names></name><etal/></person-group><article-title>Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines</article-title><source>PLoS Med.</source><year>2017</year><volume>14</volume><fpage>e1002366</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1002366</pub-id><?supplied-pmid 28746372?><pub-id pub-id-type="pmid">28746372</pub-id></element-citation></ref><ref id="CR314"><label>314.</label><mixed-citation publication-type="other"><italic>BEAM Alliance</italic>. Position Paper 2017: Key Guidelines to implement effective measures toward SMEs to revive the antibacterial R&#x00026;D field. (BEAM Alliance, 2017) <ext-link ext-link-type="uri" xlink:href="https://beam-alliance.eu/wp-content/uploads/2019/03/2017-11-16-beam-alliance-position-paper.pdf">https://beam-alliance.eu/wp-content/uploads/2019/03/2017-11-16-beam-alliance-position-paper.pdf</ext-link></mixed-citation></ref><ref id="CR315"><label>315.</label><mixed-citation publication-type="other"><italic>BEAM Alliance</italic>. A new vision for AMR innovation to support medical care. (BEAM Alliance, 2019) <ext-link ext-link-type="uri" xlink:href="https://beam-alliance.eu/wp-content/uploads/2019/10/beam-alliance-a-new-vision-to-support-amr-innovation.pdf">https://beam-alliance.eu/wp-content/uploads/2019/10/beam-alliance-a-new-vision-to-support-amr-innovation.pdf</ext-link></mixed-citation></ref><ref id="CR316"><label>316.</label><mixed-citation publication-type="other"><italic>BEAM Alliance</italic>. Reflexion paper on the EU pharmaceutical strategy roadmap. (BEAM Alliance, 2020) <ext-link ext-link-type="uri" xlink:href="https://beam-alliance.eu/wp-content/uploads/2020/07/roadmap-reflexion-paper.pdf">https://beam-alliance.eu/wp-content/uploads/2020/07/roadmap-reflexion-paper.pdf</ext-link></mixed-citation></ref><ref id="CR317"><label>317.</label><mixed-citation publication-type="other"><italic>ReAct Europe</italic>. AMR stakeholder mapping. (ReAct, 2016) <ext-link ext-link-type="uri" xlink:href="https://www.reactgroup.org/uploads/Stakeholder%20Analysis_ReActForWHO.pdf">https://www.reactgroup.org/uploads/Stakeholder%20Analysis_ReActForWHO.pdf</ext-link></mixed-citation></ref><ref id="CR318"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>JF</given-names></name><name><surname>Mobashery</surname><given-names>S</given-names></name></person-group><article-title>Endless resistance. Endless antibiotics?</article-title><source>MedChemComm</source><year>2016</year><volume>7</volume><fpage>37</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1039/C5MD00394F</pub-id><?supplied-pmid 27746889?><pub-id pub-id-type="pmid">27746889</pub-id></element-citation></ref><ref id="CR319"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMasi</surname><given-names>JA</given-names></name><name><surname>Grabowski</surname><given-names>HG</given-names></name><name><surname>Hansen</surname><given-names>RW</given-names></name></person-group><article-title>Innovation in the pharmaceutical industry: New estimates of R&#x00026;D costs</article-title><source>J. Health Econ.</source><year>2016</year><volume>47</volume><fpage>20</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.jhealeco.2016.01.012</pub-id><?supplied-pmid 26928437?><pub-id pub-id-type="pmid">26928437</pub-id></element-citation></ref><ref id="CR320"><label>320.</label><mixed-citation publication-type="other"><italic>The Boston Consulting Group</italic>. Breaking through the wall &#x02013; A call for concerted action on antibiotics research and development. (Bundesministerium f&#x000fc;r Gesundheit, 2017) <ext-link ext-link-type="uri" xlink:href="https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Berichte/GUARD_Follow_Up_Report_Full_Report_final.pdf">https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Berichte/GUARD_Follow_Up_Report_Full_Report_final.pdf</ext-link></mixed-citation></ref><ref id="CR321"><label>321.</label><mixed-citation publication-type="other"><italic>Access to Medicine Foundation</italic>. Antimicrobial resistance benchmark 2018. (Access to Medicine Foundation, 2018) <ext-link ext-link-type="uri" xlink:href="https://accesstomedicinefoundation.org/media/uploads/downloads/5f292e3996b58_Antimicrobial-Resistance-Benchmark-2018.pdf">https://accesstomedicinefoundation.org/media/uploads/downloads/5f292e3996b58_Antimicrobial-Resistance-Benchmark-2018.pdf</ext-link></mixed-citation></ref><ref id="CR322"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>SM</given-names></name><etal/></person-group><article-title>How to improve R&#x00026;D productivity: the pharmaceutical industry&#x02019;s grand challenge</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/nrd3078</pub-id><?supplied-pmid 20168317?><pub-id pub-id-type="pmid">20168317</pub-id></element-citation></ref><ref id="CR323"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieroni</surname><given-names>M</given-names></name><name><surname>Wan</surname><given-names>B</given-names></name><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Franzblau</surname><given-names>SG</given-names></name><name><surname>Costantino</surname><given-names>G</given-names></name></person-group><article-title>Design, synthesis and investigation on the structure&#x02013;activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents</article-title><source>Eur. J. Med. Chem.</source><year>2014</year><volume>72</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2013.11.007</pub-id><?supplied-pmid 24333612?><pub-id pub-id-type="pmid">24333612</pub-id></element-citation></ref><ref id="CR324"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzali</surname><given-names>E</given-names></name><etal/></person-group><article-title>Substituted <italic>N</italic>-phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides are valuable antitubercular candidates that evade innate efflux machinery</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>7108</fpage><lpage>7122</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00793</pub-id><?supplied-pmid 28749666?><pub-id pub-id-type="pmid">28749666</pub-id></element-citation></ref><ref id="CR325"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohacek</surname><given-names>RS</given-names></name><name><surname>McMartin</surname><given-names>C</given-names></name><name><surname>Guida</surname><given-names>WC</given-names></name></person-group><article-title>The art and practice of structure-based drug design: a molecular modeling perspective</article-title><source>Med. Res. Rev.</source><year>1996</year><volume>16</volume><fpage>3</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-1128(199601)16:1&#x0003c;3::AID-MED1&#x0003e;3.0.CO;2-6</pub-id><?supplied-pmid 8788213?><pub-id pub-id-type="pmid">8788213</pub-id></element-citation></ref><ref id="CR326"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartwig</surname><given-names>JF</given-names></name></person-group><article-title>Evolution of a fourth generation catalyst for the amination and thioetherification of aryl halides</article-title><source>Acc. Chem. Res.</source><year>2008</year><volume>41</volume><fpage>1534</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1021/ar800098p</pub-id><?supplied-pmid 18681463?><pub-id pub-id-type="pmid">18681463</pub-id></element-citation></ref><ref id="CR327"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Magid</surname><given-names>AF</given-names></name><name><surname>Mehrman</surname><given-names>SJ</given-names></name></person-group><article-title>A review on the use of sodium triacetoxyborohydride in the reductive amination of ketones and aldehydes</article-title><source>Org. Process. Res. Dev.</source><year>2006</year><volume>10</volume><fpage>971</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1021/op0601013</pub-id></element-citation></ref><ref id="CR328"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gedeck</surname><given-names>P</given-names></name><etal/></person-group><article-title>Benefit of retraining p<italic>K</italic><sub>a</sub> models studied using internally measured data</article-title><source>J. Chem. Inf. Model.</source><year>2015</year><volume>55</volume><fpage>1449</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.5b00172</pub-id><?supplied-pmid 26052622?><pub-id pub-id-type="pmid">26052622</pub-id></element-citation></ref><ref id="CR329"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovering</surname><given-names>F</given-names></name><name><surname>Bikker</surname><given-names>J</given-names></name><name><surname>Humblet</surname><given-names>C</given-names></name></person-group><article-title>Escape from flatland: increasing saturation as an approach to improving clinical success</article-title><source>J. Med. Chem.</source><year>2009</year><volume>52</volume><fpage>6752</fpage><lpage>6756</lpage><pub-id pub-id-type="doi">10.1021/jm901241e</pub-id><?supplied-pmid 19827778?><pub-id pub-id-type="pmid">19827778</pub-id></element-citation></ref><ref id="CR330"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zender</surname><given-names>M</given-names></name><etal/></person-group><article-title>Discovery and biophysical characterization of 2-amino-oxadiazoles as novel antagonists of PqsR, an important regulator of <italic>Pseudomonas aeruginosa</italic> virulence</article-title><source>J. Med. Chem.</source><year>2013</year><volume>56</volume><fpage>6761</fpage><lpage>6774</lpage><pub-id pub-id-type="doi">10.1021/jm400830r</pub-id><?supplied-pmid 23919758?><pub-id pub-id-type="pmid">23919758</pub-id></element-citation></ref><ref id="CR331"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zender</surname><given-names>M</given-names></name><etal/></person-group><article-title>Flexible fragment growing boosts potency of quorum-sensing inhibitors against <italic>Pseudomonas aeruginosa</italic> virulence</article-title><source>ChemMedChem</source><year>2020</year><volume>15</volume><fpage>188</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201900621</pub-id><?supplied-pmid 31709767?><pub-id pub-id-type="pmid">31709767</pub-id></element-citation></ref><ref id="CR332"><label>332.</label><mixed-citation publication-type="other">Ahmed, A. S. A. et al. PqsR inverse agonists. Patent WO2020007938A1 (2020).</mixed-citation></ref><ref id="CR333"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000fc;tz</surname><given-names>C</given-names></name><etal/></person-group><article-title>A new PqsR inverse agonist potentiates tobramycin efficacy to eradicate <italic>Pseudomonas aeruginosa</italic> biofilms</article-title><source>Adv. Sci.</source><year>2021</year><volume>8</volume><fpage>2004369</fpage><pub-id pub-id-type="doi">10.1002/advs.202004369</pub-id></element-citation></ref><ref id="CR334"><label>334.</label><mixed-citation publication-type="other">Oliver, T. J. &#x00026; Sinclair, A. C. Antibiotic M-319. US Patent US3155582A (1964).</mixed-citation></ref><ref id="CR335"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitscher</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Structure of chelocardin, a novel tetracycline antibiotic</article-title><source>J. Am. Chem. Soc.</source><year>1970</year><volume>92</volume><fpage>6070</fpage><lpage>6071</lpage><pub-id pub-id-type="doi">10.1021/ja00723a049</pub-id><?supplied-pmid 5459200?><pub-id pub-id-type="pmid">5459200</pub-id></element-citation></ref><ref id="CR336"><label>336.</label><mixed-citation publication-type="other">Petkovic, H., Raspor, P. &#x00026; Lesnik, U. Genes for biosynthesis of tetracycline compounds and uses thereof. US Patent US8361777B2 (2013).</mixed-citation></ref><ref id="CR337"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luke&#x0017e;i&#x0010d;</surname><given-names>T</given-names></name><etal/></person-group><article-title>Identification of the chelocardin biosynthetic gene cluster from <italic>Amycolatopsis sulphurea</italic>: a platform for producing novel tetracycline antibiotics</article-title><source>Microbiology</source><year>2013</year><volume>159</volume><fpage>2524</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1099/mic.0.070995-0</pub-id><?supplied-pmid 24043447?><pub-id pub-id-type="pmid">24043447</pub-id></element-citation></ref><ref id="CR338"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molnar</surname><given-names>V</given-names></name><name><surname>Matkovi&#x00107;</surname><given-names>Z</given-names></name><name><surname>Tambi&#x00107;</surname><given-names>T</given-names></name><name><surname>Kozma</surname><given-names>C</given-names></name></person-group><article-title>Klinicko-farmakolosko ispitivanje kelokardina u bolesnika s infekcijom mokra&#x00107;nih putova</article-title><source>Lijec. Vjesn.</source><year>1977</year><volume>99</volume><fpage>560</fpage><lpage>562</lpage><?supplied-pmid 339024?><pub-id pub-id-type="pmid">339024</pub-id></element-citation></ref><ref id="CR339"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luke&#x0017e;i&#x0010d;</surname><given-names>T</given-names></name><etal/></person-group><article-title>Engineering atypical tetracycline formation in <italic>Amycolatopsis sulphurea</italic> for the production of modified chelocardin antibiotics</article-title><source>ACS Chem. Biol.</source><year>2019</year><volume>14</volume><fpage>468</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1021/acschembio.8b01125</pub-id><?supplied-pmid 30747520?><pub-id pub-id-type="pmid">30747520</pub-id></element-citation></ref><ref id="CR340"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Mireles</surname><given-names>AL</given-names></name><name><surname>Walker</surname><given-names>JN</given-names></name><name><surname>Caparon</surname><given-names>M</given-names></name><name><surname>Hultgren</surname><given-names>SJ</given-names></name></person-group><article-title>Urinary tract infections: epidemiology, mechanisms of infection and treatment options</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>269</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3432</pub-id><?supplied-pmid 25853778?><pub-id pub-id-type="pmid">25853778</pub-id></element-citation></ref><ref id="CR341"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irschik</surname><given-names>H</given-names></name><name><surname>Jansen</surname><given-names>R</given-names></name><name><surname>H&#x000f6;fle</surname><given-names>G</given-names></name><name><surname>Gerth</surname><given-names>K</given-names></name><name><surname>Reichenbach</surname><given-names>H</given-names></name></person-group><article-title>The corallopyronins, new inhibitors of bacterial RNA synthesis from Myxobacteria</article-title><source>J. Antibiot.</source><year>1985</year><volume>38</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.38.145</pub-id></element-citation></ref><ref id="CR342"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>A</given-names></name><etal/></person-group><article-title>RNA polymerase inhibitors with activity against rifampin-resistant mutants of <italic>Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2000</year><volume>44</volume><fpage>3163</fpage><lpage>3166</lpage><pub-id pub-id-type="doi">10.1128/AAC.44.11.3163-3166.2000</pub-id><?supplied-pmid 11036042?><pub-id pub-id-type="pmid">11036042</pub-id></element-citation></ref><ref id="CR343"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belogurov</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Transcription inactivation through local refolding of the RNA polymerase structure</article-title><source>Nature</source><year>2008</year><volume>457</volume><fpage>332</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1038/nature07510</pub-id><?supplied-pmid 18946472?><pub-id pub-id-type="pmid">18946472</pub-id></element-citation></ref><ref id="CR344"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000e4;berle</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Insights into structure&#x02013;activity relationships of bacterial RNA polymerase inhibiting corallopyronin derivatives</article-title><source>J. Nat. Prod.</source><year>2015</year><volume>78</volume><fpage>2505</fpage><lpage>2509</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b00175</pub-id><?supplied-pmid 26431157?><pub-id pub-id-type="pmid">26431157</pub-id></element-citation></ref><ref id="CR345"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiefer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Corallopyronin A specifically targets and depletes essential obligate <italic>Wolbachia</italic> endobacteria from filarial nematodes in vivo</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>206</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis341</pub-id><?supplied-pmid 22586066?><pub-id pub-id-type="pmid">22586066</pub-id></element-citation></ref><ref id="CR346"><label>346.</label><mixed-citation publication-type="other">Pfarr, K. M. et al. Compounds for use in the treatment of filariasis. US Patent US9687470B2 (2017).</mixed-citation></ref><ref id="CR347"><label>347.</label><mixed-citation publication-type="other">Pfarr, K. M. et al. Compounds for use in the treatment of filariasis. Patent EP2704708B1 (2017).</mixed-citation></ref><ref id="CR348"><label>348.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiefer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections</article-title><source>PLoS Negl. Trop. Dis.</source><year>2020</year><volume>14</volume><fpage>e0008930</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0008930</pub-id><?supplied-pmid 33284808?><pub-id pub-id-type="pmid">33284808</pub-id></element-citation></ref><ref id="CR349"><label>349.</label><mixed-citation publication-type="other"><italic>World Health Organization (WHO)</italic>. Ending the neglect to attain the Sustainable Development Goals &#x02013; A road map for neglected tropical diseases 2021&#x02013;2030 (WHO, 2020) <ext-link ext-link-type="uri" xlink:href="https://www.who.int/neglected_diseases/resources/who-ucn-ntd-2020.01/en/">https://www.who.int/neglected_diseases/resources/who-ucn-ntd-2020.01/en/</ext-link></mixed-citation></ref><ref id="CR350"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeper</surname><given-names>N</given-names></name><etal/></person-group><article-title>Elaborations on Corallopyronin A as a novel treatment strategy against genital chlamydial infections</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>943</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.00943</pub-id><?supplied-pmid 31134007?><pub-id pub-id-type="pmid">31134007</pub-id></element-citation></ref><ref id="CR351"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kock</surname><given-names>F</given-names></name><etal/></person-group><article-title><italic>Orientia tsutsugamushi</italic> is highly susceptible to the RNA polymerase switch region inhibitor corallopyronin A <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e01732-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.01732-17</pub-id><?supplied-pmid 29358295?><pub-id pub-id-type="pmid">29358295</pub-id></element-citation></ref><ref id="CR352"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shima</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effective inhibition of rifampicin-resistant <italic>Chlamydia trachomatis</italic> by the novel DNA-dependent RNA polymerase inhibitor corallopyronin A</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>52</volume><fpage>523</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.07.025</pub-id><?supplied-pmid 30092271?><pub-id pub-id-type="pmid">30092271</pub-id></element-citation></ref><ref id="CR353"><label>353.</label><mixed-citation publication-type="other">Sucipto, H. et al. Production of myxopyronin and of its derivatives. Patent EP2994535A1 (2018).</mixed-citation></ref></ref-list></back></article>